DRUG NAME: Torasemide

ℹ️ USAN: Torsemide. Indian product labels commonly use “Torsemide.” The INN “Torasemide” is used as the primary name in this monograph.

Therapeutic Class:

Diuretic

Subclass:

Loop diuretic (high-ceiling diuretic)

Schedule (India):

Schedule H. All formulations — oral tablets and injection — are Schedule H drugs. Prescription-only; no OTC status for any formulation or strength. No Schedule H1 or Schedule X restrictions apply. Fixed-dose combinations containing torasemide are also classified as Schedule H.

Route(s)

Oral (tablets — immediate release)
IV (slow bolus or continuous infusion)

ℹ️ IM injection is NOT a standard recommended route for torasemide. If parenteral administration is needed, use the IV route exclusively. IM administration results in unpredictable absorption and local pain with no clinical advantage.

Biosimilar Status:

Not a biologic — biosimilar classification not applicable. Torasemide is a small-molecule chemical drug (pyridine-3-sulfonylurea derivative). Multiple generic versions are manufactured and marketed in India by numerous pharmaceutical companies.

Formulations Available in India

Single-Ingredient Formulations:

Dosage Form	Available Strengths	Notes
Tablets (immediate-release)	5 mg, 10 mg, 20 mg, 40 mg, 100 mg	10 mg and 20 mg are the most commonly stocked strengths. The 5 mg tablet is primarily used for hypertension. The 100 mg tablet is reserved for severe/refractory oedema, particularly in advanced CKD.
Injection (for IV use only)	10 mg/mL in 2 mL ampoule (20 mg per ampoule)	Clear, colourless solution. Some manufacturers also offer 4 mL ampoules (40 mg per ampoule) — verify brand-specific availability.

Fixed-Dose Combinations (FDCs) Available in India:

FDC Partner	Available Strengths (Torasemide / Partner, mg)	Clinical Context
Spironolactone	10/25, 10/50, 20/50	Widely prescribed in heart failure — combines loop diuretic with mineralocorticoid receptor antagonist (MRA) for additive diuresis and potassium conservation. Most commonly prescribed torasemide FDC in India.

ℹ️ The torasemide + spironolactone FDC is extensively used in Indian cardiology practice. It provides the convenience of combining two guideline-recommended heart failure drugs in a single tablet, potentially improving adherence. However, fixed-ratio FDCs limit individual dose titration of each component. When independent dose adjustment of either drug is needed, prescribe the components separately.

⛔ No torasemide-containing FDC has been banned or withdrawn by CDSCO as of this writing.

💡 Other torasemide FDCs (e.g., with eplerenone or amiloride) may be found on some online pharmacies but are NOT widely available in standard retail pharmacy channels and are not included here due to limited clinical documentation of widespread use.

PHARMACOKINETICS

Main Pharmacokinetic Parameters:

Parameter	Value
Bioavailability (oral)	~80–90% (substantially higher and more predictable than furosemide’s ~50%, range 10–100%). This is the single most clinically significant pharmacokinetic advantage of torasemide over furosemide.
Tmax	Oral: ~1 hour (range 0.5–2 hours). IV: onset of diuresis within 10 minutes, with peak effect at ~1 hour.
Protein binding	~99%, primarily to plasma albumin. Only the unbound fraction (~1%) is pharmacologically active and available for glomerular filtration. The drug reaches its site of action predominantly via active tubular secretion, not filtration.
Volume of distribution (Vd)	12–15 L (~0.15–0.2 L/kg). Low Vd reflects high protein binding and limited extravascular tissue distribution.
Metabolism	Hepatic (~80% of total clearance). Primary enzyme: CYP2C9 (major pathway). Minor contributions from CYP2C8 and CYP2C19. Three principal metabolites: M1 (methyl hydroxylation — inactive), M3 (ring hydroxylation — inactive), M5 (carboxylic acid derivative — retains ~10% of parent compound’s diuretic activity; not considered clinically significant at usual doses). Torasemide is NOT a clinically significant inhibitor or inducer of CYP enzymes at therapeutic concentrations. Prodrug status: Torasemide is NOT a prodrug — the parent compound is the active moiety.
Drug transporters	Renal secretion (essential for reaching site of action): Substrate of OAT1 (SLC22A6) and OAT3 (SLC22A8) — basolateral organic anion transporters in proximal tubule cells mediate uptake of torasemide from peritubular blood into tubule cells. Substrate of MRP4/ABCC4 — apical efflux transporter that secretes torasemide from tubule cells into the tubular lumen, where it acts on NKCC2. Clinical relevance of OAT1/OAT3: (a) NSAIDs and probenecid compete for OAT-mediated secretion → reduced torasemide delivery to luminal site of action → diminished diuretic response. (b) In uraemia/advanced CKD, accumulated endogenous organic anions (hippurate, indoxyl sulfate) compete for OAT secretion → diuretic resistance → higher doses needed. P-glycoprotein: NOT a clinically significant P-gp substrate or inhibitor.
Half-life (t½)	3–4 hours in healthy adults. Modestly prolonged to 4–5 hours in heart failure. Significantly prolonged to 7–8 hours in hepatic cirrhosis (Child-Pugh B/C), because ~80% of clearance is hepatic. NOT significantly prolonged in isolated renal impairment (a key difference from furosemide).
Excretion	Urinary: ~83% of dose recovered in urine (as parent drug + metabolites). Approximately 20–25% of dose excreted as unchanged drug in urine. Faecal: ~12% of dose. Primary route of parent drug clearance is hepatic metabolism with subsequent renal excretion of metabolites.
Dialysability	NOT significantly removed by haemodialysis or peritoneal dialysis (due to ~99% protein binding and low Vd). Supplemental post-dialysis doses are generally NOT required.
Food effect	Minimal clinical impact. Tmax may be delayed by ~30 minutes when taken with food, but total systemic exposure (AUC) is unchanged. Can be taken with or without food. Counsel patients to take consistently with or without food for predictable timing of diuresis.
Onset of action	Oral: 30–60 minutes. IV: within 10 minutes.
Duration of action	6–8 hours (notably longer than furosemide’s 4–6 hours). This longer duration reduces “post-diuretic rebound sodium retention” (diuretic braking), potentially improving net 24-hour sodium excretion.
Non-linear PK	Linear pharmacokinetics over the therapeutic dose range (5–200 mg). AUC and Cmax increase proportionally with dose. No autoinduction or saturation kinetics.

Diuretic Dose-Response Principles (Loop Diuretic Class-Specific PK-PD):

💡 Understanding these principles is essential for managing diuretic resistance:

Threshold dose: A minimum drug concentration must be achieved in the tubular lumen to inhibit NKCC2 and initiate natriuresis. Below this threshold, no clinically meaningful diuresis occurs. Unlike a linear dose-response, increasing the dose from sub-threshold to threshold produces a dramatic (“all-or-none”) change in response.
Ceiling dose: Once all luminal NKCC2 transporters are maximally inhibited, further dose increases produce no additional natriuresis — only increased risk of adverse effects (electrolyte depletion, ototoxicity, metabolic derangements). Approximate ceiling doses:
- Torasemide: 200 mg (single dose, oral or IV)
- Furosemide: 400 mg (single dose)
- In advanced CKD (eGFR <15): ceiling may be reached at even higher doses, but the absolute natriuretic response is still reduced.
Rightward shift in disease states: In heart failure, CKD, nephrotic syndrome, and cirrhosis, the dose-response curve shifts rightward — higher doses are required for the same effect due to:
- Reduced renal blood flow → less drug delivery
- OAT competition from uraemic toxins (CKD)
- Intraluminal albumin binding of torasemide (nephrotic syndrome)
- Compensatory upregulation of distal nephron sodium reabsorption
Torasemide’s longer duration advantage: Furosemide’s shorter action (4–6 hours) creates a drug-free interval during which compensatory sodium retention occurs (“diuretic braking”). Torasemide’s 6–8-hour duration reduces this phenomenon, contributing to more effective and smoother diuresis. This translates to fewer episodes of post-diuresis rebound oedema and potentially better symptom control.

Loop Diuretic Dose Equivalence Table:

Drug	Approximate Oral Equivalent Dose	Approximate IV Equivalent Dose	Oral Bioavailability	Oral:IV Dose Ratio
Torasemide	20 mg	20 mg	~80–90%	~1:1
Furosemide	40–80 mg	20–40 mg	~50% (range 10–100%)	~2:1
Bumetanide	1 mg	1 mg	~80–90%	~1:1

ℹ️ Key clinical implication: Torasemide’s oral:IV ratio is approximately 1:1 due to its high and predictable oral bioavailability. When switching a patient from IV torasemide to oral torasemide, the same dose can be used (unlike furosemide, where the oral dose is typically doubled relative to the IV dose). This simplifies IV-to-oral transitions, especially in heart failure.

⚠️ The torasemide:furosemide conversion ratio is commonly cited as 1:2 (torasemide 20 mg ≈ furosemide 40 mg), as used in the TRANSFORM-HF trial. Some sources cite a 1:4 ratio. In practice, titrate to clinical response (daily weight, oedema, urine output, symptoms of congestion) rather than relying on rigid conversion ratios. Individual responses vary substantially.

Population Pharmacokinetic Notes:

Population	PK Alteration	Clinical Implication
Renal impairment	Half-life is NOT significantly prolonged (unlike furosemide), because ~80% of clearance is hepatic. However, delivery of torasemide to tubular lumen via OAT1/OAT3 is progressively reduced as eGFR declines → diuretic resistance develops due to inadequate luminal drug concentration, not due to systemic drug accumulation or toxicity.	Higher doses are needed for adequate diuretic response as CKD advances. Dose escalation is for efficacy (overcoming diuretic resistance), not for safety/toxicity avoidance. The drug does not accumulate to toxic levels.
Hepatic impairment (cirrhosis)	Half-life prolonged to 7–8 hours (from 3–4 hours). AUC approximately doubled in Child-Pugh B/C. CYP2C9 metabolism substantially reduced. Volume of distribution may be altered by ascites/fluid shifts and hypoalbuminaemia.	Start at lower doses. Duration of effect is extended; once-daily dosing more than sufficient. Monitor electrolytes closely — hyponatraemia risk is heightened in cirrhosis.
Heart failure	Half-life modestly prolonged (4–5 hours). Reduced renal perfusion shifts dose-response curve rightward. However, gut oedema causes LESS reduction in oral absorption compared to furosemide (due to torasemide’s higher baseline bioavailability, ~80% vs ~50%).	Oral torasemide provides more predictable absorption than oral furosemide in decompensated heart failure. Oral-to-IV conversion is more reliable.
Elderly (≥60 years)	Modest reduction in clearance proportional to age-related decline in renal and hepatic function. No age-specific dosing adjustments beyond those dictated by organ function.	Start at the lower end of the dose range. Monitor electrolytes and renal function more frequently. Elderly patients are more susceptible to volume depletion, postural hypotension, and electrolyte disturbances.
Obesity	Vd may be modestly increased in severe obesity due to expanded extracellular fluid. Limited dedicated PK studies. High protein binding limits distribution into adipose tissue.	Dose to clinical response. No formal weight-based adjustment for obesity. Use ideal or adjusted body weight if any weight-based calculation is attempted.
Hypoalbuminaemia (nephrotic syndrome, cirrhosis, malnutrition, critical illness)	Free (unbound) fraction of torasemide increases (from ~1% to potentially 3–5%). In nephrotic syndrome specifically, torasemide that reaches the tubular lumen binds to urinary albumin, reducing the free drug available to inhibit NKCC2 → diuretic resistance despite adequate or elevated plasma levels.	Consider higher doses. In severe nephrotic syndrome, strategies to overcome resistance include: higher bolus doses, continuous IV infusion, or combination with a thiazide for sequential nephron blockade. Albumin co-infusion before diuretic administration has been tried but evidence is mixed and is not routinely recommended.
CYP2C9 polymorphisms	CYP2C9 poor metabolisers (e.g., 2/3, 3/3 genotypes — estimated ~1–3% of the Indian population) have significantly higher torasemide exposure (AUC increased 2–4 fold) and prolonged half-life. Intermediate metabolisers (1/2, 1/3) may also have modestly increased exposure.	Clinically, CYP2C9 poor metaboliser status may manifest as enhanced diuretic response or increased risk of electrolyte disturbances at standard doses. Genotyping is not routinely required but consider CYP2C9 polymorphism if a patient shows unexpected sensitivity to low doses (excessive diuresis, hypokalaemia at low doses) or unexpected toxicity.
Paediatric	Limited PK data in children. Based on extrapolation, clearance per kg body weight may be higher than in adults, potentially requiring relatively higher weight-based doses to achieve equivalent effect.	Weight-based dosing; titrate to clinical response under specialist supervision.
Pregnancy	Limited PK data. Expanded plasma volume in pregnancy may increase Vd. Altered hepatic metabolism (CYP2C9 activity may change during pregnancy). Placental transfer is expected but poorly quantified.	Use only if clearly indicated. No validated pregnancy-specific dosing regimen exists.
Critical illness (ICU)	Gut oedema reduces oral absorption of most drugs, but torasemide’s high baseline oral bioavailability (~80–90%) may be better preserved than furosemide’s (~50%). IV route remains preferred in haemodynamically unstable patients. Augmented renal clearance (ARC) is less relevant for torasemide (predominantly hepatically cleared) than for drugs primarily eliminated renally.	IV route preferred in ICU during active resuscitation/stabilisation. Torasemide may be preferred over furosemide when transitioning from IV to oral in ICU step-down, due to more predictable oral absorption.

Anti-Aldosterone and Anti-Fibrotic Properties — Unique Pharmacological Note:

💡 Unlike furosemide and bumetanide, torasemide has been shown in preclinical and some clinical studies to possess anti-aldosterone receptor activity and to reduce markers of myocardial collagen synthesis (procollagen type I C-terminal propeptide — PICP). This property is unique within the loop diuretic class and may theoretically contribute to reduced myocardial fibrosis in chronic heart failure. However:

The TRANSFORM-HF trial (2022, JAMA — pragmatic RCT, n=2,859) comparing torasemide to furosemide in heart failure patients found no significant difference in all-cause mortality at 12 months.
Therefore, while this pharmacological property is of academic interest and may contribute to soft endpoints, it has not translated into a mortality benefit in the largest comparative trial to date.
Torasemide’s advantages over furosemide remain primarily pharmacokinetic (bioavailability, duration of action, predictability) rather than based on this anti-fibrotic property.

ADULT INDICATIONS + DOSING

KEY LOOP DIURETIC PRESCRIBING PRINCIPLES

(Applicable to ALL torasemide indications. Read before prescribing.)

Principle	Detail
1. Dose to clinical target, not to a protocol number	The correct torasemide dose is the dose that achieves the clinical goal (euvolaemia in HF/CKD/cirrhosis, BP target in hypertension). Two patients with the same diagnosis may require vastly different doses. Never titrate to a “standard” dose when clinical response dictates otherwise.
2. Once-daily morning dosing	Torasemide’s 6–8 hour duration of diuretic action supports once-daily morning dosing (take by 10 AM). This confines diuresis to daytime hours, preserving sleep and improving adherence. ⚠️ Avoid evening dosing — causes nocturia, disrupts sleep, increases fall risk in elderly. A second dose (early afternoon, by 2–3 PM at latest) may be added temporarily for refractory oedema, but this is NOT routine.
3. Daily weight is the primary monitoring tool	Daily morning weight (same time, post-void, pre-breakfast, similar clothing) is more reliable than fluid balance charts for tracking diuretic response. Target weight loss in decompensated HF: 0.5–1 kg/day. In cirrhotic ascites with peripheral oedema: ≤1 kg/day. In cirrhotic ascites without peripheral oedema: ≤0.5 kg/day. Weight loss faster than these targets risks intravascular volume depletion, pre-renal AKI, and hepatorenal syndrome.
4. Understand the dose-response curve	See Diuretic Dose-Response Principles in Pharmacokinetics (Part 1). Key concept: below the threshold dose → no effect; above the ceiling dose → no additional benefit, only toxicity.
5. Over-diuresis is as dangerous as under-diuresis	Excessive volume removal → pre-renal AKI, RAAS activation (worsening neurohormonal milieu), hypotension, electrolyte crises (hypokalaemia → arrhythmias; hyponatraemia → seizures). The clinical target is: “Dry enough to relieve congestion, wet enough to maintain renal perfusion.”

DIURETIC RESISTANCE MANAGEMENT PROTOCOL

(Place: top of Indications section, per Diuretic class-specific checklist)

⛔ If the ceiling dose produces inadequate diuresis, do NOT simply increase the dose further — employ the following stepwise strategies:

Step	Strategy	Detail
1	Verify adherence and sodium restriction	Dietary sodium excess (>2 g/day) is the single most common cause of “diuretic resistance” in Indian outpatient practice. Check spot urine Na⁺: >100 mEq/L strongly suggests dietary non-compliance. Counsel patient. Verify medication adherence (ask about missed doses, not just whether the prescription was dispensed).
2	Switch from oral to IV route	If intestinal wall oedema or gastroparesis (common in decompensated HF and diabetic CKD) is suspected, oral absorption may be impaired. Switch to IV torasemide. 💡 Torasemide’s oral bioavailability (~80–90%) is better preserved in HF than furosemide’s (~50%), but in severe decompensation, IV is still preferred.
3	Sequential nephron blockade	Add a thiazide or thiazide-like diuretic acting at a different nephron segment (distal convoluted tubule) to overcome compensatory distal sodium reabsorption. Metolazone 2.5–5 mg orally, 30 minutes BEFORE torasemide (timing matters — metolazone blocks distal Na⁺ reabsorption before the loop diuretic–induced sodium bolus reaches the DCT). Alternative: Hydrochlorothiazide 25–50 mg orally 30 minutes before torasemide. ⚠️ This is a potent combination — monitor electrolytes (K⁺, Na⁺, Mg²⁺) every 6–12 hours when initiated. Profound hypokalaemia and hyponatraemia can develop within 24–48 hours. Use for SHORT periods only (2–5 days) until diuresis is re-established, then discontinue the thiazide and reassess.
4	Continuous IV infusion	In ICU: Loading dose 10–20 mg IV bolus → continuous infusion at 5–20 mg/hour. Provides sustained luminal drug concentration above the diuretic threshold — more effective than intermittent boluses when the dose-response curve is shifted rightward. Infusion pump MANDATORY.
5	Correct hypoalbuminaemia	In nephrotic syndrome and cirrhosis: IV albumin 20% (0.5–1 g/kg over 30 minutes) immediately before IV torasemide bolus. Rationale: transient increase in plasma albumin improves OAT-mediated drug delivery to the tubular lumen. Evidence is mixed (some studies show benefit, others equivocal) but widely practised in Indian nephrology and hepatology (AIIMS, PGIMER protocols). Not recommended as a routine strategy in HF (different pathophysiology of diuretic resistance).
6	Enforce sodium restriction	<2 g Na⁺/day (equivalent to <5 g NaCl/day). Without sodium restriction, loop diuretic efficacy is dramatically reduced — the kidney reabsorbs the sodium that the drug causes to be excreted during the diuretic phase, resulting in net zero sodium balance. Dietitian referral is valuable. In Indian dietary context: restrict pickles (achar), papad, processed snacks (namkeen, chips), added table salt, and high-sodium restaurant food.
7	Ultrafiltration / aquapheresis	For refractory cardiorenal syndrome in ICU. Mechanical fluid removal via veno-venous ultrafiltration. Requires specialised equipment and ICU setting. Consider when pharmacological diuresis has failed at maximal sequential nephron blockade.

Primary Indication 1: ACUTE DECOMPENSATED HEART FAILURE (ADHF) — Decongestive Therapy

Clinical context: Acute or acute-on-chronic heart failure presenting with signs and symptoms of congestion (dyspnoea, orthopnoea, PND, raised JVP, pulmonary rales/crepitations, peripheral oedema, hepatomegaly, ascites). This is an urgent/emergency indication requiring prompt initiation of IV loop diuretic therapy in most moderate-to-severe presentations.

Route	Starting Dose	Titration	Usual Maintenance Dose	Maximum Dose	Clinical Notes
IV bolus (preferred initial route in ADHF)	Loop diuretic–naive patient: 10–20 mg IV bolus. Already on oral torasemide: Give IV dose ≥ current total oral daily dose (1:1 oral-to-IV ratio). Example: Patient on oral torasemide 20 mg/day → start IV torasemide 20 mg. Switching from IV furosemide: Use approximate equivalence: IV furosemide 40 mg ≈ IV torasemide 20 mg.	Assess urine output at 2 hours post-dose. Target: ≥100–150 mL urine in 2 hours. If output is below target: double the IV dose. Reassess at 2 hours. Repeat dose escalation every 2–4 hours until adequate diuretic response or ceiling dose reached.	10–40 mg IV once or twice daily (while requiring IV route for ongoing decongestive therapy).	Max 200 mg/day IV. Max 100 mg per single IV bolus (higher single boluses increase ototoxicity risk without proportional additional efficacy).	⚠️ Administer IV bolus slowly over 2–5 minutes (rapid injection increases ototoxicity risk). If daily doses >100 mg needed: divide into 2–3 boluses or use continuous infusion.
IV continuous infusion (for diuretic resistance / ICU setting)	Loading dose: 10–20 mg IV bolus over 2–5 minutes, followed immediately by continuous infusion at 5–10 mg/hour.	Titrate infusion rate by 2–5 mg/hour increments every 2–4 hours based on urine output target (typically 100–200 mL/hour during active decongestive phase in ICU).	5–20 mg/hour.	Max 100 mg/hour (rarely needed; typical maximum in practice: 20 mg/hour). Max total daily dose via infusion: specialist discretion (may exceed 200 mg/day under close monitoring in ICU).	Infusion pump MANDATORY. Continuous infusion achieves sustained luminal torasemide concentration above diuretic threshold — advantageous when the sigmoid dose-response curve is shifted rightward (severe HF, CKD, hypoalbuminaemia). See Reconstitution section for stability data.
Oral (for mild ADHF presentations or IV-to-oral step-down)	10–20 mg once daily in the morning. For IV-to-oral transition: use approximately the same dose as IV (1:1 ratio). Example: Patient stable on IV torasemide 20 mg/day → prescribe oral torasemide 20 mg/day.	Increase by 10–20 mg increments every 2–3 days if diuretic response is inadequate (weight not decreasing, persistent congestion).	10–40 mg once daily.	Max 200 mg/day orally.	💡 Key advantage over furosemide for IV-to-oral transition: Torasemide oral:IV ratio is ~1:1 (same dose orally as IV). Furosemide oral:IV ratio is ~2:1 (oral dose must be doubled). This eliminates dose-conversion confusion during a high-risk transition. Additionally, torasemide’s oral bioavailability (~80–90%) is better preserved in moderate HF with intestinal wall oedema than furosemide’s (~50%, dropping to 10–30% in decompensation).

IV-to-Oral Step-Down Criteria — ADHF:

Criterion	Requirement
Haemodynamic stability	SBP >90 mmHg without vasopressor/inotropic support
Clinical improvement	Declining dyspnoea, decreasing JVP, resolving pulmonary crepitations, negative daily weight trend (at least 2 consecutive days)
Tolerating oral intake	Able to swallow tablets; no persistent vomiting; no clinical suspicion of significant intestinal wall oedema
Adequate oral diuretic response	Verify that the first oral dose produces comparable urine output (~80% or more) to the preceding IV dose within 4 hours of administration
No ongoing need for rapid dose titration	IV diuretic dose has stabilised for ≥24 hours

💡 Practical IV-to-oral conversion table:

Previous IV Regimen	Oral Torasemide Dose	Notes
IV torasemide 20 mg/day	Oral torasemide 20 mg OD	1:1 ratio — same number
IV torasemide 40 mg/day	Oral torasemide 40 mg OD	1:1 ratio
IV furosemide 40 mg/day	Oral torasemide 10–20 mg OD	Furosemide IV 40 mg ≈ furosemide oral 80 mg ≈ torasemide oral 20 mg
IV furosemide 80 mg/day	Oral torasemide 20–40 mg OD	Titrate to clinical response
IV furosemide 120 mg/day	Oral torasemide 40–60 mg OD	May need BD dosing initially if large single oral dose ineffective

⚠️ These are approximate starting conversions. Always titrate to clinical response (daily weight, symptoms, urine output) rather than relying on fixed conversion ratios. Individual responses vary substantially.

Mandatory Clinical Notes — ADHF:

When to prefer torasemide over alternatives:
- (a) Advantage over furosemide: (i) More predictable oral bioavailability (~80–90% vs ~50%, range 10–100%), which is practically significant when transitioning from IV to oral — the most error-prone moment in ADHF management. (ii) Longer duration of action (6–8 hours vs 4–6 hours) → less post-dose rebound sodium retention → more consistent 24-hour sodium excretion. (iii) 1:1 oral-to-IV dose ratio simplifies route transitions (vs 2:1 for furosemide). (iv) Unique anti-aldosterone and anti-fibrotic properties (see Unique Pharmacological Note in PK section, Part 1 — cross-reference only, not repeated here).
- (a) Advantage over bumetanide: Similar oral bioavailability (~80%), but torasemide has a longer half-life (3–4 hours vs 1–1.5 hours) and correspondingly longer duration of diuretic action. Bumetanide is less commonly available in India.
- (b) Torasemide is an acceptable first-line loop diuretic for ADHF. CSI Heart Failure Guidelines and API Textbook recognise both furosemide and torasemide as first-line loop diuretics. Torasemide is NOT established as categorically “superior” — the TRANSFORM-HF trial (2022, JAMA, n=2,859) showed no mortality difference vs furosemide. Its advantages are pharmacokinetic (bioavailability, predictability, duration), not outcome-based.
- © Compared against: Furosemide (most commonly used in Indian practice, NLEM-listed, cheapest), bumetanide (limited availability in India, not widely stocked).
- Honest assessment: Switching a furosemide-responding patient to torasemide is NOT necessary for outcomes. Consider switching when: (i) variable oral furosemide absorption is suspected (escalating oral doses with inconsistent response), (ii) simpler IV-to-oral transition is desired, (iii) once-daily dosing preferred for adherence (furosemide often requires BD in chronic HF), (iv) furosemide not tolerated.
When NOT to use:
- ⛔ Anuric patient (no renal urine formation — loop diuretic has no target).
- ⛔ Severe uncorrected hypovolaemia / dehydration (worsens pre-renal AKI).
- ⛔ Hypertrophic obstructive cardiomyopathy (HOCM) with significant outflow tract gradient — volume depletion worsens dynamic obstruction. Use diuretics very cautiously and only under cardiologist guidance.
- ⛔ Severe hyponatraemia (Na⁺ <125 mEq/L) without specialist oversight — loop diuretics can worsen hyponatraemia in certain contexts (though in hypervolaemic hyponatraemia of HF, loop diuretics with free water restriction are appropriate under monitoring).
- ⛔ Known hypersensitivity to torasemide or sulfonamide-derived drugs (see Contraindications, Part 4).
NLEM India status: ⚠️ Torasemide is NOT listed in NLEM India 2022. Furosemide is the NLEM-listed loop diuretic (tablets 20 mg, 40 mg; injection 10 mg/mL). Furosemide is available in government hospitals, PHCs, and PMBJP stores. In government/resource-limited settings, furosemide remains the default choice.
Time to expected clinical response:
- IV bolus: Diuretic effect within 10 minutes; peak urine output at ~1 hour. Expect measurable clinical improvement (reduced dyspnoea, decreasing weight) within 6–12 hours of adequate IV dosing.
- Oral: Diuretic effect within 30–60 minutes; peak at 1–2 hours. Weight reduction of 0.5–1 kg/day expected with adequate dosing and sodium restriction.
- ℹ️ If no significant urine output increase within 2 hours of IV bolus → dose is below the threshold. Double the dose and reassess.
Criteria for treatment failure: Persistent or worsening congestion (weight gain, rising JVP, increasing dyspnoea) despite ceiling-dose torasemide (200 mg/day). Action: Follow the Diuretic Resistance Management Protocol (above). Specifically: (a) Confirm sodium restriction compliance (spot urine Na⁺). (b) Add sequential nephron blockade (metolazone). © Switch to continuous IV infusion. (d) Evaluate for cardiorenal syndrome. (e) Consider ultrafiltration.
Mandatory baseline investigations:
- MANDATORY: Serum electrolytes (Na⁺, K⁺, Cl⁻, Mg²⁺), serum creatinine / eGFR, blood urea, baseline body weight, BP (supine and standing if feasible), urine output assessment (catheterise in ICU if needed for accurate measurement).
- RECOMMENDED: BNP or NT-proBNP (for diagnostic confirmation and trending), CBP, LFT, serum uric acid, random blood glucose, ECG (baseline rhythm, QTc — hypokalaemia from diuretics can prolong QTc), chest X-ray, echocardiography (if not done recently).
Specialist initiation: ADHF requiring IV diuretic therapy: typically managed by cardiologist or internal medicine physician in emergency/ICU setting. Can be initiated by trained emergency medicine physicians. ⚠️ Primary care initiation of IV diuretics is not recommended — refer to higher centre.
Indian guideline source: CSI (Cardiological Society of India) Heart Failure Management Guidelines (2018 / 2022 update); API Textbook of Medicine — Heart Failure chapter; ESC Heart Failure Guidelines (2021/2023) as adapted in Indian tertiary centre protocols (AIIMS, PGIMER, SCTIMST).
Key disease-specific safety warning: ⚠️ “Pseudo-Worsening Renal Function” (WRF) during decongestion: A modest rise in serum creatinine (0.3–0.5 mg/dL) during active diuresis in ADHF is common and does NOT necessarily indicate harm. This is often haemoconcentration-related “pseudo-WRF” reflecting successful intravascular volume reduction. It may also reflect improved renal venous decongestion (paradoxically beneficial long-term). ⛔ Do NOT reflexively discontinue torasemide for a modest creatinine rise if the patient is clinically improving (reducing congestion, declining weight, improving symptoms). Concern is warranted when: creatinine rises >0.5 mg/dL, oliguria develops (<0.5 mL/kg/h for >6 hours), or clinical improvement is absent despite rising creatinine. Consult cardiology/nephrology in such cases.
Common scenarios requiring dose adjustment:
- Concurrent ACEi/ARB/ARNI initiation: May improve diuretic efficacy → reduce torasemide dose by 25–50% to avoid over-diuresis. Monitor creatinine and K⁺ within 48–72 hours.
- ⚠️ Concurrent SGLT2 inhibitor initiation (dapagliflozin/empagliflozin): Additive natriuretic and diuretic effect. When initiating SGLT2i in a patient already on torasemide: reduce torasemide dose by 25–50% or monitor closely for over-diuresis. Under-recognition of this additive effect is an increasingly common prescribing error in India as SGLT2i use in HF expands (DAPA-HF, EMPEROR-Reduced evidence).
- Acute illness with vomiting/diarrhoea: Hold or reduce torasemide temporarily to prevent dehydration and AKI.
- Post-discharge: Patients often need lower diuretic doses than inpatient doses — reassess within 1–2 weeks post-discharge. Many readmissions are due to either over-diuresis (AKI, hypotension) or under-diuresis (recurrent congestion) from failure to adjust the outpatient dose.
- Indian summer months (April–June): Increased insensible losses from sweating compound diuretic-induced volume depletion → higher AKI and dehydration risk. Counsel patients to weigh daily and report reduced urine output or dizziness.
Common investigation misconception flag: ℹ️ BNP/NT-proBNP should NOT be used as the sole guide for diuretic dose titration. BNP levels correlate with ventricular wall stress and may remain elevated despite adequate decongestion (especially in HFpEF, renal impairment, atrial fibrillation, and obesity). Use clinical assessment (weight, JVP, lung auscultation, peripheral oedema, urine output) as the PRIMARY guide. BNP trending is a SUPPORTIVE adjunct, not the primary dose-adjustment criterion.
Dose escalation rationale: In ADHF patients with concurrent CKD (eGFR <30 mL/min), higher torasemide doses (50–200 mg) may be needed to achieve diuretic threshold concentrations at the tubular lumen. This dose escalation is for efficacy (overcoming reduced OAT-mediated drug delivery to the luminal NKCC2 target due to uraemic organic anion competition), NOT for safety/toxicity avoidance. Torasemide does not accumulate to systemically toxic levels because ~80% of its clearance is hepatic, not renal. Do NOT reflexively reduce the torasemide dose in CKD — this leads to therapeutic failure (persistent congestion).

Primary Indication 2: CHRONIC HEART FAILURE — Maintenance Diuresis

Clinical context: Euvolaemic or mildly hypervolaemic patient with chronic HF (HFrEF, HFmrEF, or HFpEF) requiring daily oral diuretic therapy to prevent fluid reaccumulation and maintain functional status. The therapeutic goal is the lowest effective dose that maintains stable weight and prevents congestive symptoms, while minimising electrolyte derangements and neurohormonal activation.

Route	Starting Dose	Titration	Usual Maintenance Dose	Maximum Dose	Clinical Notes
Oral (primary route for chronic maintenance)	Loop diuretic–naive: 5–10 mg once daily in the morning. Converting from oral furosemide: Use approximate equivalence (oral furosemide 40 mg ≈ oral torasemide 10–20 mg). Start at the equivalent dose; assess response over 3–5 days by daily weight. Converting from IV torasemide (post-ADHF): Same dose orally (1:1 ratio).	Increase by 5–10 mg increments every 2–3 days until target weight / euvolaemia is achieved. If weight is stable and patient is asymptomatic: do NOT increase. If weight trends up (>0.5 kg/day for ≥2 consecutive days): increase dose. Decrease by 5–10 mg increments if signs of over-diuresis appear (postural dizziness, rising creatinine, excessive thirst, weight dropping below target).	10–20 mg once daily (majority of patients). Some patients with advanced HF or concurrent CKD require 40–100 mg daily.	Max 200 mg/day orally. ℹ️ Doses >100 mg/day in stable chronic maintenance suggest diuretic resistance — reassess using the Diuretic Resistance Protocol above rather than continuing dose escalation.	Take in the morning (by 10 AM). Can be taken with or without food. Once-daily dosing is usually sufficient due to torasemide’s 6–8 hour duration + diminished post-diuretic rebound sodium retention compared to furosemide.
IV	Same as ADHF dosing (Primary Indication 1).	—	—	—	Chronic HF patients who develop acute decompensation → manage per ADHF protocol. Return to oral maintenance dose once stabilised.

Duration: Indefinite — lifelong, or for as long as the underlying HF condition persists and diuretic therapy is needed.

Mandatory Clinical Notes — Chronic HF Maintenance:

When to prefer torasemide over alternatives:
- (a) Advantage over furosemide for chronic oral maintenance: (i) Once-daily dosing with smoother diuretic profile. Furosemide’s shorter action (4–6 hours) creates a “sine wave” pattern: intense diuresis followed by a prolonged drug-free interval during which the kidney avidly reabsorbs sodium (post-diuretic sodium retention / diuretic braking). Torasemide’s 6–8 hour action reduces this rebound. (ii) Furosemide often requires BD dosing for adequate chronic control, reducing adherence. (iii) Torasemide’s more predictable oral bioavailability (~80–90% vs furosemide’s ~50%) provides more consistent diuresis day-to-day.
- (b) Torasemide is a reasonable first-line or switch option for chronic HF diuresis. Not categorically superior to furosemide in mortality outcomes (TRANSFORM-HF trial), but pharmacokinetically more predictable.
- © Compared against: Furosemide (most commonly used, NLEM-listed, cheapest), bumetanide (limited Indian availability).
- Practical Indian scenario where switching to torasemide is most justified: (i) Patient requires unpredictable dose escalation of oral furosemide, suggesting variable absorption. (ii) Patient requires BD furosemide and adherence is problematic — torasemide OD may improve adherence. (iii) Patient has persistent rebound oedema in the evening despite adequate morning furosemide dosing. (iv) IV-to-oral transition (torasemide’s 1:1 ratio is simpler).
When NOT to use: Same as ADHF — anuria, severe uncorrected hypovolaemia, HOCM with significant obstruction. Additionally: do not prescribe torasemide for chronic maintenance in patients whose HF is well-controlled on furosemide with no adherence or absorption concerns — switching for the sake of switching is not evidence-based.
NLEM India status: NOT NLEM. Furosemide is the NLEM-listed loop diuretic for chronic HF. In government hospitals and resource-limited settings, furosemide is the pragmatic first choice.
Time to expected clinical response: Stable weight and symptom control typically achieved within 1–2 weeks of appropriate dose titration with sodium restriction. If no improvement after 2 weeks of adequate dosing + verified sodium compliance: reassess diagnosis, evaluate for diuretic resistance.
Criteria for treatment failure: Progressive fluid retention despite adequate dose + sodium restriction. Weight gain >1 kg/week. Worsening NYHA class. Repeated ADHF hospitalisations. Action: (a) Add spironolactone/eplerenone if not already on MRA — mortality benefit in HFrEF (RALES, EMPHASIS-HF). (b) Add sequential nephron blockade (metolazone). © Reassess optimisation of neurohormonal blockade (ACEi/ARB/ARNI, beta-blocker, SGLT2i). (d) Consider advanced HF therapies.
Mandatory baseline investigations: MANDATORY: Serum electrolytes (K⁺, Na⁺, Mg²⁺), serum creatinine / eGFR, body weight. RECOMMENDED: BNP/NT-proBNP, echocardiography (if not done in past 12 months), serum uric acid, fasting glucose, LFT.
Specialist initiation: Initial HF diagnosis and treatment: cardiologist or trained internal medicine physician. Chronic maintenance dose adjustments: can be managed by trained primary care physician with periodic cardiologist review (every 3–6 months if stable). ℹ️ Patient-directed flexible dosing (“take an extra 10 mg if your weight goes up by >1 kg over 2 days; reduce by 10 mg if you feel dizzy or notice very low urine output”) can improve self-management. Implement only in patients who can reliably weigh themselves daily and understand the instructions. Requires adequate patient education — provide a simple written action plan.
Indian guideline source: CSI Heart Failure Guidelines; API Textbook of Medicine — Heart Failure chapter; adapted ESC HF Guidelines used at AIIMS, PGIMER, CMC Vellore.
Key disease-specific safety warning: ⚠️ SGLT2 inhibitor co-prescribing (see item 10 under ADHF). ⚠️ Potassium monitoring: When torasemide is combined with an MRA (spironolactone/eplerenone) — standard HF therapy — the net potassium effect depends on the balance of kaliuretic (torasemide) and potassium-sparing (MRA) forces. Monitor K⁺ within 1 week of initiation/dose change and at least monthly thereafter. Maintain K⁺ ≥4.0 mEq/L in HF patients (hypokalaemia + HF + digoxin = dangerous arrhythmia risk).
Common scenarios requiring dose adjustment: Same as ADHF (SGLT2i initiation, ACEi/ARB/ARNI initiation, inter-current illness, hot weather). Additionally: post-cardiac surgery (diuretic requirements often change significantly — reassess).
Common investigation misconception flag: ℹ️ Serum creatinine alone does NOT reflect diuretic adequacy. A patient with “normal” creatinine may be significantly congested (under-diuresed). Conversely, a modest creatinine rise (0.3 mg/dL) with clinical improvement (weight loss, reduced oedema) does not indicate diuretic harm. Use clinical assessment (weight, JVP, oedema, lung auscultation) as primary efficacy markers, not creatinine alone.
Dose escalation rationale: In chronic HF patients with concurrent CKD: higher doses are for efficacy (overcoming rightward shift of dose-response curve), not toxicity avoidance. See ADHF item 12. Additionally, in patients with very high urinary albumin excretion (concurrent nephrotic-range proteinuria): intraluminal albumin binding of torasemide further shifts the curve rightward, requiring higher doses.

Primary Indication 3: OEDEMA ASSOCIATED WITH RENAL DISEASE (Chronic Kidney Disease, Nephrotic Syndrome)

Clinical context: Fluid overload and oedema in CKD stages 3–5 (pre-dialysis) or nephrotic syndrome. Loop diuretics remain effective in CKD (unlike thiazides, which lose efficacy below eGFR ~30 mL/min) because the thick ascending limb handles ~25% of filtered sodium regardless of GFR, provided sufficient drug reaches the tubular lumen.

Route	Starting Dose	Titration	Usual Maintenance Dose	Maximum Dose	Clinical Notes
Oral	CKD eGFR 30–60: 10–20 mg OD. CKD eGFR <30: 20–50 mg OD (higher starting dose needed — see item 12 below). Nephrotic syndrome: 20–50 mg OD (higher starting dose due to intratubular albumin binding).	Increase by 10–20 mg increments every 2–3 days based on weight and oedema response.	20–100 mg OD (CKD stage 3–4). 50–200 mg OD (CKD stage 5, pre-dialysis with residual urine output). 20–100 mg OD (nephrotic syndrome).	Max 200 mg/day orally.	Morning dosing. Sodium restriction (<2 g/day) is essential — without it, loop diuretic efficacy is dramatically reduced.
IV bolus (for severe oedema, gut oedema, acute fluid overload)	20–50 mg IV (CKD 3–5); higher starting doses for lower eGFR.	Double the dose every 2–4 hours if inadequate urine response at 2-hour assessment.	20–100 mg IV OD or BD.	Max 200 mg/day IV.	⚠️ In anuric CKD 5 / ESRD patients: loop diuretics are INEFFECTIVE (no urine formation to act on). Do NOT prescribe. For oliguric CKD 5 with some residual urine output: a trial of high-dose IV torasemide (100–200 mg) may be attempted — if no response within 4 hours, accept futility and plan dialysis/ultrafiltration.
IV continuous infusion (for refractory oedema in CKD)	Loading dose 20 mg IV bolus → infusion at 5–10 mg/hour.	Titrate per urine output.	5–15 mg/hour.	As per ICU protocol; specialist supervision.	Reserve for hospitalised CKD patients with refractory oedema unresponsive to oral therapy and IV bolus.

Duration: As long as oedema management is needed. CKD: often indefinite until dialysis initiation or transplant. Nephrotic syndrome: until remission of proteinuria (steroid-responsive NS) or ongoing as maintenance in steroid-resistant disease.

Condition-Specific Notes — Nephrotic Syndrome:

ℹ️ Mechanism of diuretic resistance in nephrotic syndrome (distinct from CKD resistance): Massive proteinuria → albumin filtered through damaged glomerulus appears in the tubular lumen. Torasemide (>99% protein-bound in blood) reaches the lumen via OAT1/OAT3 → MRP4 active secretion in its FREE form. Once in the lumen, it encounters filtered albumin that binds torasemide, rendering it unavailable to act on NKCC2. This intraluminal drug binding is the primary mechanism — not reduced OAT-mediated delivery (OAT competition is more relevant in CKD without heavy proteinuria).

💡 Management of nephrotic diuretic resistance:

Higher bolus doses (overcome binding by mass action)
Continuous IV infusion (sustain luminal concentration above threshold despite binding)
Sequential nephron blockade: Metolazone 2.5–5 mg orally 30 minutes before torasemide. ⚠️ Monitor electrolytes Q6–12h when using this combination — profound hypokalaemia and hyponatraemia can develop within 24–48 hours.
Albumin co-infusion: IV albumin 20% (0.5–1 g/kg over 30 minutes) immediately before IV torasemide bolus. Rationale: transient increase in plasma albumin improves OAT-mediated drug delivery. API Textbook notes this as a therapeutic option. Evidence is mixed but widely practised at AIIMS and PGIMER nephrology departments.

Mandatory Clinical Notes — Renal Oedema:

When to prefer torasemide over alternatives:
- (a) Advantage over furosemide in CKD: More predictable oral absorption — particularly valuable in CKD patients with GI oedema or diabetic gastroparesis (common in diabetic CKD, which constitutes the majority of CKD in India per ICMR data). 1:1 oral-to-IV ratio simplifies transitions. Longer duration reduces rebound sodium retention.
- (b) Acceptable alternative first-line loop diuretic for CKD oedema. Furosemide remains most widely used and NLEM-listed.
- © Compared against: Furosemide (NLEM, cheapest, most widely available), bumetanide (limited Indian availability).
- No specific advantage over furosemide in CKD outcomes. Consider torasemide when: oral furosemide absorption is suspected to be unreliable, adherence with BD furosemide is problematic, or IV-to-oral transition is needed.
When NOT to use: Anuric patients (eGFR <5 mL/min with no residual urine output — loop diuretics are futile). Pre-renal AKI with hypovolaemia (correct volume first). Severe uncorrected electrolyte derangements (K⁺ <3.0 mEq/L, Na⁺ <120 mEq/L) — correct before initiating or escalating diuretics.
NLEM India status: NOT NLEM. Furosemide is NLEM-listed.
Time to expected clinical response: Diuretic onset per route (as above). Weight loss of 0.5–1 kg/day expected. If no weight loss after 48–72 hours of adequate dosing: evaluate for diuretic resistance per the Protocol above.
Criteria for treatment failure: No meaningful diuresis at ceiling dose (200 mg/day) despite sodium restriction. Action: Sequential nephron blockade (metolazone), IV route, albumin co-infusion (nephrotic), dialysis/ultrafiltration referral.
Mandatory baseline investigations: MANDATORY: Serum electrolytes (K⁺, Na⁺, Mg²⁺, Ca²⁺), serum creatinine / eGFR, body weight, urine output monitoring. RECOMMENDED: Spot urine Na⁺ (to assess sodium restriction compliance — urine Na⁺ >100 mEq/L suggests dietary non-compliance), serum albumin, serum uric acid, urine protein/creatinine ratio or 24-hour urine protein.
Specialist initiation: CKD stages 1–3 with mild oedema: trained primary care physician can manage. CKD stages 4–5 and nephrotic syndrome: nephrology specialist.
Indian guideline source: Indian Society of Nephrology (ISN-India) CKD management guidelines; API Textbook of Medicine — CKD and Nephrotic Syndrome chapters; AIIMS nephrology protocols.
Key disease-specific safety warning: ⚠️ Torasemide can mask declining renal function: Adequate urine output from loop diuretic may give false reassurance while eGFR is actually declining. Monitor creatinine/eGFR regularly — do NOT rely on urine output alone. ⚠️ Gout exacerbation risk: Torasemide increases proximal tubular uric acid reabsorption (competition for OAT-mediated secretion). CKD patients already have elevated uric acid → loop diuretics can precipitate acute gout, which is common in Indian CKD patients. Monitor serum uric acid periodically and treat/prophylax as needed.
Common scenarios requiring dose adjustment: ACEi/ARB initiation (recheck electrolytes and creatinine within 1–2 weeks). SGLT2i initiation (additive natriuresis — reduce torasemide by 25–50%). Inter-current illness with reduced oral intake (hold diuretic temporarily). Dialysis initiation (loop diuretics usually discontinued once anuric; may be continued for residual renal function in early dialysis).
Common investigation misconception flag: ℹ️ Spot urine sodium is more clinically useful than 24-hour urine sodium for quick outpatient assessment of dietary compliance. Urine Na⁺ <50 mEq/L suggests reasonable sodium restriction. Urine Na⁺ >100 mEq/L strongly suggests dietary sodium excess — the most common cause of apparent “diuretic resistance.”
Dose escalation rationale: ⚠️ This is the most critical dose-escalation concept for this indication. In CKD, torasemide dose escalation is needed for efficacy, NOT for safety/toxicity avoidance. The drug does NOT accumulate to systemically toxic levels (80% hepatic clearance). Rather, reduced OAT1/OAT3-mediated tubular secretion (due to competition from accumulated uraemic organic anions — hippurate, indoxyl sulfate) delivers less drug to the luminal site of action. Higher oral/IV doses are needed to overcome this pharmacodynamic resistance and achieve threshold luminal concentrations. ⛔ Do NOT reflexively reduce torasemide dose in CKD. This is the opposite of the correct action and will result in therapeutic failure (persistent oedema, worsening congestion). Dose REDUCTION is appropriate only if the patient develops signs of over-diuresis (hypovolaemia, pre-renal AKI, hypotension).

Primary Indication 4: OEDEMA ASSOCIATED WITH HEPATIC CIRRHOSIS (Ascites)

Clinical context: Fluid overload (ascites, pedal oedema) in chronic liver disease. Spironolactone is the FIRST-LINE diuretic for cirrhotic ascites; torasemide (or furosemide) is ADDED when spironolactone alone is insufficient.

⚠️ In cirrhotic ascites, torasemide must NEVER be used as monotherapy — always combine with spironolactone.

Route	Starting Dose	Titration	Usual Maintenance Dose	Maximum Dose	Clinical Notes
Oral (standard)	Torasemide 5–10 mg OD + Spironolactone 50–100 mg OD. Maintain approximate 1:5 torasemide-to-spironolactone ratio (analogous to the furosemide 40 mg : spironolactone 100 mg ratio recommended by INASL/AASLD).	Increase both drugs together every 3–5 days if weight loss is inadequate (< 0.5 kg/day with peripheral oedema; <0.25 kg/day with ascites only). Torasemide increments: 5–10 mg. Spironolactone increments: 50 mg.	Torasemide 10–20 mg OD + Spironolactone 100–200 mg OD.	Torasemide: Max 40 mg/day (some guidelines allow up to 80 mg/day, but hepatic encephalopathy and electrolyte disturbance risk rises steeply beyond 40 mg). Spironolactone: Max 400 mg/day.	⚠️ Maximum weight loss targets: With peripheral oedema: ≤1 kg/day. Without peripheral oedema (ascites only): ≤0.5 kg/day. Faster fluid removal exceeds ascitic fluid reabsorption rate → intravascular depletion → hepatorenal syndrome risk.
IV (tense ascites with GI oedema, or when oral absorption unreliable)	10–20 mg IV OD (always with concurrent oral spironolactone).	As above.	10–20 mg IV OD.	Max 40 mg/day IV.	Short-term use only (to establish initial diuresis). Transition to oral as soon as feasible.

Duration: As long as ascites management is needed. Often indefinite in decompensated cirrhosis until transplant.

Mandatory Clinical Notes — Cirrhotic Ascites:

When to prefer torasemide over furosemide in cirrhosis:
- (a) Advantage: Better oral bioavailability (~80–90% vs ~50%) — relevant because cirrhotic patients often have intestinal wall oedema from portal hypertension that impairs furosemide absorption. Longer duration provides smoother natriuresis. ℹ️ Torasemide’s half-life is further prolonged in cirrhosis (7–8 hours due to reduced CYP2C9 metabolism), extending the effective diuretic window per dose.
- (b) Acceptable alternative to furosemide. Indian hepatology practice predominantly uses furosemide (NLEM-listed, familiar). INASL guidelines (2019) mention furosemide as the standard loop diuretic for ascites but do not specifically recommend against torasemide.
- © Compared against: Furosemide (NLEM, most commonly used), bumetanide (rarely used in India for this indication).
When NOT to use:
- ⛔ Hepatic coma or pre-coma (diuretic-induced dehydration and electrolyte disturbances precipitate/worsen hepatic encephalopathy).
- ⛔ Active gastrointestinal bleeding (volume depletion worsens haemorrhagic shock).
- ⛔ Severe hyponatraemia (Na⁺ <120 mEq/L) — hold ALL diuretics, restrict free water.
- ⛔ Hepatorenal syndrome (HRS) type 1 — diuretics are contraindicated; treatment is albumin + terlipressin.
- ⛔ Active spontaneous bacterial peritonitis (SBP) — hold diuretics during SBP treatment (increased renal impairment risk). Resume after SBP resolution.
- ⛔ Torasemide monotherapy (without spironolactone) in cirrhosis — ineffective due to overwhelming distal aldosterone-mediated sodium reabsorption.
NLEM India status: NOT NLEM. Furosemide and spironolactone are both NLEM-listed.
Time to expected clinical response: Weight loss of 0.25–0.5 kg/day (ascites only) or 0.5–1 kg/day (with peripheral oedema) over 1–2 weeks. If no response after 5–7 days: consider refractory ascites.
Criteria for treatment failure (Refractory ascites — INASL definition): Ascites that cannot be mobilised or recurs despite maximum diuretic therapy (torasemide 40 mg + spironolactone 400 mg) AND strict sodium restriction (<2 g/day). OR: Diuretic-induced complications (encephalopathy, renal impairment, hyponatraemia <125 mEq/L, K⁺ <3.0 or >6.0 mEq/L) precluding dose escalation. Action: Large-volume paracentesis (LVP) with albumin infusion (6–8 g albumin per litre removed beyond 5 L). TIPS in selected patients. Liver transplant evaluation.
Mandatory baseline investigations: MANDATORY: Serum electrolytes (K⁺, Na⁺), serum creatinine / eGFR, LFT (including serum albumin — critical for assessing protein binding and disease severity), body weight. RECOMMENDED: Diagnostic paracentesis with ascitic fluid analysis (cell count, albumin — SAAG ≥1.1 g/dL confirms portal hypertension; culture if SBP suspected), spot urine Na⁺, serum ammonia (if encephalopathy suspected).
Specialist initiation: Hepatologist or gastroenterologist. Stable patients on established regimen: primary care can manage with periodic specialist review.
Indian guideline source: INASL (Indian National Association for Study of the Liver) Guidelines on Management of Ascites in Cirrhosis (2019); API Textbook of Medicine — Cirrhosis and Ascites chapters.
Key disease-specific safety warning: ⚠️ Hepatic encephalopathy: Diuretic-induced hypovolaemia, hypokalaemia, and metabolic alkalosis all increase renal ammonia production and decrease hepatic ammonia clearance → precipitate/worsen hepatic encephalopathy. Monitor mental status at EVERY visit. If new confusion, asterixis, or altered sensorium: ⛔ STOP ALL diuretics immediately, check electrolytes and ammonia, hydrate, initiate lactulose ± rifaximin. Resume diuretics cautiously at lower dose only after encephalopathy resolves. ⚠️ Muscle cramps: Prevalence ~50–70% in cirrhotic patients on diuretics. Management: correct electrolytes (Mg²⁺, K⁺), consider baclofen 10 mg TDS (used at some Indian hepatology centres), albumin infusion.
Common scenarios requiring dose adjustment: After LVP (hold diuretics 24–48 hours, then resume at reduced dose). AKI during diuretic therapy (hold, hydrate, rule out HRS). Post-TIPS (diuretic requirements often decrease substantially — reduce doses, monitor for over-diuresis).
Common investigation misconception flag: ℹ️ Serum creatinine is UNRELIABLE in cirrhosis as a true GFR marker. Cirrhotics have low muscle mass (low creatinine production) and high bilirubin (Jaffé assay interference). A “normal” creatinine of 1.0 mg/dL in a cachectic cirrhotic patient may represent eGFR <30 mL/min. Use cystatin C–based eGFR if available. If unavailable: use measured 24-hour creatinine clearance or clinical judgement (urine output, fluid responsiveness).
Dose escalation rationale: In cirrhosis, diuretic resistance is primarily pharmacodynamic (overwhelmingly active RAAS/aldosterone axis driving distal sodium reabsorption, reduced effective circulating volume, reduced renal perfusion) rather than pharmacokinetic. Higher doses of torasemide alone are often insufficient — adding/escalating spironolactone is more effective than escalating the loop diuretic. The ceiling dose for torasemide in cirrhosis (40 mg) is lower than in CKD/HF (200 mg) because of the heightened risk of electrolyte derangement and encephalopathy in cirrhosis.

Primary Indication 5: HYPERTENSION

Clinical context: Torasemide at low doses (2.5–10 mg) has an antihypertensive effect through vasodilation and mild natriuresis, distinct from its high-dose diuretic effect. Loop diuretics are NOT first-line antihypertensives in most patients — thiazide/thiazide-like diuretics (chlorthalidone, hydrochlorothiazide, indapamide) are preferred based on stronger outcome data. Torasemide is reserved for hypertension in specific clinical scenarios.

Route	Starting Dose	Titration	Usual Maintenance Dose	Maximum Dose	Clinical Notes
Oral (only route for chronic hypertension)	2.5 mg once daily in the morning. Elderly or those prone to orthostatic hypotension: start at 2.5 mg, titrate cautiously.	Increase by 2.5 mg increments every 4–6 weeks. ⚠️ Do NOT titrate more frequently — full antihypertensive response takes 4–6 weeks. (This is slower than the diuretic dose titration, which can be adjusted every 2–3 days.)	2.5–5 mg once daily.	Max 10 mg/day for hypertension. ℹ️ Doses >10 mg produce significant diuresis without proportional additional BP reduction — the drug shifts from antihypertensive to diuretic mode.	Morning dosing. At these low doses, significant diuresis is usually not problematic, but some patients notice mildly increased urination in the first 2–3 weeks (attenuates with continued use).

Duration: Indefinite (hypertension is a chronic condition).

Antihypertensive Class-Specific Items:

BP Target Guidance (per IGH-IV, CSI/HSI recommendations)

Patient Category	Target BP	Source
Uncomplicated hypertension	<140/90 mmHg (office); <130/80 if tolerated	IGH-IV (2019); API Textbook
Diabetes mellitus	<130/80 mmHg	IGH-IV; RSSDI guidelines
CKD with proteinuria (>0.5 g/day)	<130/80 mmHg	ISN-India; KDIGO adapted
Post-stroke (chronic)	<130/80 mmHg	IGH-IV
Elderly (60–80 years)	<140/90 mmHg; accept <150/90 if tolerability issues	IGH-IV
Very elderly (>80 years)	<150/90 mmHg (avoid aggressive lowering — fall and syncope risk)	IGH-IV; HYVET trial
HF with hypertension	<130/80 mmHg (but SBP must remain >100 mmHg)	CSI HF guidelines

Compelling Indications for Torasemide (scenarios where torasemide offers specific advantage over thiazide diuretics)

Compelling Indication	Rationale	Evidence Level
Hypertension + CKD with eGFR <30 mL/min	Thiazide diuretics lose antihypertensive and diuretic efficacy below eGFR ~30 mL/min (DCT handles only ~5% of sodium). Loop diuretics retain efficacy because TAL handles ~25% of sodium. Torasemide preferred within the loop class due to predictable oral bioavailability.	Moderate (IGH-IV, KDIGO — guideline-endorsed)
Hypertension + concurrent fluid overload (HF, nephrotic syndrome, CKD)	When BP control AND volume management are both needed, a loop diuretic addresses both goals with one drug.	Practice-based
Resistant hypertension (≥3 drugs at optimal doses including a diuretic, BP not at target)	If already on a thiazide and eGFR <30: replace thiazide with loop diuretic. If eGFR >30 but thiazide-related adverse effects prevent adequate dosing: switch to loop diuretic.	Moderate (IGH-IV, AHA Scientific Statement 2018)

ℹ️ For most patients with uncomplicated hypertension and eGFR >30: Thiazide-type diuretics (chlorthalidone 12.5–25 mg, hydrochlorothiazide 12.5–25 mg, or indapamide 1.5 mg) are preferred based on stronger outcome data (ALLHAT, SHEP, HYVET). Torasemide should NOT be used as a first-line antihypertensive in this population.

Combination Therapy Positioning:

Step	Approach
Monotherapy	NOT first-line for uncomplicated hypertension. Preferred first-line: ACEi/ARB, CCB (amlodipine), or thiazide-type diuretic.
Dual therapy	Add torasemide as a second agent only if: (a) eGFR <30 (thiazide ineffective), (b) concurrent fluid overload, © thiazide-related adverse effects (hyponatraemia, symptomatic hyperuricaemia) are intolerable.
Triple therapy	ACEi/ARB + CCB + diuretic. Torasemide replaces thiazide when eGFR <30. ⛔ Do NOT use both thiazide + loop diuretic simultaneously for routine hypertension (sequential nephron blockade creates excessive diuresis and electrolyte crises — acceptable only for short-term oedema management).
Combinations to AVOID	⛔ Torasemide + thiazide for chronic hypertension (excessive, dangerous). ⛔ Torasemide + metolazone for hypertension (metolazone is for acute/subacute diuretic resistance only).

First-Dose Hypotension Risk:

Mild first-dose postural hypotension is possible, especially in: volume-depleted patients, elderly, those on concurrent ACEi/ARB, and patients starting from a low baseline BP. Risk is lower than with ACEi/ARBs or alpha-blockers, but advise patients to rise slowly from sitting/lying during the first few days of therapy. Monitor standing BP at the first follow-up visit (1–2 weeks).

Withdrawal / Rebound Risk:

No rebound hypertension upon torasemide discontinuation (unlike clonidine or beta-blockers). However, fluid reaccumulation will occur in patients with concurrent oedema-forming conditions. If stopping torasemide: no tapering needed. BP will gradually rise to pre-treatment level over days to weeks.

Home BP Monitoring Guidance:

Recommended for all hypertensive patients on torasemide. Target home BP: <135/85 mmHg (equivalent to office <140/90). Advise morning measurement (before medication and breakfast) and evening measurement. Record in a diary for physician review.

Orthostatic BP Check:

Recommended at baseline and at each dose change visit. Measure BP supine (after 5 minutes rest) and standing (at 1 minute and 3 minutes). Orthostatic drop ≥20 mmHg systolic or ≥10 mmHg diastolic: consider dose reduction, slower titration, or alternative agent. Especially important in elderly patients on concurrent vasodilators.

Mandatory Clinical Notes — Hypertension:

When to prefer torasemide over alternatives:
- (a) Advantage: Only when thiazide diuretics are ineffective (eGFR <30), not tolerated (severe hyponatraemia, symptomatic hyperuricaemia with gout), or when concurrent fluid overload needs management. No specific advantage over thiazides for uncomplicated hypertension with eGFR >30.
- (b) NOT first-line. Alternative agent for specific scenarios.
- © Compared against: Chlorthalidone (preferred thiazide-type per ALLHAT data), hydrochlorothiazide, indapamide (all preferred for uncomplicated hypertension), furosemide (alternative loop diuretic — less commonly used for chronic hypertension due to BD dosing requirement and shorter duration).
When NOT to use: Uncomplicated hypertension with eGFR >30 and no fluid overload. Isolated systolic hypertension in elderly (CCB or thiazide preferred). Hypertensive emergency (torasemide is NOT an acute BP-lowering drug).
NLEM India status: NOT NLEM. Hydrochlorothiazide (NLEM-listed diuretic for hypertension). Chlorthalidone and furosemide also NLEM-listed.
Time to expected clinical response: 4–6 weeks for full antihypertensive effect. Do NOT assess response or escalate dose before 4 weeks.
Criteria for treatment failure: BP not at target after 6–8 weeks on maximum antihypertensive dose (10 mg/day). Action: Add second agent (ACEi/ARB or CCB). Reassess for secondary causes of hypertension.
Mandatory baseline investigations: MANDATORY: BP measurement (office + home if available), serum electrolytes (K⁺, Na⁺), serum creatinine / eGFR, fasting blood glucose. RECOMMENDED: Fasting lipid profile, serum uric acid, urine routine (protein, glucose), ECG, echocardiography if LVH suspected.
Specialist initiation: Can be initiated by any registered medical practitioner. Specialist referral if resistant hypertension (uncontrolled on ≥3 drugs at optimal doses including a diuretic).
Indian guideline source: IGH-IV (Indian Guidelines on Hypertension, 4th edition, 2019); CSI/HSI recommendations; API Textbook — Hypertension chapter.
Key disease-specific safety warning: ⚠️ Hypokalaemia-induced arrhythmias: Torasemide-induced hypokalaemia prolongs QTc and predisposes to ventricular arrhythmias (torsades de pointes), especially with concurrent digoxin, antiarrhythmics, or other QT-prolonging drugs. Monitor K⁺ within 1–2 weeks of initiation and periodically. Maintain K⁺ ≥4.0 mEq/L in patients at arrhythmia risk.
Common scenarios requiring dose adjustment: ACEi/ARB initiation (additive hypotension). NSAID use (blunts antihypertensive effect — see Interactions, Part 4). Hot weather (dehydration risk). Inter-current illness with reduced oral intake.
Common investigation misconception flag: Not specifically applicable for the hypertension indication.
Dose escalation rationale: Not applicable for hypertension — doses above 10 mg/day do not provide additional BP reduction and shift the drug into diuretic mode.

Secondary Indications — Adults Only (Off-label)

Secondary Indication 1: ACUTE HYPERCALCAEMIA — Adjunct to IV Saline Hydration

OFF-LABEL — used as class effect of loop diuretics

Parameter	Detail
Indication	Acute symptomatic hypercalcaemia (corrected Ca²⁺ >12 mg/dL with symptoms, or >14 mg/dL regardless). Loop diuretics increase renal calcium excretion by inhibiting NKCC2 in the TAL, disrupting the lumen-positive transepithelial potential that drives paracellular Ca²⁺ reabsorption.
Route	IV (preferred) or oral
Starting dose	20–40 mg IV AFTER adequate saline hydration (1–2 L NS over 2–4 hours). ⛔ Do NOT administer loop diuretic BEFORE adequate hydration — worsens dehydration and can paradoxically worsen hypercalcaemia by reducing GFR and filtered calcium load.
Titration	Repeat 20–40 mg IV every 6–8 hours based on urine output and serum calcium response.
Maximum dose	Max 200 mg/day.
Duration	Short-term only (24–72 hours) until bisphosphonate or definitive therapy takes effect.
Specialist only	⚠️ Recommended — endocrinologist or internist.
Evidence basis	Class effect of loop diuretics, established in textbooks and clinical practice. No RCTs specifically for torasemide; most evidence is with furosemide.
Level of evidence quality	Weak — expert consensus. Furosemide is the standard loop diuretic used for this indication.

Key Notes:

Modern hypercalcaemia management emphasises IV saline hydration and bisphosphonates (zoledronic acid 4 mg IV single dose). Loop diuretics are now considered adjunctive — used primarily to prevent volume overload from aggressive hydration or to enhance calciuresis in severe/refractory cases.
Monitor K⁺, Mg²⁺, Na⁺, Ca²⁺ every 4–6 hours during active calciuresis.
Zoledronic acid is available in India (NLEM-listed for malignancy-associated hypercalcaemia).

Secondary Indication 2: RESISTANT HYPERTENSION — Loop Diuretic Switch Strategy

OFF-LABEL but accepted standard practice in India — endorsed by IGH-IV and international expert statements

Parameter	Detail
Indication	Resistant hypertension: BP above target despite ≥3 antihypertensives at optimal doses (including a diuretic) + confirmed adherence + excluded secondary causes. Specifically when: thiazide is being used but eGFR <30, OR thiazide-related adverse effects prevent adequate dosing.
Route	Oral
Starting dose	5–10 mg OD (replacing the thiazide — do NOT add to it for routine hypertension)
Titration	Every 4–6 weeks by 2.5–5 mg increments
Maintenance	5–10 mg OD
Maximum dose	20 mg/day (higher doses shift into diuretic territory)
Specialist only	⚠️ Recommended — hypertension specialist or cardiologist.
Evidence basis	IGH-IV (2019); AHA Scientific Statement on Resistant Hypertension (2018); observational data; expert consensus.
Level of evidence quality	Moderate — guideline-endorsed, observational data.

Key Notes:

When replacing thiazide with torasemide for resistant hypertension: cross-titrate (start torasemide, then discontinue thiazide after 1–2 weeks once torasemide effect is established) to avoid BP rebound during transition.
Monitor electrolytes closely during the switch period.

MISSED DOSE / DELAYED DOSE GUIDANCE

Dosing Frequency	Threshold Guidance
Once-daily (standard for all indications)	If <12 hours late (i.e., remembered before ~6 PM for a morning dose): Take the missed dose immediately, then resume usual timing the next morning. If >12 hours late (evening or nighttime): Skip the missed dose entirely. Take the next dose at the usual time the following morning. Rationale for skipping evening dose: Taking torasemide in the evening causes nocturia, disrupts sleep, increases fall risk (especially in elderly). The clinical consequence of one missed dose — modest fluid retention (0.5–1 kg) — is correctable with the next morning’s dose. ⛔ Never take a double dose the following morning to “catch up.”
Twice-daily (rare — used temporarily in refractory oedema)	If <4 hours late: Take immediately. If >4 hours late: Skip that dose; take the next scheduled dose. Do not double up.
IV (hospital-administered)	Per nursing schedule. If a dose is delayed by >2 hours, notify prescribing clinician. Document the delay. In critically ill patients, even short delays reduce cumulative natriuresis — minimise dose omissions.

Narrow therapeutic index / steady-state considerations:

Torasemide is NOT a narrow therapeutic index drug. It does NOT require steady-state maintenance for efficacy. Each dose produces an independent diuretic response. Therefore:

A single missed dose does NOT cause dangerous rebound (unlike clonidine or beta-blockers).
No re-titration is needed after a single missed dose.
No rebound hypertension occurs upon missing a dose.

Prolonged Non-Adherence / Drug Holiday Guidance:

Duration of Missed Therapy	Clinical Consequence	Action
1–2 days	Mild fluid reaccumulation (0.5–2 kg weight gain). Usually asymptomatic in stable patients.	Resume at previous dose. No re-titration. Weigh daily for 3 days to confirm return to baseline.
3–7 days	Moderate fluid reaccumulation. Possible return of ankle oedema, mild dyspnoea (HF), or increasing abdominal girth (cirrhosis).	Resume at previous dose. Monitor weight closely for 3–5 days. May need a brief period of slightly higher dose (e.g., 50% increase for 2–3 days) to re-establish euvolaemia, then return to maintenance dose.
>7 days	Significant fluid reaccumulation likely. Risk of acute decompensation (HF → pulmonary oedema; cirrhosis → tense ascites).	⚠️ Clinical reassessment recommended before resuming. Check serum electrolytes and creatinine (baseline may have changed). Resume at previous dose or slightly higher if clinically congested. If severely decompensated: may require IV therapy and hospitalisation.

ℹ️ No rebound hypertension on torasemide discontinuation (unlike clonidine, beta-blockers). However, BP will gradually return to pre-treatment levels over days to weeks if the drug is stopped.

ℹ️ No immunogenicity risk from drug holidays (torasemide is a small molecule, not a biologic).

RECONSTITUTION / ADMINISTRATION QUICK REFERENCE

(For Nurses & Clinical Staff)

IV ADMINISTRATION

A. IV Bolus (Standard Method):

Step	Detail
Reconstitution	NOT required. Torasemide injection is supplied as a ready-to-use clear, colourless solution (10 mg/mL concentration in 2 mL or 4 mL ampoules). No reconstitution or dilution is needed for bolus administration. Inspect visually before use — ⛔ discard if cloudy, discoloured, or contains particulate matter.
Rate of administration	Inject slowly over 2–5 minutes. ⚠️ Do NOT administer as a rapid IV push — rapid injection increases the risk of ototoxicity (transient or permanent hearing loss, tinnitus). This risk is dose-dependent and potentiated by concurrent aminoglycosides and renal impairment.
Infusion pump required?	Not required for bolus injection (syringe administration via vein or running IV line).
Maximum single bolus	100 mg (5 mL of 10 mg/mL solution, or split from two ampoules). Administer higher daily doses as divided boluses or continuous infusion.

B. IV Continuous Infusion (ICU / Diuretic Resistance Protocol):

Step	Detail
Dilution	Withdraw the calculated dose from ampoule(s). Dilute in 50–250 mL of compatible IV fluid.
Compatible IV fluids	0.9% NaCl (NS) — preferred. 5% Dextrose (D5W) — compatible.
Incompatible solutions	⛔ Alkaline solutions — torasemide solution has acidic pH (~6.0–8.5); mixing with strongly alkaline solutions may cause precipitation. ⛔ Ringer’s Lactate — limited compatibility data; prefer NS or D5W.
Final concentration	Typically 0.4–1.0 mg/mL (flexible based on total dose and fluid volume limitations).
Rate of administration	Loading dose: 10–20 mg IV bolus over 2–5 minutes. Then infusion: 5–20 mg/hour. Titrate based on urine output target (typically 100–200 mL/hour in active decongestion).
Infusion pump	MANDATORY for continuous infusion.

Weight-Based Dosing Calculation Example (for ICU continuous infusion):

Patient: 70 kg, decompensated HF, CKD stage 3b (eGFR 35 mL/min), poor response to IV bolus torasemide 40 mg.
Decision: Initiate continuous infusion.

Loading dose: 20 mg IV bolus (2 mL of 10 mg/mL solution) over 2–5 minutes.
Infusion preparation: Draw 200 mg torasemide (five 4 mL ampoules of 10 mg/mL = 20 mL) into 180 mL NS → total volume 200 mL, concentration = 1 mg/mL.
Start infusion at 10 mL/hour = 10 mg/hour.
Titrate upward by 5 mL/hour (5 mg/hour) increments every 2–4 hours if urine output remains below 100 mL/hour.
Maximum: 20 mL/hour = 20 mg/hour.
Daily total: 20 mg loading + (10 mg/hour × 24h) = 260 mg/day (specialist supervision required for doses exceeding the standard 200 mg/day ceiling in this context).

STABILITY AFTER DILUTION

Solution	Room Temperature (≤25°C)	Refrigerated (2–8°C)	Notes
Undiluted ampoule (unopened)	Stable per manufacturer’s shelf life (typically 24–36 months). Store below 30°C. Protect from light. Do not freeze.	Not routinely refrigerated.
Diluted in 0.9% NaCl	24 hours	48 hours	Protect from direct light during infusion.
Diluted in D5W	24 hours	48 hours

⚠️ Indian conditions note: In non-air-conditioned wards during Indian summer (ambient temperature >30–35°C), reduce room-temperature stability assumption to 12–18 hours for diluted solutions. Prepare fresh solutions for each 12-hour infusion period if refrigerated storage is unavailable at ward level.

Light protection: Protect from prolonged direct sunlight during storage and infusion. Amber-coloured tubing is NOT mandatory for short-term infusion. ⛔ Discard if solution becomes cloudy, discoloured, or contains visible particulate matter.

Y-SITE / LINE COMPATIBILITY

Compatible	Known Incompatibilities
NS, D5W, heparin, potassium chloride. Limited formal Y-site compatibility data available for torasemide specifically — verify locally against manufacturer’s insert before co-infusion.	⛔ Highly alkaline solutions — risk of precipitation. ⛔ Do NOT mix with other drugs in the same syringe unless specific compatibility data confirms safety. When uncertain: flush line with 10–20 mL NS between torasemide and any other drug.

ORAL ADMINISTRATION

Parameter	Detail
Swallowing	Tablets can be swallowed whole with water. Not scored for splitting on most brands (verify brand-specific tablet design).
Crush/Split	✅ Torasemide immediate-release tablets can be crushed for patients unable to swallow whole tablets. Crush and disperse in 10–15 mL water. Administer immediately (do not store crushed suspension).
Enteral tube compatibility	✅ Compatible with NG/OG tube. Crush tablet, disperse in 15–30 mL water, administer via tube, flush with 15–30 mL water post-administration. ℹ️ No oral liquid/suspension formulation is marketed in India — crushing and dispersing the tablet is the only option for enteral tube administration.
Timing relative to meals	Can be taken with or without food. Food delays peak absorption by ~30 minutes without reducing total bioavailability. For patients with nausea: take with food. For patients needing rapid diuretic onset (e.g., worsening dyspnoea): take on empty stomach. Counsel patients to take consistently (always with food or always without) for predictable diuresis timing.
Time of day	Morning dosing (by 10 AM) to confine diuresis to daytime hours. Second dose (if needed for refractory oedema, prescribed temporarily): early afternoon (by 2–3 PM at latest). ⛔ Avoid evening/night dosing — causes nocturia, disrupts sleep, increases fall risk.

STORAGE

Condition	Guidance
Tablets (before opening)	Store below 25–30°C. Protect from moisture. Keep in original blister pack until use. Shelf life: per manufacturer (typically 24–36 months).
Injection ampoules (before opening)	Store below 30°C. Protect from light. Do not freeze.
After opening ampoule	Use immediately. Single-use ampoule — ⛔ discard any unused portion. No preservative in most formulations. Do NOT store opened ampoules for later use.
Cold-chain requirement	NOT a cold-chain drug. Stable at Indian room temperatures (up to 30°C) in both tablet and injectable forms. No special cold-chain measures needed.

PAEDIATRIC DOSING (Specialist Only)

General Notes

Regulatory status in India: Torasemide does NOT have a specific CDSCO-approved paediatric indication or dosing recommendation. All paediatric use is OFF-LABEL.
Standard of care: Furosemide is the established first-line loop diuretic in paediatric practice across India, endorsed by IAP guidelines and MoHFW protocols. Torasemide is NOT included in IAP drug lists, WHO EML for Children, or Indian paediatric treatment guidelines.
Evidence base: Limited to small observational studies, case series, and pharmacokinetic extrapolation from adult data. No paediatric randomised controlled trials establish safety and efficacy of torasemide in children. Level of evidence: Weak.
NLEM India status: Not listed for paediatric use.

Formulation suitability for children:

Only tablet formulations (5 mg, 10 mg, 20 mg, 40 mg, 100 mg) are marketed in India. No commercially available oral liquid, suspension, or dispersible tablet formulation exists in the Indian market.
Tablets may be crushed and dispersed in a small volume of water (5–10 mL) for younger children unable to swallow tablets whole. However, stability and bioequivalence data for such extemporaneous preparations are lacking; use within 15 minutes of preparation.
Palatability: Torasemide tablets have a bitter taste. If crushed, mixing with a small volume of fruit juice or honey (in children >1 year) may improve acceptance, but this is not formally studied and may not fully mask the taste.
The 5 mg tablet is the smallest available strength. For children requiring doses <5 mg, accurate subdivision of tablets is unreliable — this limits use in young/small children.

Age-specific pharmacokinetic considerations:

CYP2C9 (the primary metabolising enzyme for torasemide) is immature at birth, reaching approximately 20–30% of adult catalytic activity by 1 month of age and near-adult levels by 1–3 years.
In neonates and young infants (<6 months), significantly reduced CYP2C9 activity results in unpredictable hepatic clearance and prolonged half-life of torasemide.
Protein binding may be lower in neonates and infants (lower albumin concentrations, competitive displacement by bilirubin), increasing the free drug fraction and potentially amplifying both therapeutic and adverse effects.
Renal maturation (GFR, tubular secretory function) is incomplete at birth and reaches adult-equivalent values (normalised to BSA) by approximately 1–2 years. This affects drug delivery to the tubular site of action via OAT-mediated secretion.
Net effect in young infants: Combination of immature hepatic metabolism AND immature renal secretion makes torasemide pharmacokinetics doubly unpredictable below 1 year of age.

Safety monitoring requirements specific to paediatric use:

Serum electrolytes (K⁺, Na⁺, Mg²⁺, Ca²⁺) — baseline and within 48–72 hours of initiation, then weekly during dose titration
Renal function (serum creatinine, blood urea) — baseline and weekly during titration
Daily weight and strict fluid balance charting (input/output)
Blood pressure monitoring at every dose change (risk of hypotension, particularly in volume-depleted children)
Growth monitoring (height, weight percentiles) for chronic use — no specific growth suppression data for torasemide, but chronic diuretic-related electrolyte derangement can impair growth
Urine output documentation — target 1–2 mL/kg/hour in acute settings

Minimum age: No formally established minimum age. Based on CYP2C9 maturation data, use below 1 year of age is inadvisable except in extraordinary circumstances. Use only under paediatric subspecialist supervision (paediatric cardiologist, paediatric nephrologist) when furosemide is unavailable, not tolerated, or there is a specific clinical rationale for switching.

When to consider torasemide over furosemide in children (all scenarios below have limited evidence):

Poor or erratic oral absorption of furosemide (furosemide oral bioavailability ~40–60%, highly variable, vs torasemide ~80%, more consistent) — relevant when transitioning a stable child from IV to oral diuretic and consistent oral diuresis is needed
Documented furosemide hypersensitivity (⚠️ cross-reactivity between loop diuretics containing sulfonamide moiety is possible — see Contraindications in Part 4)
Clinical suspicion of excessive post-diuretic rebound sodium retention with furosemide (torasemide’s longer duration of action may theoretically reduce this, though paediatric evidence is absent)

ℹ️ None of these scenarios have robust paediatric evidence supporting the switch. The decision to use torasemide over furosemide in a child must be made by a specialist after individualised benefit-risk assessment.

Neonatal Dosing

⚠️ Neonatal use — NICU supervision only

No established neonatal dosing regimen for torasemide exists.

Torasemide is NOT a preferred agent for neonatal fluid management. Furosemide (1 mg/kg IV/oral, up to 2 mg/kg in preterm) and, in select cases, chlorothiazide or hydrochlorothiazide, are the standard diuretics in neonatal practice with established dosing and safety data.

Rationale for avoidance in neonates:

Factor	Clinical Concern
CYP2C9 immaturity	Only ~20–30% of adult activity at birth; results in markedly prolonged half-life and risk of unpredictable accumulation
Lower protein binding	Reduced albumin, bilirubin displacement → increased free drug fraction → amplified pharmacological and toxic effects
Immature renal tubular secretion	Reduced OAT1/OAT3-mediated secretion into tubular lumen → unpredictable diuretic response
No PK studies	No pharmacokinetic studies of torasemide have been conducted in neonates (preterm or term)
No clinical experience	Case reports/series in neonates are essentially absent
Oral-only availability in India	No IV torasemide formulation available in India; sick neonates typically require IV diuretics

Exceptional/last-resort use only:

If torasemide is the only available loop diuretic in an emergency situation where furosemide is genuinely unobtainable, an extrapolated dose based on pharmacokinetic first principles would be:

Gestational Age	Extrapolated Dose	Frequency	Route
Term neonates (≥37 weeks GA)	0.05–0.1 mg/kg/dose	Once daily	Oral (crushed tablet dispersed in small volume of expressed breast milk or sterile water)
Preterm neonates (<37 weeks GA)	⛔ Not recommended	—	—

⚠️ Critical caveats:

“Based on extrapolation from limited adult pharmacokinetic data and CYP2C9 ontogeny principles; no validated neonatal dosing regimen exists.”
NICU supervision only — continuous cardiorespiratory monitoring, strict intake/output, daily electrolytes
This is an exceptional/last-resort option, NOT a preferred agent
Onset of action following oral administration in neonates is unpredictable
Monitor: serum electrolytes (K⁺, Na⁺, Ca²⁺), urine output, blood pressure, weight — at least every 12 hours initially
Discontinue and switch to furosemide as soon as it becomes available

Primary Indications — Paediatric (All OFF-LABEL)

ℹ️ All paediatric indications for torasemide are OFF-LABEL in India. Furosemide remains the standard first-line loop diuretic in paediatric practice for all oedematous conditions. Torasemide use in children requires paediatric specialist decision-making.

1. Oedema Associated with Congestive Heart Failure — Paediatric

[OFF-LABEL | Level of evidence: Weak — case series and PK extrapolation only]

Weight-based dosing table:

Weight Category	Starting Dose	Titration	Usual Maintenance	Max Single Dose	Max Daily Dose
10–20 kg (typically ~1–5 years)	0.1 mg/kg OD orally	Increase by 0.1 mg/kg every 2–3 days based on response and electrolytes	0.1–0.2 mg/kg OD	0.4 mg/kg (max 5 mg)	0.4 mg/kg (max 5 mg)
20–40 kg (typically ~5–12 years)	0.1 mg/kg OD orally (or 2.5 mg OD)	Increase by 0.05–0.1 mg/kg every 2–3 days	0.1–0.2 mg/kg OD	0.4 mg/kg (max 10 mg)	0.4 mg/kg (max 10 mg)
≥40 kg or ≥12 years (adolescent)	5 mg OD orally	Increase by 5 mg every 3–5 days	5–10 mg OD	20 mg	20 mg

Mandatory Clinical Notes:

When to prefer over alternatives: No established advantage over furosemide in paediatric heart failure. Consider only when: (a) oral furosemide absorption is documented to be unreliable (e.g., gut oedema, malabsorption); (b) documented furosemide intolerance/allergy; © excessive rebound fluid retention with furosemide (theoretical — unproven in children). This makes it an alternative when furosemide is unsuitable, NOT a first-line choice. It is being compared against furosemide (first-line) and bumetanide (alternative — limited paediatric availability in India).
When NOT to use: Do not use in children <1 year (CYP2C9 immaturity). Do not use when IV diuretic is required (no IV torasemide in India). Do not use in haemodynamically unstable children requiring rapid diuresis (oral onset slower and unpredictable in children).
NLEM status: Not included in NLEM India for paediatric use.
Time to expected response: Onset of diuresis: 1–2 hours after oral dose (extrapolated from adult data); peak diuresis: 2–4 hours. If no increase in urine output within 4–6 hours of first dose, the dose is likely subtherapeutic.
Criteria for treatment failure: No increase in urine output or weight loss after 48–72 hours at the maximum dose for the child’s weight. Action: switch to IV furosemide if available; consider sequential nephron blockade with thiazide diuretic under specialist guidance.
Baseline investigations (MANDATORY): Serum electrolytes (K⁺, Na⁺, Mg²⁺, Ca²⁺), serum creatinine, blood urea, weight, blood pressure. RECOMMENDED: Echocardiography to guide volume status.
Specialist initiation: ⚠️ Specialist initiation recommended — paediatric cardiologist. Not for primary care prescribing in children.
Indian guideline source: Not included in IAP or MoHFW paediatric treatment guidelines. Furosemide dosing referenced in IAP Textbook of Pediatrics (current edition).
Key safety warning: ⚠️ Risk of excessive diuresis and hypovolaemia in children with already compromised cardiac output. Over-diuresis can precipitate low cardiac output state. Monitor weight loss — do not target >1–2% body weight loss per day in children.
Common dose adjustment scenarios: If concurrent potassium-losing state (diarrhoea, vomiting), hold diuretic and correct electrolytes before resumption. If concomitant digoxin therapy, maintain serum K⁺ ≥4.0 mEq/L.
Investigation misconception: Not applicable for this indication.
Dose escalation rationale: Not typically applicable in paediatric HF — doses are modest. If dose escalation is needed beyond 0.4 mg/kg/day, reconsider whether the child needs IV diuretics rather than further oral dose escalation.

2. Oedema Associated with Nephrotic Syndrome — Paediatric

[OFF-LABEL | Level of evidence: Weak — case series and clinical experience only]

Weight-based dosing table:

Weight Category	Starting Dose	Titration	Usual Maintenance	Max Single Dose	Max Daily Dose
10–20 kg	0.1–0.2 mg/kg OD orally	Increase by 0.1 mg/kg every 2–3 days	0.2–0.4 mg/kg OD	0.5 mg/kg (max 10 mg)	0.5 mg/kg (max 10 mg)
20–40 kg	0.2 mg/kg OD orally (or 5 mg OD)	Increase by 0.1 mg/kg (or 2.5 mg) every 2–3 days	0.2–0.4 mg/kg OD	0.5 mg/kg (max 20 mg)	0.5 mg/kg (max 20 mg)
≥40 kg or ≥12 years	5–10 mg OD orally	Increase by 5 mg every 3–5 days	10–20 mg OD	20 mg	20 mg

Mandatory Clinical Notes:

When to prefer over alternatives: No established advantage over furosemide in paediatric nephrotic syndrome. In practice, furosemide remains preferred because: (a) IV furosemide + IV albumin (0.5–1 g/kg over 2–4 hours, followed by IV furosemide 1–2 mg/kg) is the standard for severe symptomatic oedema per IAP guidelines; (b) torasemide has no IV formulation in India. Torasemide may be an acceptable alternative for chronic oral maintenance diuresis in children with relapsing/frequently relapsing nephrotic syndrome where oral furosemide response is suboptimal or erratic.
When NOT to use: Do not use for initial management of severe anasarca/respiratory distress from nephrotic syndrome — IV albumin + IV furosemide is preferred. Do not use in children <1 year. Do not use if reliable oral intake is compromised (e.g., vomiting, gut oedema).
NLEM status: Not listed.
Time to expected response: Diuresis onset: 1–2 hours. In nephrotic syndrome, diuretic response is blunted (see below) — clinical response may take 24–48 hours to become apparent as meaningful weight loss.
Criteria for treatment failure: <0.5 kg weight loss per day after 72 hours at maximal dose. Action: (a) assess dietary sodium compliance; (b) switch to IV furosemide + IV albumin; © consider sequential nephron blockade with metolazone or hydrochlorothiazide.
Baseline investigations (MANDATORY): Serum electrolytes, serum creatinine, serum albumin, urinalysis (proteinuria quantification), weight. RECOMMENDED: Serum albumin guides whether albumin co-infusion is needed before diuretic (albumin <1.5 g/dL: consider IV albumin first).
Specialist initiation: Paediatric nephrologist.
Indian guideline source: IAP revised guidelines on management of steroid-sensitive nephrotic syndrome (Indian Pediatrics, 2021) recommend furosemide for oedema management. Torasemide is not specifically mentioned.
Key safety warning: ⚠️ In nephrotic syndrome, aggressive diuresis without adequate albumin can precipitate intravascular volume depletion and acute kidney injury, even though the child appears oedematous. Monitor serum albumin and intravascular volume status clinically (capillary refill, heart rate, blood pressure).
Common dose adjustment scenarios: Higher mg/kg doses may be needed compared to heart failure because of:
- Intratubular albumin binding: Filtered albumin in the tubular lumen binds torasemide, reducing the free drug available to inhibit NKCC2
- Reduced renal blood flow in hypovolaemic nephrotic state → less drug delivered to the tubule
- Compensatory distal sodium reabsorption activated by ENaC upregulation
Investigation misconception: ℹ️ Serum drug levels of torasemide are NOT clinically useful and should NOT be ordered. The therapeutic target is urinary drug concentration at the tubular site of action, which cannot be measured clinically.
Dose escalation rationale: If dose escalation is needed, it is for efficacy (overcoming reduced tubular drug delivery and intratubular binding), not for safety. The systemically higher drug levels at these doses are tolerated because torasemide is hepatically cleared.

3. Oedema Associated with Chronic Kidney Disease — Paediatric

[OFF-LABEL | Level of evidence: Very weak — PK extrapolation and expert opinion only]

Weight-based dosing table:

Weight Category	Starting Dose	Titration	Usual Maintenance	Max Single Dose	Max Daily Dose
10–20 kg	0.2 mg/kg OD orally	Increase by 0.1–0.2 mg/kg every 3–5 days	0.2–0.5 mg/kg OD	1 mg/kg (max 20 mg)	1 mg/kg (max 20 mg)
20–40 kg	0.2 mg/kg OD orally	Increase by 0.1–0.2 mg/kg every 3–5 days	0.3–0.5 mg/kg OD	1 mg/kg (max 40 mg)	1 mg/kg (max 40 mg)
≥40 kg or ≥12 years	10–20 mg OD orally	Increase by 10 mg every 3–7 days	20–40 mg OD	100 mg (specialist supervision)	100 mg

Mandatory Clinical Notes:

When to prefer over alternatives: In paediatric CKD, torasemide’s advantage of more predictable oral bioavailability (~80% vs furosemide’s variable ~40–60%) is theoretically relevant for chronic oral diuretic therapy. However, this advantage remains unproven in paediatric CKD populations. Furosemide is preferred due to IV availability and established paediatric dosing. Torasemide is an acceptable alternative ONLY under paediatric nephrologist supervision when oral furosemide response is documented as inconsistent.
When NOT to use: Acute fluid overload requiring urgent IV diuresis. Children <1 year. Anuric children (diuretics are ineffective in absent renal function).
NLEM status: Not listed for paediatric CKD.
Time to expected response: Onset 1–2 hours; response may be significantly attenuated in advanced CKD (eGFR <30 mL/min/1.73 m²).
Criteria for treatment failure: Inadequate weight loss or persistent oedema after 72 hours at maximum dose. Action: (a) verify sodium restriction compliance; (b) add metolazone 0.1–0.2 mg/kg (specialist only); © consider ultrafiltration/dialysis initiation.
Baseline investigations (MANDATORY): Serum electrolytes, serum creatinine, eGFR (Schwartz formula for paediatric GFR estimation), weight.
Specialist initiation: Paediatric nephrologist only.
Indian guideline source: No specific Indian paediatric guideline addresses torasemide use in paediatric CKD. IPNA clinical practice recommendations (2021) recommend loop diuretics for oedema in paediatric CKD without specifying agent preference.
Key safety warning: ⚠️ In paediatric CKD, aggressive diuresis can accelerate decline in residual renal function. Target gradual decongestion (0.5–1% body weight loss per day). Monitor serum creatinine closely — a rise of >0.3 mg/dL during active diuresis warrants dose reassessment.
Common dose adjustment scenarios: Higher mg/kg doses needed in advanced CKD (same principle as adults — reduced OAT-mediated tubular secretion). See Dose Escalation Rationale below.
Investigation misconception: Not applicable.
Dose escalation rationale: In paediatric CKD, dose escalation is for efficacy (overcoming impaired tubular drug delivery due to competing uraemic anions, reduced renal blood flow, and fewer functioning nephrons). The drug does not accumulate to systemically toxic levels because it is predominantly hepatically cleared. ⚠️ Do not reflexively reduce the dose in a child with CKD — if diuresis is inadequate, escalate the dose (up to the ceiling for the child’s weight and CKD stage) before concluding the drug has failed.

Secondary Indications — Paediatric (Off-label)

No secondary indications for torasemide are established in paediatric practice.

The antihypertensive indication (low-dose torasemide 2.5–5 mg) has no paediatric data whatsoever. Loop diuretics are not first-line antihypertensives in children. If a diuretic is needed for paediatric hypertension, thiazide/thiazide-like diuretics (hydrochlorothiazide 0.5–1 mg/kg/day, chlorthalidone 0.3 mg/kg/day, amlodipine as non-diuretic first-line) are preferred per IAP and Indian paediatric nephrology practice.
No paediatric data exists for torasemide use in hepatic oedema/ascites. In children with cirrhotic ascites, spironolactone (1–3 mg/kg/day) ± furosemide is the standard approach.

ℹ️ “No established paediatric dosing for secondary indications. Use only under specialist supervision if all standard alternatives are exhausted.”

RENAL ADJUSTMENT

eGFR Formula Specification

Dosing adjustment recommendations for torasemide in renal impairment are derived from pharmacokinetic studies that used creatinine clearance (CrCl) estimated by the Cockcroft-Gault (CG) formula. In current clinical practice, eGFR by CKD-EPI is more commonly reported by laboratories and may be used as a reasonable proxy, with the following caveats:

Population	CG CrCl vs CKD-EPI eGFR
Elderly (≥60 years)	CG typically yields lower values than CKD-EPI → using CKD-EPI may underestimate the degree of renal impairment and lead to inappropriately low diuretic doses
Obese patients	CG (using actual body weight) may overestimate renal function; use adjusted or ideal body weight for CG in obese patients
Low muscle mass (cachexia, heart failure, cirrhosis)	CG and creatinine-based eGFR overestimate true GFR → may underestimate dose requirement
Paediatric patients	Use Schwartz formula for eGFR estimation, not CG or CKD-EPI

💡 For torasemide dosing decisions at threshold values (e.g., deciding between moderate vs high dose escalation), CG CrCl is preferred. For routine monitoring, CKD-EPI eGFR is acceptable.

Dose Escalation Framing — Efficacy vs Safety

⚠️ For torasemide (and all loop diuretics), dose adjustment in renal impairment is driven PRIMARILY by EFFICACY concern — NOT by safety/toxicity avoidance.

This is Category (b) per formulary classification.

Dose escalation is for efficacy (overcoming reduced drug delivery to the tubular site of action), NOT for safety/toxicity avoidance. Torasemide does not accumulate to systemically toxic levels at the higher doses used in CKD because it is predominantly (~80%) hepatically cleared.

Mechanistic rationale — why higher doses are needed in CKD:

Torasemide must reach the luminal (apical) surface of the thick ascending limb to inhibit NKCC2. The multi-step transporter pathway delivering it there (see Pharmacokinetics) is impaired in CKD:

Step	Normal Function	Impairment in CKD
1. Renal blood flow	Delivers torasemide to peritubular capillaries	↓ Renal blood flow in CKD → less drug delivered to kidney
2. Basolateral OAT1/OAT3 uptake	Transports torasemide from peritubular blood into proximal tubule cells	Accumulated uraemic organic anions (hippurate, indoxyl sulphate, p-cresol sulphate) compete for OAT1/OAT3 binding sites → reduced tubular cell uptake
3. Apical MRP4 (ABCC4) efflux	Secretes torasemide from tubule cells into luminal fluid	Fewer functioning nephrons → reduced total secretory capacity
4. Luminal action on NKCC2	Torasemide inhibits NKCC2 in the thick ascending limb	Fewer functional loop segments; compensatory increased sodium reabsorption in the distal nephron and collecting duct

Result: At standard doses, insufficient torasemide reaches the tubular lumen to produce a threshold natriuretic response. Higher systemic doses are needed to overcome these barriers and achieve adequate luminal drug concentrations.

Why systemic accumulation is NOT the primary concern:

Torasemide clearance is ~80% hepatic (via CYP2C9) → systemic elimination is largely preserved in CKD
Half-life increases modestly (from ~3.5 h to ~5–8 h in severe CKD/ESRD), unlike furosemide (where renal clearance is the dominant elimination pathway and half-life can increase dramatically)
The modest half-life prolongation actually benefits diuretic efficacy by extending the duration of adequate luminal concentrations

⛔ Critical prescribing instruction: Do NOT reflexively reduce torasemide doses in CKD patients. If diuresis is inadequate at standard doses, the correct action is to INCREASE the dose (up to the ceiling dose for the patient’s renal function category). Reducing the dose in CKD will worsen fluid overload.

Safety caveats at high doses in CKD:

Ototoxicity risk increases at very high single-bolus doses (particularly relevant for IV furosemide; less data for oral torasemide, but caution applies above 100 mg single dose)
Electrolyte disturbances (hypokalaemia, hyponatraemia, hypomagnesaemia) are dose-related and require monitoring — but these also occur at equivalent diuretic doses in patients with normal renal function
Hypokalaemia risk may paradoxically be lower in advanced CKD (stages 4–5) because potassium excretion is already impaired; hyperkalaemia from CKD may partially offset diuretic-induced potassium loss
Over-diuresis leading to pre-renal AKI is the most clinically relevant safety concern — monitor daily weight and do not target excessive fluid removal.

Renal Adjustment Table — Torasemide for Oedema (Heart Failure, Renal Disease, Nephrotic Syndrome, Hepatic Oedema)

eGFR (mL/min)	Starting Dose	Titration	Usual Maintenance	Ceiling Dose (single dose)	Ceiling Dose (daily)	Formulation	Key Clinical Notes
>60	5–10 mg OD	Increase by 5–10 mg every 2–3 days	10–20 mg OD	40 mg	40 mg/day	IR preferred; PR acceptable	Standard dose-response expected. Most patients respond to ≤20 mg/day
30–60 (CKD Stage 3)	10–20 mg OD	Increase by 10 mg every 2–3 days based on weight loss and urine output	20–40 mg OD	80 mg	80 mg/day	IR preferred for titration flexibility	Response attenuated; expect need for higher-than-standard doses. If inadequate at 80 mg: consider adding metolazone 2.5 mg 30 min before torasemide (sequential nephron blockade) rather than further torasemide escalation. Monitor electrolytes weekly during titration
15–30 (CKD Stage 4)	20–40 mg OD	Increase by 20 mg every 3–5 days	40–100 mg OD	200 mg	200 mg/day	⚠️ Use IR tablets only. Avoid PR formulations — dose-response is steep and unpredictable; IR provides better dose control	Significantly impaired drug delivery. Twice-daily dosing (e.g., 50 mg BD rather than 100 mg OD) may be considered if single large dose produces excessive peak diuresis followed by rebound retention. Monitor electrolytes 2–3 times weekly during titration. Co-prescribe KCl supplementation if K⁺ <4.0 mEq/L and patient is on digoxin or has arrhythmia risk
<15 (CKD Stage 5, non-dialysis)	40–50 mg OD	Increase by 20–50 mg every 3–7 days based on residual urine output	100–200 mg OD	200 mg	200 mg/day	IR tablets only	Diuretic response depends entirely on residual renal function — if the patient is oliguric/anuric, loop diuretics are ineffective regardless of dose. If residual urine output >200–500 mL/day, trial of high-dose torasemide is reasonable. ⛔ Do NOT exceed 200 mg/day — above the ceiling, only toxicity increases (ototoxicity, electrolyte derangement) without additional natriuretic benefit. If inadequate: (1) Add metolazone 2.5–5 mg 30 min before torasemide; (2) Strict sodium restriction <2 g/day; (3) Consider ultrafiltration/dialysis initiation
Haemodialysis	20–50 mg on dialysis-free days (if residual urine output present)	Titrate based on interdialytic weight gain and residual urine output	Individualised	200 mg	200 mg/day	IR tablets	NOT removed by haemodialysis (>99% protein-bound → remains in vascular compartment during dialysis). No supplemental post-HD dose needed. Timing: Give on non-dialysis days for fluid management between sessions. If patient is anuric (no residual renal function), loop diuretics are ineffective — interdialytic fluid restriction and adequate dialysis prescription are more important. Torasemide has a role ONLY in patients with preserved residual urine output (>200 mL/day)
Peritoneal dialysis	20–50 mg OD (if residual urine output present)	Titrate based on fluid balance and residual output	Individualised	200 mg	200 mg/day	IR tablets	NOT removed by peritoneal dialysis (protein-bound). Role limited to patients with residual renal function. As residual function declines over time on PD, diuretic efficacy diminishes — eventually discontinue when anuric
CRRT	20–40 mg OD (if residual renal function present and attempting CRRT weaning)	Individualised — specialist decision	Data limited	Data limited	Data limited	—	In patients on CRRT, diuretic use is limited to: (a) Attempting to augment fluid removal alongside mechanical CRRT; (b) Transitioning off CRRT as renal function recovers. Torasemide is NOT removed by CRRT (protein-bound). Specialist/intensivist decision only. If used during CRRT weaning, start at 20–40 mg OD and assess urine output response before escalation

Renal Adjustment Table — Torasemide for Hypertension (Low-Dose Indication)

eGFR (mL/min)	Dose Adjustment	Notes
>30	No dose adjustment required	Standard 2.5–5 mg OD. The low doses used for hypertension are well below the diuretic ceiling dose
15–30	No dose reduction needed; monitor electrolytes more frequently (monthly)	At these low doses, systemic accumulation is negligible. However, the antihypertensive mechanism at low doses is primarily vascular (reduced peripheral vascular resistance) rather than diuretic, so efficacy may be partially preserved even in advanced CKD
<15	Consider alternative antihypertensive class	Loop diuretics at low antihypertensive doses have minimal efficacy in advanced CKD. If volume-mediated hypertension: use higher doses (oedema dosing range — see table above) rather than low-dose antihypertensive dosing. If hypertension is not volume-mediated: switch to calcium channel blocker (amlodipine — no renal adjustment needed) or beta-blocker

Condition-Specific Renal Dosing Notes

Heart Failure with CKD (Cardiorenal Syndrome):

This is the most common clinical scenario requiring dose escalation
Reduced cardiac output → reduced renal perfusion → diuretic resistance
The “rightward shift” in dose-response is due to BOTH cardiac and renal factors
Target weight loss: 0.5–1 kg/day. Do not target more aggressive diuresis even if high doses are used
See Diuretic Resistance Management Protocol in Part 2 if ceiling dose is inadequate

Nephrotic Syndrome:

Additional diuretic resistance mechanism: filtered albumin in the tubular lumen binds torasemide, reducing the free drug available to act on NKCC2
Some experts advocate co-administering IV albumin (25% albumin, 0.5–1 g/kg over 30 min) followed by the diuretic to “ferry” the drug to the kidney and reduce intraluminal binding — evidence is debated (meta-analyses inconclusive)
Higher doses may be needed compared to heart failure at the same level of renal impairment

Cirrhosis with CKD:

See Hepatic Adjustment section below for the added complexity of hepatic metabolism impairment
In hepatorenal syndrome: diuretics are generally ineffective and may worsen renal function. Discontinue diuretics if hepatorenal syndrome is suspected

Formulation-Specific Renal Adjustment

Formulation	eGFR >60	eGFR 30–60	eGFR 15–30	eGFR <15
Immediate-release (IR) tablets	✔ Suitable	✔ Suitable — preferred	✔ Suitable — REQUIRED	✔ Suitable — REQUIRED
Prolonged-release (PR) tablets (if available)	✔ Acceptable	⚠️ Use with caution — dose titration less flexible	⛔ Avoid — switch to IR. Dose-response becomes steep; IR provides better control for titration of high doses	⛔ Avoid — use IR only
FDC with spironolactone	✔ Suitable (if combination indicated and doses match)	⚠️ Use only if both components are at appropriate doses; spironolactone accumulates in CKD → hyperkalaemia risk increases	⚠️ Spironolactone use in eGFR 15–30 requires frequent K⁺ monitoring (twice weekly); FDC limits dose independence — prescribe components separately	⛔ FDC not recommended. Spironolactone is generally avoided below eGFR 15 (hyperkalaemia risk). Prescribe torasemide separately if needed

Augmented Renal Clearance (ARC)

Definition: CrCl >130 mL/min, typically seen in young (18–40 years), non-elderly ICU patients with sepsis, trauma, burns, or major surgery.

Impact on torasemide:

Torasemide is primarily hepatically cleared (~80%), so ARC has less impact on systemic drug clearance compared to predominantly renally-cleared drugs (aminoglycosides, vancomycin, meropenem).
However, ARC may enhance the diuretic effect of torasemide because:
- Increased renal blood flow → more drug delivered to peritubular capillaries
- Enhanced OAT1/OAT3 activity → more efficient tubular secretion into the lumen
- Result: standard doses may produce a more vigorous diuresis than expected

Clinical implication:

No formal dose increase is required for ARC (unlike aminoglycosides/vancomycin where ARC mandates dose escalation to maintain therapeutic systemic levels)
In young ICU patients with ARC, monitor closely for excessive diuresis and electrolyte depletion at standard doses
If the clinical intent is aggressive decongestion (e.g., decompensated heart failure in a young patient), the enhanced renal delivery in ARC is therapeutically advantageous
If the patient is euvolaemic and torasemide is being used for hypertension, consider the possibility of excessive diuresis and start at the lower end of the dose range

HEPATIC ADJUSTMENT

Overview

Torasemide is approximately 80% hepatically metabolised, primarily via CYP2C9 (major pathway) with minor contributions from CYP2C8 and CYP2C18. Hepatic impairment significantly reduces torasemide clearance, prolongs half-life, and increases systemic exposure (AUC) of the parent drug.

Pharmacokinetic data in cirrhosis (from controlled pharmacokinetic studies in patients with compensated and decompensated cirrhosis):

PK Parameter	Normal	Cirrhosis (Compensated)	Cirrhosis (Decompensated)
AUC	Reference	~1.6–2× increased	~2–3× increased
Half-life	~3.5 h	~5–6 h	~6–8 h
Clearance	~40 mL/min	~20–25 mL/min	~15–20 mL/min
Protein binding	>99%	>99% (mild-moderate)	May decrease in severe hypoalbuminaemia → increased free fraction
Bioavailability	~80%	May increase (reduced first-pass)	Further increased

Active metabolite consideration: Torasemide’s primary metabolites (methyl-hydroxylated metabolite and carboxylic acid derivative — see Pharmacokinetics, Part 1 for detailed metabolite identification) have minimal pharmacological activity. In hepatic impairment, formation of these metabolites via CYP2C9 is reduced while the parent compound accumulates. Since the parent drug is the pharmacologically active species, the diuretic effect per mg dose is enhanced in hepatic impairment (higher AUC of active drug), partially offset by the pharmacodynamic resistance seen in cirrhotic patients (see below).

The Cirrhosis Paradox — Pharmacokinetic-Pharmacodynamic Dissociation

In cirrhotic patients with ascites and/or peripheral oedema, a clinically important paradox exists:

Pharmacokinetic effect (favours dose REDUCTION):

Reduced CYP2C9 activity → slower metabolism → higher plasma levels and longer half-life for any given dose
Reduced first-pass metabolism → higher oral bioavailability → even more drug reaches systemic circulation
In severe hypoalbuminaemia: decreased protein binding → higher free drug fraction → enhanced pharmacological activity per mg and increased risk of dose-related adverse effects

Pharmacodynamic effect (favours dose ESCALATION):

Secondary hyperaldosteronism (the hallmark of cirrhotic ascites) drives avid distal sodium reabsorption via ENaC and Na/K-ATPase → this counteracts loop diuretic-induced natriuresis at the thick ascending limb
Reduced effective renal blood flow (hepatorenal physiology, even before overt hepatorenal syndrome) → reduced drug delivery to the tubular lumen via OAT pathway
Activation of sympathetic nervous system and RAAS → further sodium and water retention
Post-diuretic sodium rebound may be exaggerated in cirrhosis

Clinical resolution — how to manage this paradox:

Principle	Practical Action
Start at the lower end of the dose range	The higher AUC per mg in cirrhosis means a given dose produces a more intense (and longer) pharmacological effect than in patients with normal liver function
Titrate more slowly	Allow 3–5 days between dose increments (instead of 2–3 days in non-cirrhotic patients) to account for prolonged half-life and delayed steady-state
Spironolactone FIRST	Spironolactone is the first-line diuretic in cirrhotic ascites because it directly counteracts the hyperaldosteronism driving sodium retention. Initiate spironolactone (starting 50–100 mg/day, up to 400 mg/day) BEFORE adding a loop diuretic. Add torasemide only when spironolactone alone is insufficient — this is a fundamental principle of cirrhotic ascites management per API Textbook of Medicine and AASLD/EASL guidelines
Maintain the spironolactone:loop diuretic ratio	In cirrhosis, the traditional ratio for furosemide is spironolactone 100 mg : furosemide 40 mg. For torasemide, the approximate equivalent ratio is spironolactone 100 mg : torasemide 10–20 mg (based on equidiuretic potency; see Dose Equivalence Table in Part 1). This ratio helps maintain potassium balance
Monitor electrolytes intensively	Cirrhotic patients are at high risk of hypokalaemia (loop diuretic) AND hyperkalaemia (spironolactone + renal impairment) — the balance is delicate
Target conservative fluid removal	Ascites only: ≤0.5 kg/day; ascites with peripheral oedema: ≤1 kg/day. Exceeding this rate risks intravascular volume depletion, pre-renal AKI, and hepatorenal syndrome

Child-Pugh Classification-Based Adjustment

Child-Pugh Score	Dose Adjustment	Starting Dose (Oedema)	Starting Dose (Hypertension)	Max Recommended Daily Dose	Monitoring Frequency	Key Clinical Guidance
A (Mild, 5–6 pts)	No routine dose reduction required	Standard: 5–10 mg OD	Standard: 2.5–5 mg OD	40 mg/day	Electrolytes and renal function: weekly × 4, then monthly	Drug levels modestly higher than expected for dose. Clinical response usually adequate at standard doses. May observe slightly prolonged duration of action (6–8 h diuresis vs 4–6 h in normal liver function). No formulation restriction — IR or PR acceptable
B (Moderate, 7–9 pts)	⚠️ Use with caution; start at lower end of dose range; slower titration	5 mg OD (add to existing spironolactone — do NOT initiate as sole diuretic for ascites)	2.5 mg OD	20–40 mg/day	Electrolytes and renal function: twice weekly × 2 weeks, then weekly; daily weight and fluid balance; mental status assessment at each visit	⚠️ Risk of precipitating hepatic encephalopathy through: excessive diuresis → hypovolaemia → reduced hepatic perfusion; hypokalaemia → increased renal ammoniagenesis; metabolic alkalosis → conversion of NH₄⁺ to diffusible NH₃. Maintain serum K⁺ ≥4.0 mEq/L. Use IR formulations only — better dose control for cautious titration. If encephalopathy develops or worsens: hold loop diuretic, correct K⁺ and alkalosis, treat encephalopathy (lactulose, rifaximin), reassess diuretic need
C (Severe, 10–15 pts)	⚠️ Use only under hepatologist supervision; prefer spironolactone monotherapy when possible	5 mg OD only if loop diuretic absolutely required (refractory to spironolactone 400 mg/day)	Avoid for hypertension — use non-diuretic antihypertensives (CCB, beta-blocker for portal hypertension)	20 mg/day	Daily: electrolytes, renal function (serum creatinine), weight, mental status. Twice weekly: serum albumin	⚠️ High risk of: (1) Hepatic encephalopathy; (2) Hepatorenal syndrome precipitated by over-diuresis — even modest intravascular volume depletion can trigger HRS in decompensated cirrhosis; (3) Severe electrolyte derangements; (4) Hyponatraemia (dilutional — common in advanced cirrhosis, worsened by diuretics). Strict targets: Weight loss ≤0.5 kg/day (ascites only) or ≤1 kg/day (with peripheral oedema). Stop loop diuretic and reassess if: serum Na⁺ <125 mEq/L, serum creatinine rises >0.5 mg/dL from baseline, hepatic encephalopathy develops grade ≥2, severe muscle cramps unresponsive to management. Consider large-volume paracentesis (with albumin replacement: 6–8 g per litre removed) as alternative to aggressive diuretic therapy in tense ascites

Formulation-Specific Hepatic Adjustment

Formulation	Child-Pugh A	Child-Pugh B	Child-Pugh C
IR tablets	✔ Suitable	✔ Preferred — allows precise dose titration	✔ Required — only formulation recommended
PR/SR tablets (if available)	✔ Acceptable	⚠️ Avoid — reduced first-pass metabolism alters the absorption profile of modified-release formulations unpredictably; switch to IR	⛔ Avoid — use IR only
FDC with spironolactone	✔ Suitable if both components at appropriate doses	⚠️ FDC limits independent dose titration. In cirrhosis, the spironolactone:loop diuretic ratio needs frequent adjustment. Prescribe components separately to allow independent titration of each	⛔ FDC not recommended — prescribe components separately for maximum flexibility

CYP2C9 Polymorphism Interaction with Hepatic Impairment

CYP2C9 is the primary metabolising enzyme for torasemide. Patients who are CYP2C9 poor metabolisers (PM) — estimated 2–3% of the Indian population — AND have concurrent hepatic impairment face a compounded reduction in torasemide clearance:

Scenario	Expected PK Effect	Clinical Action
CYP2C9 normal metaboliser + normal liver	Reference	Standard dosing
CYP2C9 PM + normal liver	AUC increased ~2×; half-life prolonged	Start at lower dose; titrate slower
CYP2C9 normal metaboliser + cirrhosis (Child-Pugh B–C)	AUC increased ~2–3×	Follow hepatic adjustment table above
CYP2C9 PM + cirrhosis (Child-Pugh B–C)	AUC potentially increased 4–6×; markedly prolonged half-life	⚠️ Start at the lowest available dose (5 mg OD or every other day); titrate very cautiously at ≥7-day intervals; monitor electrolytes daily initially. Consider furosemide as alternative (not CYP2C9-dependent — primarily renally cleared)

ℹ️ CYP2C9 genotyping is not routinely performed in India and is not mandatory before initiating torasemide. However, if a patient on standard doses develops unexpectedly prolonged diuresis, severe electrolyte derangements, or signs of overdose at low doses — particularly in the setting of hepatic impairment — suspect CYP2C9 PM status. Pharmacogenomic testing is available at select centres (AIIMS, CMC Vellore, Tata Memorial).

Concurrent Hepatotoxin Note

When torasemide is co-administered with hepatotoxic drugs commonly used in Indian practice, additional monitoring is warranted because hepatotoxicity from the co-administered drug will further impair CYP2C9-mediated torasemide clearance:

Co-administered Hepatotoxin	Specific Interaction with Torasemide	Additional Monitoring
Rifampicin	Dual effect: (a) Rifampicin is a potent CYP2C9 inducer → acutely may DECREASE torasemide levels (see Drug Interactions, Part 4); (b) Rifampicin-induced hepatotoxicity → subsequently INCREASES torasemide levels when hepatic function declines	LFTs every 2 weeks for first 2 months; reassess torasemide dose if LFTs become deranged
Isoniazid	Isoniazid-induced hepatotoxicity (particularly in CYP2C9/NAT2 slow acetylators) can reduce torasemide clearance	LFTs every 2 weeks; if ALT >3× ULN with symptoms or >5× ULN without symptoms: hold isoniazid per ATT guidelines and reassess torasemide dosing
Pyrazinamide	Hepatotoxicity (common in first 2 months of ATT) + hyperuricaemia (additive with torasemide-induced hyperuricaemia)	LFTs and uric acid levels every 2 weeks during intensive phase
Methotrexate	Hepatotoxicity (chronic use); also, torasemide may reduce methotrexate renal clearance (competitive OAT inhibition — see Drug Interactions, Part 4)	LFTs monthly; monitor methotrexate toxicity signs
Valproate	Hepatotoxicity (rare but severe, especially in children <2 years); valproate is also highly protein-bound — potential displacement interaction with torasemide	LFTs at baseline and monthly for first 6 months
Antiretrovirals (particularly NNRTIs — nevirapine, efavirenz; protease inhibitors)	Variable hepatotoxicity; some ARVs are CYP2C9 substrates/inhibitors — complex PK interaction	LFTs as per NACO ART guidelines; specialist consultation for diuretic dose adjustment

💡 Practical guidance: In patients receiving ATT (anti-tubercular therapy) who also require torasemide, use the minimum effective diuretic dose and monitor LFTs more frequently. If significant hepatotoxicity develops from ATT, torasemide clearance will decrease — watch for signs of over-diuresis (excessive weight loss, postural hypotension, electrolyte derangement) and reduce the diuretic dose pre-emptively.

Additional Hepatic Adjustment Notes

Hypoalbuminaemia in liver disease — impact on torasemide pharmacology:

Torasemide is >99% protein-bound. In severe hypoalbuminaemia (serum albumin <2.5 g/dL, common in Child-Pugh C cirrhosis), the free (unbound) fraction increases, potentially amplifying both therapeutic and toxic effects.
However, in clinical practice, the increased free fraction often leads to more rapid distribution and elimination of the drug, partially compensating for the increased free concentration at the receptor level.
Clinical translation: In severe hypoalbuminaemia, the drug may work faster but shorter. If duration of diuresis is inadequate, consider twice-daily dosing (e.g., 5 mg BD instead of 10 mg OD) rather than increasing the single dose.
See Population PK — Hypoalbuminaemia in Part 1 for cross-cutting PK analysis.

When to switch from torasemide to furosemide in hepatic impairment:

If torasemide clearance is severely impaired and dose titration becomes unpredictable: consider switching to furosemide, which is ~60–70% renally cleared and less dependent on hepatic CYP metabolism.
However, this introduces furosemide’s own disadvantage: variable oral bioavailability (~40–60% vs torasemide’s ~80%), which may worsen in patients with gut oedema.
Clinical decision: In Child-Pugh C with unstable hepatic function, IV furosemide (if inpatient) provides the most predictable pharmacokinetics. If outpatient oral therapy is needed, low-dose oral torasemide (5 mg OD, IR) with close monitoring may still be preferable to oral furosemide due to more reliable absorption.

Hepatorenal syndrome (HRS):

⛔ If hepatorenal syndrome type 1 (rapidly progressive) is diagnosed or suspected: discontinue all diuretics (including torasemide and spironolactone). Diuretics are ineffective in HRS and may worsen renal hypoperfusion.
Definitive management: terlipressin + albumin (per Indian guidelines — API Textbook of Medicine; INASL guidelines).
In HRS type 2 (slowly progressive): diuretics may be cautiously continued at low doses if there is documented response (urine output, weight change), but with very close monitoring.

CONTRAINDICATIONS

⛔ 1. Anuria / Anuric renal failure
Torasemide requires active tubular secretion via OAT1/OAT3 to reach its luminal site of action; in anuric patients, the drug cannot reach the Na⁺-K⁺-2Cl⁻ cotransporter (NKCC2) and offers zero diuretic benefit while exposing the patient to systemic adverse effects (ototoxicity, electrolyte shifts). Differentiate from oliguria — in oliguria with residual nephron function, torasemide may still elicit a response at higher doses.

⛔ 2. Hepatic coma or pre-coma (hepatic encephalopathy grades III–IV)
Loop diuretic–induced hypokalaemia and metabolic alkalosis shift ammonium (NH₄⁺) equilibrium toward un-ionised ammonia (NH₃), which crosses the blood-brain barrier more readily and worsens encephalopathy. Intravascular volume depletion further reduces hepatic perfusion. Do not initiate torasemide until encephalopathy is controlled to grade ≤ II and electrolytes are corrected. (Note: Use in stable cirrhotic ascites with grade 0–I encephalopathy is NOT contraindicated — see Cautions.)

⛔ 3. Known hypersensitivity to torasemide or any excipient
True allergic reactions to torasemide include urticaria, angioedema, anaphylaxis, and severe cutaneous adverse reactions (SCAR). Even a single episode of confirmed torasemide-mediated anaphylaxis is an absolute bar to re-challenge. See cross-reactivity table below.

⛔ 4. Severe, uncorrected hypokalaemia (K⁺ < 3.0 mEq/L)
Further potassium depletion can precipitate life-threatening cardiac arrhythmias (torsades de pointes, ventricular fibrillation), especially in patients on digoxin or with underlying QTc prolongation. Correct potassium to ≥ 3.5 mEq/L before initiating torasemide.

⛔ 5. Severe, uncorrected hyponatraemia (Na⁺ < 125 mEq/L)
Additional sodium and free water losses can precipitate seizures, osmotic demyelination (if subsequent rapid correction occurs), or cardiovascular collapse. Correct sodium to ≥ 128 mEq/L and address underlying cause before diuretic initiation.

⛔ 6. Severe hypovolaemia / dehydration with haemodynamic instability
Diuretic use in an already volume-depleted patient causes pre-renal AKI, hypotension, and cardiovascular collapse. Volume-resuscitate first.

⛔ 7. Concurrent ethacrynic acid
Co-administration of two loop diuretics acting at NKCC2 confers no additional natriuretic benefit beyond the ceiling dose of either agent alone, but synergistically amplifies ototoxicity risk. Never combine two loop diuretics.

Sulfonamide Cross-Reactivity — Structured Assessment

Torasemide is a pyridine-3-sulfonamide derivative (non-antibiotic sulfonamide). The following table addresses the clinical question of cross-reactivity in both directions — whether torasemide can be used in patients with known “sulfa allergy,” and whether patients allergic to torasemide can receive other sulfonamide-containing drugs.

Related Drug/Class	Cross-Reactivity Risk	Nature	Clinical Action
Sulfonamide antibiotics (sulfamethoxazole, sulfadiazine, sulfasalazine)	Low	The primary allergenic determinant in sulfonamide antibiotics is the N1-aromatic amine substituent, which is ABSENT in torasemide’s structure. Epidemiological data (Strom BL, NEJM 2003) suggest increased reaction rates with non-antibiotic sulfonamides in “sulfa-allergic” patients reflect a general drug allergy propensity rather than specific cross-reactivity.	If prior reaction to sulfonamide antibiotic was mild (rash, GI upset): Torasemide may be used with standard monitoring. If prior reaction was severe (anaphylaxis, SJS/TEN, DRESS): Use torasemide with caution under observation for first dose; consider ethacrynic acid as alternative loop diuretic (does NOT contain sulfonamide moiety).
Furosemide (5-sulfamoylanthranilic acid derivative)	Moderate	Both are sulfonamide-containing loop diuretics but have structurally distinct side chains. True immunological cross-reactivity is possible though not universal.	If allergy to furosemide was IgE-mediated (urticaria, angioedema, anaphylaxis): Torasemide may be attempted under supervised setting with graded challenge protocol. If prior reaction was severe: Ethacrynic acid is the safest alternative (non-sulfonamide). If allergy was non-IgE (serum sickness–like reaction): Cross-reactivity pattern is less predictable — specialist allergy referral recommended.
Bumetanide (sulfonamide-containing loop diuretic)	Moderate	Structural similarity via sulfonamide core, though side chains differ from torasemide.	Same approach as furosemide allergy above.
Thiazide diuretics (HCTZ, chlorthalidone, indapamide)	Low	All contain a sulfonamide moiety but structurally distinct from torasemide. Cross-reactivity case reports are very rare.	Generally considered safe to use in patients allergic to thiazides, and vice versa. Monitor first dose.
Sulfonylureas (glibenclamide, glimepiride, gliclazide)	Low–Negligible	Structurally distant despite shared sulfonamide core. No convincing cross-reactivity data.	May use torasemide in sulfonylurea-allergic patients with standard monitoring.
Celecoxib, acetazolamide, sumatriptan	Negligible	Different structural classes with incidental sulfonamide moiety.	No clinical concern.

ℹ️ Clinical bottom line for Indian practice: The phrase “sulfa allergy” on a patient’s chart is often poorly documented. Before withholding torasemide, ascertain: (a) WHICH sulfonamide drug caused the reaction? (b) WHAT was the reaction (rash vs anaphylaxis vs GI intolerance)? © Was the reaction CONFIRMED (positive rechallenge, skin test) or assumed? In most cases, torasemide can be safely used in patients with a history of mild reactions to sulfonamide antibiotics.

CAUTIONS

⚠️ High-Priority Cautions

⚠️ 1. Electrolyte imbalance — Metabolic Adverse Effects Checklist

This is the most common and clinically consequential adverse effect category for all loop diuretics.

Electrolyte Effect	Mechanism	Dose-Dependent?	Clinical Consequence	Management
Hypokalaemia	Increased distal sodium delivery → enhanced K⁺ secretion via ROMK and BK channels in collecting duct; secondary hyperaldosteronism from volume depletion	Yes	Muscle weakness, cramps, cardiac arrhythmias (especially dangerous with concurrent digoxin), prolonged QTc	Maintain K⁺ ≥ 4.0 mEq/L in patients on digoxin or at arrhythmia risk; ≥ 3.5 mEq/L in others. Supplement with KCl (oral or IV). Consider adding MRA (spironolactone 12.5–25 mg or eplerenone) in HF patients.
Hyponatraemia	Impaired free water clearance combined with continued free water intake; more common with concurrent thiazide use or in elderly	Partially (threshold effect)	Confusion, seizures, osmotic demyelination if corrected too rapidly	Restrict free water if Na⁺ < 130 mEq/L. Monitor Na⁺ more frequently in elderly, in those on concurrent thiazides, and in cirrhotics.
Hypomagnesaemia	Impaired paracellular Mg²⁺ reabsorption in thick ascending limb (same site as NKCC2 inhibition)	Yes	Often clinically silent but causes refractory hypokalaemia (Mg²⁺ is required for ROMK channel closure), cardiac arrhythmias, muscle cramps	Check serum Mg²⁺ at baseline and periodically. Supplement with oral magnesium oxide 400 mg/day if Mg²⁺ < 1.8 mg/dL.
Hypocalcaemia	Increased urinary calcium excretion (loop diuretics inhibit paracellular Ca²⁺ reabsorption in thick ascending limb) — OPPOSITE to thiazides which are calcium-sparing	Partially	Usually mild; clinically significant only with chronic high-dose use or pre-existing vitamin D deficiency/hypoparathyroidism	Ensure adequate calcium and vitamin D intake. Monitor serum calcium in long-term high-dose use.
Hyperuricaemia / gout	Volume contraction → increased proximal uric acid reabsorption; competition for OAT-mediated uric acid secretion	Yes	Asymptomatic hyperuricaemia in 40–60% of patients; clinical gout in 2–5%	Monitor uric acid at baseline and periodically. Do NOT initiate allopurinol solely for asymptomatic hyperuricaemia. Manage acute gout flares; consider drug switch if recurrent.
Hyperglycaemia	Impaired pancreatic insulin secretion (hypokalaemia-mediated); reduced peripheral glucose uptake	Yes (more at doses > 40 mg/day)	Usually mild (fasting glucose ↑ 10–20 mg/dL); may unmask latent diabetes	Monitor fasting glucose/HbA1c at baseline, 3 months, then annually. Adjust antidiabetic therapy if needed.
Metabolic alkalosis	Volume contraction → increased proximal bicarbonate reabsorption; increased H⁺ secretion in collecting duct to reclaim sodium; chloride depletion	Yes	Usually mild; worsens hepatic encephalopathy risk in cirrhotics	Monitor serum bicarbonate and chloride. Replace chloride (NaCl or KCl).

💡 Torasemide-specific advantage (cross-reference: See Unique Pharmacological Note — Anti-Aldosterone Activity in PK section, Part 1): Torasemide may produce less hypokalaemia than equinatriuretic doses of furosemide, attributed to its anti-aldosterone activity and longer duration of action (reducing post-diuretic rebound sodium reabsorption). This relative advantage does NOT eliminate the need for potassium monitoring — it reduces but does not abolish hypokalaemia risk.

⚠️ 2. Diuretic-Induced AKI vs “Pseudo-Worsening Renal Function” (WRF) — Critical Distinction in Heart Failure

This is one of the most important prescribing concepts for loop diuretics in decompensated heart failure:

Feature	True Diuretic-Induced AKI	“Pseudo-WRF” / Haemoconcentration
Mechanism	Over-diuresis → hypovolaemia → pre-renal injury	Effective decongestion → haemoconcentration → creatinine concentration rises despite stable or improved renal perfusion
Creatinine rise	Often > 0.5 mg/dL; may be > 1.0 mg/dL	Modest: 0.1–0.5 mg/dL
Clinical status	Patient shows signs of hypovolaemia: postural hypotension, tachycardia, poor skin turgor, dry mucosae, low JVP, oliguria	Patient is clinically IMPROVING: reduced dyspnoea, reduced peripheral oedema, reduced JVP, good urine output
Urine output	Decreasing or oliguria despite diuretic	Maintained or previously robust
Haematocrit	May rise (haemoconcentration) but with clinical deterioration	Rises with clinical improvement (positive prognostic marker per PROTECT trial data)
Outcome	HARMFUL — associated with increased mortality	Generally BENIGN — studies (Testani JM, JACC 2011; DOSE trial sub-analysis) show modest creatinine rises during effective decongestion are associated with BETTER outcomes
Action required	⚠️ REDUCE or HOLD diuretic. IV fluid resuscitation if hypovolaemic.	⚠️ Do NOT reflexively discontinue diuretic. Continue decongestion. Monitor creatinine trend.

⛔ Critical prescribing error to avoid: Do NOT reflexively discontinue torasemide for a modest creatinine rise (≤ 0.3–0.5 mg/dL) if the patient is clinically improving with signs of decongestion. Premature diuretic withdrawal leads to recongestion and worse outcomes. Concern is warranted ONLY if: creatinine rises > 0.5 mg/dL, oliguria develops (< 0.5 mL/kg/hr), or clinical status deteriorates.

⚠️ 3. Hepatic cirrhosis with ascites (without encephalopathy)

Loop diuretics in cirrhosis must be used with extreme caution. Aggressive diuresis can precipitate:
- Hepatorenal syndrome (via intravascular volume depletion in the setting of systemic vasodilation)
- Hepatic encephalopathy (via hypokalaemia and metabolic alkalosis)
- Severe hyponatraemia (dilutional, worsened by impaired free water excretion)
Target weight loss: ≤ 0.5 kg/day in patients with ascites ONLY; ≤ 1.0 kg/day in patients with BOTH ascites AND peripheral oedema
Torasemide is typically used as second-line after spironolactone in cirrhotic ascites (spironolactone:torasemide ratio analogous to the standard spironolactone:furosemide 100 mg:40 mg ratio used in practice)
Monitor serum electrolytes (K⁺, Na⁺), renal function, and encephalopathy grade at least twice weekly during active titration
⛔ HOLD diuretic if: Na⁺ < 125 mEq/L, K⁺ < 3.0 mEq/L, creatinine rises > 0.5 mg/dL above baseline, or encephalopathy worsens to ≥ grade II

⚠️ 4. Concurrent digoxin therapy

Hypokalaemia and hypomagnesaemia from torasemide significantly increase the risk of digitalis toxicity (nausea, visual disturbance, arrhythmias including fatal ventricular tachycardia/fibrillation)
Maintain K⁺ ≥ 4.0 mEq/L and Mg²⁺ ≥ 2.0 mg/dL in all patients receiving concurrent digoxin
Monitor digoxin levels more frequently during torasemide dose changes
Consider adding spironolactone/eplerenone (which have potassium-sparing AND anti-aldosterone benefit in HF) to mitigate risk

⚠️ 5. Diabetes mellitus

Torasemide may worsen glycaemic control via hypokalaemia-mediated impairment of insulin secretion
Effect is generally modest and dose-dependent
Monitor fasting blood glucose and HbA1c; may need to adjust antidiabetic medication
At equinatriuretic doses, torasemide may cause less glucose intolerance than furosemide (limited data)

⚠️ 6. Gout / history of gouty arthritis

Hyperuricaemia is dose-dependent and occurs in 40–60% of patients on chronic loop diuretics
Patients with history of gout are at high risk of acute flares during diuretic initiation or dose escalation
Prophylactic use of allopurinol/febuxostat may be considered in high-risk patients requiring chronic loop diuretic therapy
An acute gout flare is NOT a reason to discontinue the diuretic if the original indication (e.g., decompensated HF) is still present — treat the gout flare while continuing the diuretic

⚠️ 7. “Triple whammy” combination — NSAID + ACEi/ARB + Diuretic

The concurrent use of ALL THREE drug classes produces a synergistic increase in AKI risk
- NSAID: reduces prostaglandin-mediated afferent arteriolar vasodilation
- ACEi/ARB: reduces angiotensin II–mediated efferent arteriolar vasoconstriction
- Diuretic: reduces intravascular volume
Combined effect: precipitous fall in GFR → AKI (Lapi F, BMJ 2013: 31% increased AKI risk with triple therapy)
⚠️ This scenario is EXTREMELY common in Indian practice because NSAIDs are widely available OTC and patients may self-medicate without informing the prescriber
Action: Actively ASK about NSAID use (including “pain tablets,” “body pain medicine”) at every visit. If triple combination is unavoidable for a short period, ensure adequate hydration and monitor creatinine within 48–72 hours

⚠️ 8. Pre-existing QTc prolongation / concurrent QT-prolonging drugs

Hypokalaemia and hypomagnesaemia from torasemide can prolong QTc interval and predispose to torsades de pointes
Risk is amplified when combined with other QT-prolonging drugs (amiodarone, sotalol, fluoroquinolones, antipsychotics, ondansetron at high doses, domperidone)
Obtain baseline ECG; maintain K⁺ ≥ 4.0 mEq/L and Mg²⁺ ≥ 2.0 mg/dL
Monitor ECG after any dose change or new QT-prolonging drug addition

Standard Cautions

9. Prostatic hypertrophy / urinary obstruction
Increased urine flow may worsen acute urinary retention in patients with significant bladder outlet obstruction. Ensure adequate voiding capability before starting diuretic.

10. Systemic lupus erythematosus (SLE)
Loop diuretics may exacerbate or activate SLE. Mechanism unclear — possibly related to immune complex deposition or photosensitivity. Use with monitoring.

11. Porphyria
Safety in acute porphyria is uncertain. Use with caution.

12. Photosensitivity
Loop diuretics can cause photosensitivity reactions. Advise sun protection, especially during Indian summer months.

13. Elderly patients (see dedicated Elderly section below)

14. Patients on concurrent potassium-depleting drugs (corticosteroids, amphotericin B, stimulant laxatives)
Additive hypokalaemia risk. Monitor K⁺ closely.

15. Severe aortic or mitral stenosis
Excessive diuresis may critically reduce preload-dependent cardiac output. Use cautiously with close haemodynamic monitoring.

16. Hypertrophic obstructive cardiomyopathy (HOCM)
Volume depletion worsens dynamic outflow tract obstruction. Use only if overt fluid overload present; avoid aggressive diuresis.

17. Seasonal/climate caution (India-specific)
During hot Indian summers (April–June), insensible fluid losses from sweating compound diuretic-induced volume depletion, significantly increasing the risk of dehydration, AKI, and electrolyte disturbance. Consider temporary dose reduction (by 25–50%) in stable patients during extreme heat, with clinical reassessment. Counsel patients to maintain adequate fluid intake and monitor daily weight.

PREGNANCY

Parameter	Detail
Overall safety statement	⚠️ Avoid unless clearly indicated. Diuretics are NOT recommended for treatment of physiological oedema of pregnancy.
Teratogenicity risk	No evidence of teratogenicity in animal studies (rat and rabbit). No adequate and well-controlled human studies. Former US-FDA pregnancy category B.
Teratogenicity window	No specific teratogenic window identified (no organogenesis-related malformations in animal data).
Trimester-specific risks	First trimester: Theoretical concern for uteroplacental hypoperfusion from volume depletion, but no confirmed teratogenic risk. Second/Third trimester: Can cause maternal hypovolaemia → reduced uteroplacental perfusion → fetal growth restriction. May cause fetal electrolyte disturbances (hypokalaemia, hyponatraemia). Oligohydramnios from reduced fetal urine output. Can cause neonatal electrolyte imbalance, thrombocytopenia (rare).
Placental transfer	Likely crosses the placenta based on molecular properties (MW ~348 Da, moderate protein binding ~99% — but unbound fraction crosses). Specific human placental transfer data limited.
When it may be used	ONLY if the maternal condition necessitates diuretic therapy AND the benefit clearly outweighs fetal risk — e.g., decompensated heart failure in pregnancy, pulmonary oedema. Must be under specialist (cardiologist + obstetrician) supervision.
Preferred alternatives	Furosemide — substantially more clinical experience in pregnancy; considered the loop diuretic of choice when loop diuresis is essential during pregnancy. For gestational hypertension without fluid overload, diuretics are NOT first-line — preferred antihypertensives: labetalol, methyldopa, nifedipine (as per FOGSI/API Obstetric guidelines).
What to monitor	Maternal: electrolytes (K⁺, Na⁺, Mg²⁺), renal function, BP, fluid balance. Fetal: growth (serial USG), amniotic fluid index, Doppler studies of umbilical artery.
Pre-conception counselling	If a woman of childbearing potential requires chronic diuretic therapy (e.g., for HF), discuss: switching to furosemide before planned conception; contraceptive counselling if pregnancy is not desired; the importance of informing the prescriber immediately upon confirmed pregnancy.

Pregnancy Prevention Programme: Not required. Torasemide is not a known teratogen — pregnancy avoidance is advised because of haemodynamic effects, not because of direct embryotoxicity.

Fertility Effects: No known effect on male or female fertility based on available animal and human data.

LACTATION

Parameter	Detail
Compatibility with breastfeeding	Use with caution — insufficient data to confirm safety.
Expected drug levels in milk	Not known whether torasemide is excreted in human breast milk. Given its high protein binding (~99%), only the unbound fraction (~1%) would be expected to enter milk; however, milk:plasma ratio has not been established. Relative Infant Dose (RID): Data not available.
Preferred alternatives	Furosemide — considered compatible with breastfeeding per LactMed (NIH); low levels in breast milk with no reported adverse effects in nursing infants. If loop diuretic is needed during lactation, furosemide is preferred.
What to monitor in infant	If torasemide use is unavoidable: monitor infant for signs of dehydration (reduced wet nappies, dry mouth, sunken fontanelle), poor feeding, irritability, or electrolyte disturbance.
Timing advice	If used, take the dose immediately after completing a breastfeed; avoid breastfeeding for 4–6 hours post-dose to minimise infant exposure (empiric advice given the absence of specific PK data in milk).
Effect on milk production	⚠️ Diuretics may SUPPRESS lactation by reducing intravascular volume and potentially affecting prolactin-mediated milk synthesis. This effect is more pronounced with aggressive diuresis. Minimise diuretic dose to the lowest effective amount.
Temporary incompatibility guidance	If torasemide is used as a short course (e.g., acute HF decompensation requiring IV diuresis), consider pump-and-discard for the treatment duration + 24 hours post last dose, then resume breastfeeding. Maintain milk supply by pumping regularly.

ELDERLY

Definition: ≥ 60 years (per Indian NPHCE definition).

Parameter	Recommendation
Recommended starting dose	5 mg once daily (oral) for oedema/HF; 2.5 mg once daily for hypertension. Start at HALF the usual adult starting dose in frail elderly or those with multiple comorbidities.
Need for slower titration	Yes. Increase dose no more frequently than every 7 days (vs every 2–3 days in younger adults). Assess clinical response, orthostatic BP, electrolytes, and renal function before each increment.
Extra risks specific to elderly	• Orthostatic hypotension and falls: Elderly patients have impaired baroreceptor reflexes. Loop diuretics exacerbate orthostatic drop. Falls are a leading cause of morbidity — hip fractures, head injuries. Measure lying and standing BP at every visit. • Dehydration and AKI: Reduced total body water, impaired thirst perception, concurrent ACEi/ARB use, and self-restricted fluid intake make elderly particularly vulnerable to over-diuresis. • Severe hyponatraemia: Elderly patients are disproportionately affected by diuretic-induced hyponatraemia (age-related impaired free water excretion, concurrent SSRI use, reduced dietary solute intake). Risk further amplified with concurrent thiazide use. • Hypokalaemia: Dietary potassium intake is often low in elderly; concurrent use of potassium-wasting drugs (corticosteroids) increases risk. • Cognitive impairment / delirium: Electrolyte disturbances and dehydration can precipitate or worsen delirium, which may be misattributed to progression of dementia. • Urinary incontinence / nocturia: Diuretics worsen urinary urgency and frequency, particularly problematic in elderly with pre-existing incontinence or benign prostatic hypertrophy. May impair sleep quality and increase nocturnal fall risk. • Polypharmacy: Elderly HF patients typically take 8–12 medications; vigilance for interactions (especially the “triple whammy”).
Beers Criteria / STOPP-START	STOPP: Loop diuretics as first-line monotherapy for hypertension in elderly — potentially inappropriate (thiazide-like diuretics such as chlorthalidone/indapamide preferred for BP). Loop diuretics for dependent ankle oedema without clinical evidence of HF — potentially inappropriate (consider non-pharmacological measures first). START: Loop diuretic IS appropriate (recommended) for symptomatic HF with volume overload.
Monitoring frequency in elderly	Electrolytes (K⁺, Na⁺, Mg²⁺) and renal function: check at baseline, 3–5 days after initiation or dose change, then monthly for 3 months, then every 3 months when stable. Orthostatic BP at every visit. Daily weight if possible.
Anticholinergic burden	No anticholinergic burden. Torasemide has no anticholinergic properties. No contribution to cumulative anticholinergic load.

Deprescribing Guidance

Torasemide is a common candidate for deprescribing review in elderly patients:

Criterion	Detail
When to consider stopping	(a) Original indication has resolved (e.g., acute episode of fluid overload, post-surgical oedema). (b) Stable compensated HF on optimal neurohormonal therapy (ACEi/ARB + beta-blocker + MRA) with no signs of congestion for ≥ 3 months — consider cautious dose reduction or trial of cessation under close monitoring. © Drug was prescribed for “ankle swelling” without confirmed HF — reassess indication. (d) Persistent adverse effects (significant hypotension, recurrent AKI, refractory electrolyte disturbance) outweigh clinical benefit.
Tapering schedule	If the patient has been on chronic therapy (> 4 weeks): reduce dose by 50% for 1 week → then 50% of the reduced dose for another week → then discontinue. Monitor daily weight and clinical signs of recongestion (dyspnoea, weight gain > 1 kg in 2 days, peripheral oedema). Do NOT taper during an acute illness or hospital admission.
Expected effects after discontinuation	No pharmacological withdrawal syndrome occurs with loop diuretics. However, rebound fluid retention can occur due to activation of the RAAS and post-diuretic sodium retention mechanisms. Monitor weight daily for 2 weeks after discontinuation. If weight increases > 1.5 kg or symptoms of congestion recur, resume the lowest effective dose.
Caution	Do NOT deprescribe loop diuretics in patients with active HFrEF symptoms, persistent volume overload, or who have not achieved euvolaemia. Deprescribing is a TRIAL — always have a clear plan for re-initiation.

MAJOR DRUG INTERACTIONS

Interacting Drug/Substance	Mechanism	Clinical Effect	Onset Type	Action Required
Aminoglycosides (gentamicin, amikacin, tobramycin, streptomycin)	Additive ototoxicity: both loop diuretics and aminoglycosides damage cochlear outer hair cells — loop diuretics via NKCC1 inhibition in stria vascularis, aminoglycosides via mitochondrial oxidative stress. Additive nephrotoxicity via different mechanisms.	Irreversible sensorineural hearing loss; vestibular toxicity; AKI	Acute onset (ototoxicity can occur within days)	⛔ AVOID concurrent use if possible. If combination is essential (e.g., endocarditis, severe gram-negative sepsis): use lowest effective torasemide dose, avoid rapid IV bolus administration, monitor auditory function (clinical symptoms + audiometry if available), monitor renal function daily. Separate IV administration times.
Cisplatin	Additive ototoxicity (cisplatin is directly cochleotoxic) and nephrotoxicity. Loop diuretic–induced volume depletion amplifies cisplatin nephrotoxicity.	Severe, often irreversible sensorineural hearing loss; AKI	Acute onset	⛔ AVOID concurrent use during cisplatin chemotherapy. If diuresis required, use with extreme caution; ensure aggressive pre-hydration with NS. Oncology and nephrology co-management.
Lithium	Loop diuretics reduce renal lithium clearance via two mechanisms: (a) sodium depletion → increased proximal tubular sodium (and lithium) reabsorption; (b) reduced GFR from volume depletion.	Lithium toxicity — tremor, ataxia, confusion, seizures, cardiac arrhythmias, renal injury; potentially fatal	Gradual onset (develops over days to weeks as lithium accumulates)	⚠️ If combination is unavoidable: reduce lithium dose by approximately 25–50% when initiating torasemide. Check lithium levels within 3–5 days of any torasemide dose change, and weekly for the first month. Maintain consistent sodium intake. Consider alternative diuretic (amiloride — does NOT significantly affect lithium clearance).
NSAIDs (diclofenac, ibuprofen, naproxen, piroxicam, ketorolac, aceclofenac — ALL non-selective and COX-2 selective)	(a) NSAIDs inhibit renal prostaglandin synthesis → reduced renal blood flow and GFR → blunted diuretic response. (b) NSAIDs compete with torasemide for OAT1/OAT3-mediated tubular secretion → reduced torasemide delivery to luminal site of action. © Volume depletion from diuretic + NSAID-induced afferent arteriolar vasoconstriction → AKI risk.	Reduced diuretic efficacy (up to 20–50% reduction in natriuretic response); increased risk of AKI — especially “triple whammy” with concurrent ACEi/ARB	Gradual onset (efficacy loss over days; AKI may be acute if dehydration coexists)	⚠️ Avoid concurrent NSAIDs if possible. If short-term NSAID use is essential: choose lowest dose for shortest duration; ensure adequate hydration; check creatinine at 48–72 hours. Paracetamol is the preferred analgesic. For the “triple whammy” (NSAID + ACEi/ARB + torasemide): ⛔ Avoid this triple combination. If unavoidable, monitor creatinine within 48 hours. Actively ask patients about OTC NSAID use at every visit — common source of unintentional triple therapy in India.
Digoxin	Torasemide-induced hypokalaemia and hypomagnesaemia increase myocardial sensitivity to digoxin toxicity (enhanced inhibition of Na⁺/K⁺-ATPase at lower digoxin concentrations).	Digoxin toxicity — nausea, visual disturbances (yellow-green halos), cardiac arrhythmias (paroxysmal atrial tachycardia with block, bidirectional VT, ventricular fibrillation); potentially fatal	Gradual onset (develops as electrolytes deplete over days to weeks)	⚠️ Maintain K⁺ ≥ 4.0 mEq/L and Mg²⁺ ≥ 2.0 mg/dL at ALL times. Check electrolytes within 3–5 days of any torasemide dose change. Consider addition of spironolactone/eplerenone (potassium-sparing + HF benefit). Monitor digoxin levels more frequently during titration.
Rifampicin	Potent CYP2C9 inducer → increased hepatic metabolism of torasemide → reduced plasma levels and reduced diuretic efficacy. Rifampicin also induces P-glycoprotein and OATPs, further altering torasemide disposition.	Clinically significant reduction in torasemide efficacy — may result in loss of diuretic response and worsening oedema/congestion. AUC reduced by approximately 50–80%.	Gradual onset (maximal enzyme induction over 1–2 weeks)	⚠️ Highly relevant to Indian practice — rifampicin is widely used for TB. If concurrent use is unavoidable: increase torasemide dose by approximately 50–100% and titrate to clinical response (daily weight, oedema assessment). Consider switching to furosemide (less CYP2C9-dependent metabolism). Monitor for recurrence of oedema/congestion. Upon rifampicin discontinuation, reduce torasemide dose to avoid over-diuresis (enzyme de-induction takes 2–3 weeks).
Fluconazole (≥ 200 mg/day)	Moderate-to-strong CYP2C9 inhibitor → reduced hepatic metabolism of torasemide → increased plasma levels and prolonged half-life.	Excessive diuresis, hypotension, severe electrolyte disturbance (hypokalaemia, hyponatraemia). AUC may increase by 50–100%.	Gradual onset (accumulation over 3–5 days)	⚠️ Reduce torasemide dose by approximately 50% when initiating fluconazole ≥ 200 mg/day. Monitor electrolytes and renal function within 3–5 days. Resume usual torasemide dose 3–5 days after fluconazole discontinuation. Low-dose fluconazole (50–100 mg/day) — less likely to cause clinically significant interaction, but monitor.
Desmopressin	Torasemide counteracts the antidiuretic effect of desmopressin by promoting renal water excretion.	Reduced efficacy of desmopressin for its indications (central diabetes insipidus, nocturnal enuresis, haemophilia A).	Acute onset	⛔ Avoid concurrent use. If both are clinically required (rare), manage under specialist supervision with close monitoring of urine output and serum sodium.
Other ototoxic drugs — Vancomycin	Additive ototoxicity (vancomycin → cochlear damage) and nephrotoxicity. Less well-established synergy than with aminoglycosides, but clinically relevant in ICU settings.	Hearing loss, AKI	Acute to gradual onset	⚠️ Avoid rapid IV bolus torasemide in patients receiving vancomycin. Monitor renal function daily when combination is used. Maintain adequate hydration. Target vancomycin troughs per protocol.
Methotrexate (high-dose)	Loop diuretics reduce renal clearance of methotrexate by competing for tubular secretion and reducing GFR through volume depletion.	Prolonged methotrexate exposure → increased risk of methotrexate toxicity (myelosuppression, mucositis, nephrotoxicity, hepatotoxicity)	Acute onset (relevant during high-dose MTX protocols)	⛔ AVOID concurrent loop diuretics during high-dose methotrexate protocols. If diuresis is essential, consult oncology for methotrexate dose adjustment and leucovorin rescue timing. Low-dose weekly methotrexate (7.5–25 mg) for RA: less risk, but monitor CBC and renal function.

Food-Drug and Herb-Drug Interactions (Major)

Interacting Substance	Mechanism	Clinical Effect	Action Required
Licorice root (Mulethi / Yashtimadhu)	Glycyrrhizin in licorice inhibits 11-beta-hydroxysteroid dehydrogenase type 2 → cortisol acts as mineralocorticoid → sodium retention, potassium wasting, water retention.	Counteracts natriuretic effect of torasemide; WORSENS hypokalaemia synergistically; may cause hypertension, oedema, and metabolic alkalosis.	⚠️ Traditional medicine interaction. Avoid regular consumption of licorice-containing products (mulethi tea, paan masala with mulethi, some ayurvedic formulations) during torasemide therapy. Occasional use in small quantities is unlikely to be significant.

MODERATE DRUG INTERACTIONS

Interacting Drug/Substance	Mechanism	Clinical Effect	Onset Type	Action Required
ACE inhibitors / ARBs (enalapril, ramipril, telmisartan, losartan, etc.)	(a) ACEi/ARBs reduce angiotensin II–mediated efferent arteriolar tone; combined with torasemide-induced volume depletion → reduced GFR. (b) First-dose hypotension risk in diuretic-treated patients.	Symptomatic hypotension (especially first dose of ACEi); AKI risk (especially if combined with NSAID — see “triple whammy” above)	Acute onset (first-dose hypotension within hours); Gradual onset (AKI risk over days)	This is a STANDARD and BENEFICIAL combination in HF and hypertension — do NOT avoid. Management: (a) When initiating ACEi/ARB in patient already on torasemide: consider withholding torasemide dose on the morning of ACEi initiation or give first ACEi dose at bedtime; start at lowest ACEi dose. (b) Check renal function and K⁺ at 1 week. © When adding torasemide to patient already on ACEi/ARB: start torasemide at lower dose.
SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin)	SGLT2 inhibitors produce osmotic diuresis and natriuresis through a mechanism independent of NKCC2 (proximal tubule SGLT2 blockade). Effect is ADDITIVE to loop diuretic–induced natriuresis.	Excessive diuresis, volume depletion, hypotension, AKI, particularly in first 2 weeks of SGLT2i initiation. Risk of euglycaemic DKA may be increased by volume depletion.	Acute to gradual onset (develops over days)	⚠️ Increasingly common clinical scenario in India as SGLT2i use in HF expands. When initiating SGLT2i in a patient already on torasemide: (a) REDUCE torasemide dose by 25–50% at the time of SGLT2i initiation. (b) Instruct patient to monitor daily weight. © Check renal function and electrolytes at 1 week. (d) Reassess torasemide dose at 2–4 weeks. If initiating torasemide in patient already on SGLT2i: start at lowest dose with close monitoring.
Spironolactone / Eplerenone	Opposing effects on potassium: torasemide causes kaliuresis; MRA causes potassium retention. Combination is pharmacologically rational and guideline-recommended in HF.	Risk of hyperkalaemia (especially if renal function worsens or high MRA doses used) or persistent hypokalaemia (if MRA dose is insufficient).	Gradual onset	This is a RECOMMENDED combination in HF (RALES trial, EMPHASIS-HF trial). Monitor K⁺ at 3 days, 1 week, and 1 month after initiation or dose change. Target K⁺ 4.0–5.0 mEq/L. ⛔ Hold MRA if K⁺ > 5.5 mEq/L. Recheck in 48 hours.
Corticosteroids (prednisolone, dexamethasone, methylprednisolone — systemic)	Additive hypokalaemia (corticosteroids have intrinsic mineralocorticoid activity, especially at high doses). Corticosteroid-induced sodium and water retention may partially counteract diuretic effect.	Hypokalaemia (potentially severe); paradoxically reduced diuretic efficacy due to sodium retention.	Gradual onset	Monitor K⁺ more frequently (every 3–5 days during high-dose corticosteroid therapy). Supplement K⁺ prophylactically if both drugs are at significant doses.
Amphotericin B (conventional and liposomal)	Additive hypokalaemia (amphotericin B causes renal potassium wasting via direct tubular damage). Additive nephrotoxicity.	Severe, refractory hypokalaemia; AKI.	Gradual onset	Monitor K⁺ and Mg²⁺ daily during concurrent use. Aggressive K⁺ and Mg²⁺ supplementation usually required. Monitor renal function daily.
Probenecid	Competes with torasemide for OAT1/OAT3-mediated tubular secretion. Since torasemide must reach the tubular lumen via OAT-mediated secretion to act on NKCC2, probenecid blocks drug delivery to the site of action.	Reduced diuretic efficacy — may appear as “diuretic resistance.”	Gradual onset	Increase torasemide dose to compensate (may need 50–100% dose increase). Monitor diuretic response by daily weight and urine output. Consider alternative uricosuric agent if possible.
Cholestyramine / Colestipol	Binds torasemide in the GI tract, reducing oral absorption.	Reduced oral bioavailability and diuretic efficacy.	Acute onset (per-dose basis)	Separate administration by at least 2–4 hours (take torasemide 1 hour before or 4 hours after cholestyramine).
Sucralfate	May reduce torasemide absorption via physical binding in GI tract.	Reduced diuretic efficacy.	Acute onset	Separate by at least 2 hours.
Antidiabetic agents (sulfonylureas, metformin, insulin, DPP-4i, etc.)	Torasemide-induced hyperglycaemia (via hypokalaemia-mediated impaired insulin secretion and reduced peripheral glucose uptake) counteracts antidiabetic efficacy.	Worsened glycaemic control — usually modest (FBG increase 10–20 mg/dL; HbA1c increase 0.1–0.3%).	Gradual onset	Monitor fasting glucose and HbA1c. Adjust antidiabetic dose if needed. Effect is dose-dependent — less at lower torasemide doses.
Other antihypertensives (all classes — CCBs, alpha-blockers, centrally acting agents, nitrates, hydralazine)	Additive blood pressure lowering and orthostatic hypotension risk.	Symptomatic hypotension, dizziness, syncope, falls (especially elderly).	Acute onset (postural)	Expected and usually beneficial in hypertensive patients. Warn patients about positional changes. Monitor standing BP. Start new antihypertensives at lower doses in patients already on torasemide.
Warfarin	Both torasemide and warfarin are CYP2C9 substrates — potential competition for metabolism. Also, highly protein-bound torasemide (~99%) may theoretically displace warfarin from albumin. Clinical significance is modest.	Slightly increased warfarin effect (INR increase).	Gradual onset	Monitor INR more frequently (every 3–5 days) when torasemide is initiated, dose-changed, or discontinued in a warfarin-treated patient. Adjust warfarin dose as needed based on INR.
Phenytoin	Both are CYP2C9 substrates — bidirectional competition for metabolism.	Unpredictable: may increase or decrease levels of either drug.	Gradual onset	Monitor phenytoin levels when torasemide is initiated or dose-changed. Monitor diuretic response.
Cyclosporine	Additive nephrotoxicity. Additive hyperuricaemia (both reduce uric acid excretion).	AKI, gout.	Gradual onset	Monitor renal function and uric acid closely. Ensure adequate hydration.
Stimulant laxatives (bisacodyl, senna — chronic use)	Chronic stimulant laxative use causes potassium loss via the GI tract, additive to renal potassium losses from torasemide.	Severe hypokalaemia.	Gradual onset	Discourage chronic stimulant laxative use. If bowel regimen needed, prefer osmotic laxatives (lactulose, polyethylene glycol). Monitor K⁺.

Food-Drug and Herb-Drug Interactions (Moderate)

Interacting Substance	Mechanism	Clinical Effect	Action Required
Alcohol	Additive vasodilation and hypotension; exacerbates dehydration.	Orthostatic hypotension, dizziness, syncope.	Counsel patients to limit alcohol intake and be cautious when standing from sitting/lying position.
High-sodium diet	Excessive dietary sodium overwhelms the natriuretic effect of torasemide.	Apparent diuretic resistance — patient fails to lose weight or resolve oedema despite adequate diuretic doses.	Dietary sodium restriction (< 2 g/day sodium or < 5 g/day NaCl) is an essential adjunct to diuretic therapy. This should be actively verified before escalating diuretic dose.
Ashwagandha (Withania somnifera — ayurvedic use)	May have mild diuretic and hypotensive properties.	Additive hypotension and volume depletion — usually modest.	Traditional medicine interaction. Counsel patients to inform their doctor about regular ashwagandha use. Generally low risk but monitor BP.
Arjuna (Terminalia arjuna — ayurvedic cardiotonic)	May have mild diuretic, hypotensive, and inotropic properties. Commonly used by HF patients in India as complementary therapy.	Additive hypotension; unpredictable effect on fluid balance.	Traditional medicine interaction. No specific dose adjustment known. Advise patients to inform prescriber about concurrent use. Do not rely on Arjuna as a substitute for evidence-based HF therapy.

COMMON ADVERSE EFFECTS

Grouped by system. Frequencies derived from pooled clinical trial data.

Very Common (≥ 10%)

System	Adverse Effect	Notes
Renal	Polyuria / increased urination frequency	Expected pharmacological effect; not a true adverse event. More pronounced in first 1–2 weeks. Dose-dependent.

Common (1–10%)

System	Adverse Effect	Approximate Incidence	Notes
CNS	Headache	7–8%	Usually transient; resolves within first week. Not dose-dependent.
CNS	Dizziness / light-headedness	3–5%	Dose-dependent. Related to hypotension and/or volume depletion. Warn about driving and operating machinery.
CNS	Fatigue / asthenia	2%	May reflect volume depletion or electrolyte disturbance (check K⁺, Mg²⁺, Na⁺).
GI	Nausea	1–2%	Usually transient. May improve if taken with food (food does not significantly affect efficacy).
GI	Diarrhoea	1–2%	Usually transient. If persistent, check for Mg²⁺ supplementation as cause.
GI	Constipation	1–2%	Dose-dependent — related to hypokalaemia (hypokalemic ileus at extreme).
GI	Dyspepsia	1–2%	Taking with food may help.
Musculoskeletal	Muscle cramps / myalgia	1–3%	Dose-dependent. Most commonly indicates hypokalaemia and/or hypomagnesaemia. Check electrolytes before attributing to “drug intolerance.” Correct Mg²⁺ first (refractory cramps often indicate Mg²⁺ depletion even if K⁺ appears normal).
Metabolic	Hypokalaemia (K⁺ 3.0–3.5 mEq/L)	4–6%	Dose-dependent. Less frequent than with equinatriuretic furosemide (see PK section — anti-aldosterone activity). Threshold: clinically significant below 3.5 mEq/L; dangerous below 3.0 mEq/L.
Metabolic	Hyperuricaemia	5–8%	Dose-dependent. Usually asymptomatic; clinical gout in 2–5% of patients.
Metabolic	Hyperglycaemia	2–4%	Dose-dependent. Clinically significant mainly at doses > 40 mg/day.
Respiratory	Rhinitis	1–2%	Uncertain causal relationship.
Cardiovascular	Orthostatic hypotension	1–3%	Dose-dependent. More common in elderly, volume-depleted patients, and those on concurrent antihypertensives.

SERIOUS ADVERSE EFFECTS

⚠️ Ototoxicity — Loop Diuretic Class Effect

Parameter	Detail
Classification	Loop diuretic class effect, NOT a torasemide-specific signature ADR. Torasemide has LOWER ototoxic potential than furosemide or ethacrynic acid.
Incidence	At standard oral doses: very rare (< 0.1%). At high IV doses or with concurrent ototoxic agents: reported incidence 1–6%.
Timing	Can occur within minutes to hours of high-dose IV administration.
Mechanism	Inhibition of NKCC1 (the Na⁺-K⁺-2Cl⁻ cotransporter isoform in the stria vascularis of the cochlea — distinct from NKCC2 in the kidney). NKCC1 inhibition disrupts endolymph potassium recycling, altering the endocochlear potential required for auditory transduction. Torasemide has lower affinity for NKCC1 relative to NKCC2 compared to furosemide, which may explain its lower ototoxic potential.
Risk factors	(a) High IV bolus doses (especially > 200 mg furosemide equivalent; less well-defined for torasemide). (b) Rapid IV injection rate. © Concurrent aminoglycosides, cisplatin, or vancomycin. (d) Renal impairment (reduced clearance → higher sustained plasma levels). (e) Pre-existing hearing impairment.
Manifestation	Tinnitus (early warning sign), hearing loss (sensorineural, initially high-frequency), vertigo.
Reversibility	Usually REVERSIBLE if drug is discontinued promptly. However, may become irreversible with concurrent aminoglycosides or if exposure continues despite symptoms.
Prevention	(a) Inject IV torasemide slowly — over at least 2 minutes for doses ≤ 20 mg; over 3–5 minutes for higher doses. (b) For doses > 50 mg IV, consider administration as a slow IV infusion (over 30–60 minutes) rather than bolus. © Avoid concurrent ototoxic drugs when possible. (d) Reduce dose in renal impairment.
Management	If tinnitus or hearing changes develop: STOP torasemide immediately. Assess hearing (clinical + pure-tone audiometry if available). Most cases reverse within 24–48 hours of drug discontinuation. If aminoglycoside co-administration is ongoing, discontinue that as well and obtain ENT consultation.

Other Serious Adverse Effects

Adverse Effect	Approximate Frequency	Clinical Detail	Action Required
Severe hypokalaemia (K⁺ < 2.5 mEq/L)	Rare at standard doses; higher with excessive dosing, concurrent K⁺-wasting drugs, or diarrhoea	Life-threatening cardiac arrhythmias (ventricular tachycardia/fibrillation, torsades de pointes), respiratory muscle weakness, rhabdomyolysis, paralytic ileus	⛔ URGENT correction: IV KCl via central line (rate ≤ 20 mEq/hr peripherally; ≤ 40 mEq/hr centrally in ICU with continuous ECG monitoring). Hold torasemide until K⁺ ≥ 3.0 mEq/L. Correct concurrent hypomagnesaemia (essential for K⁺ repletion).
Severe hyponatraemia (Na⁺ < 120 mEq/L)	Rare; higher risk in elderly, concurrent thiazide, or SIADH	Confusion, seizures, coma. Risk of osmotic demyelination if corrected too rapidly.	⛔ HOLD torasemide. Restrict free water. Correct Na⁺ slowly (≤ 8 mEq/L per 24 hours). Specialist input.
Hypovolaemic shock / severe dehydration	Rare; risk increases with excessive dosing, concurrent diuretics, intercurrent illness (GI losses)	Severe hypotension, tachycardia, oliguria, organ hypoperfusion	⛔ STOP diuretic. IV fluid resuscitation (0.9% NaCl). Monitor urine output. May require ICU admission.
Acute kidney injury (non-haemoconcentration type)	Uncommon	Pre-renal AKI from true over-diuresis; distinguish from pseudo-WRF (see Cautions). Creatinine rise > 0.5 mg/dL with signs of hypovolaemia.	Hold torasemide. Volume resuscitation. Monitor creatinine trajectory.
Precipitation of hepatic encephalopathy (in cirrhotic patients)	Uncommon in carefully managed patients; common if electrolyte monitoring is neglected	Worsened confusion, asterixis, coma — via hypokalaemia-mediated alkalosis shifting NH₄⁺ → NH₃	Hold diuretic. Correct hypokalaemia. Administer lactulose. Titrate rifaximin. Resume diuretic at lower dose once encephalopathy resolves to ≤ grade I.
Pancreatitis	Very rare (< 0.01%)	Mechanism uncertain; reported as class effect of loop diuretics. Abdominal pain, elevated lipase/amylase.	Discontinue torasemide. Supportive management. Consider alternative diuretic class if diuresis still needed.
Thrombocytopenia	Very rare	Immune-mediated or direct marrow toxicity — mechanism unclear.	Discontinue torasemide. Monitor platelet count. Usually reversible. Do not rechallenge.
Aplastic anaemia	Extremely rare (case reports only)	Idiosyncratic.	Discontinue immediately. Haematology referral.
Stevens-Johnson syndrome (SJS) / Toxic Epidermal Necrolysis (TEN)	Extremely rare	Severe cutaneous adverse reaction. More commonly reported with furosemide than torasemide, but possible as sulfonamide class effect.	⛔ Discontinue IMMEDIATELY. Dermatology consultation. ICU/burn unit if > 10% BSA involved. ⛔ NEVER rechallenge. Consider cross-reactivity with other sulfonamide-containing drugs (see cross-reactivity table).
Interstitial nephritis (allergic)	Very rare	Fever, rash, eosinophilia, rising creatinine occurring days to weeks after initiation.	Discontinue torasemide. Renal biopsy if diagnosis uncertain. Corticosteroids may be required.
Photosensitivity — severe	Rare (mild photosensitivity is more common)	Severe phototoxic or photoallergic dermatitis with blistering.	Discontinue or reduce dose. Sun protection. Dermatology referral.
Anaphylaxis	Extremely rare	Immediate hypersensitivity reaction — urticaria, angioedema, bronchospasm, hypotension, cardiovascular collapse.	⛔ Epinephrine (adrenaline) 0.5 mg IM (0.01 mg/kg in children; max 0.3 mg). Standard anaphylaxis protocol. Never rechallenge.

Antidote / Overdose Management

Parameter	Detail
Specific antidote	⛔ No specific antidote exists for torasemide overdose.
Overdose presentation	Massive diuresis → severe dehydration, hypotension, electrolyte depletion (hypokalaemia, hyponatraemia, hypochloraemia), metabolic alkalosis, circulatory collapse. Ototoxicity possible at very high doses.
Management	Supportive: (a) IV fluid resuscitation with 0.9% NaCl. (b) Aggressive electrolyte replacement — K⁺, Mg²⁺, Na⁺, Cl⁻ as needed. © Haemodynamic support — vasopressors if fluid-refractory hypotension. (d) Cardiac monitoring for arrhythmias. (e) Haemodialysis is NOT effective for removing torasemide (highly protein-bound, ~99%). Gastric decontamination with activated charcoal may be useful if oral ingestion within 1 hour.
Antidote availability in India	Not applicable (no specific antidote). Supportive care drugs (IV NaCl, KCl, MgSO₄, vasopressors) are universally available.

⚠️ Report to nearest ADR Monitoring Centre under PvPI (Pharmacovigilance Programme of India) or via the ADR reporting form on CDSCO website for all serious adverse effects — including suspected serious events even if causality is uncertain.

LABORATORY TEST INTERFERENCE

Test	Type of Interference	Clinical Implication	Alternative Test Method
Serum potassium	True pharmacological decrease (not assay interference)	K⁺ decreases by 0.3–0.8 mEq/L on average at therapeutic doses. Must be interpreted in context of diuretic use — a “normal” K⁺ of 3.6 may actually represent significant total body K⁺ depletion in a patient on chronic torasemide.	Not applicable (this is a real effect, not an assay artefact). Supplement if K⁺ < 3.5 mEq/L (or < 4.0 mEq/L in patients on digoxin).
Serum sodium	True pharmacological decrease	Hyponatraemia may develop, especially in elderly or with concurrent thiazide use.	Not applicable (real effect).
Serum magnesium	True pharmacological decrease	Often under-checked in practice. Refractory hypokalaemia suggests concurrent hypomagnesaemia.	Not applicable. Always request Mg²⁺ alongside K⁺ during diuretic monitoring.
Serum calcium	True pharmacological decrease (calciuria)	Loop diuretics INCREASE urinary calcium excretion — opposite to thiazides. May affect interpretation of calcium studies. ℹ️ Loop diuretics can be used therapeutically for acute hypercalcaemia management (forced saline diuresis).	When evaluating calcium metabolism or hyperparathyroidism, note concurrent loop diuretic use — serum calcium may be artefactually low, and urinary calcium will be artefactually high.
Serum uric acid	True pharmacological increase	Hyperuricaemia occurs in 40–60% of patients. Should not be mistaken for a new diagnosis of gout diathesis — it is drug-induced. Do not initiate urate-lowering therapy solely for asymptomatic diuretic-induced hyperuricaemia unless uric acid is very high (> 13 mg/dL) or recurrent gout flares occur.	Not applicable (real effect).
Blood glucose (fasting)	True pharmacological increase	Mild elevation (10–20 mg/dL). May confound diabetes screening. If fasting glucose is borderline elevated in a patient on torasemide, repeat after dose reduction or use HbA1c (less affected by acute glucose changes) for screening.	HbA1c is more reliable for diabetes screening/monitoring in patients on loop diuretics.
BUN / Serum creatinine	True pharmacological increase (pre-renal effect from volume contraction)	Rise in BUN disproportionate to creatinine (BUN:creatinine ratio > 20:1) suggests pre-renal azotaemia from over-diuresis. Must distinguish from “pseudo-WRF” during active decongestion (see Cautions).	Not assay interference. Interpret in clinical context — assess volume status.
Urine glucose (Benedict’s reagent method)	No direct interference	Unlike some cephalosporins, torasemide does not cause false-positive Benedict’s test.	Not applicable.
Serum creatinine (Jaffé reaction)	No direct interference from torasemide itself	However, haemoconcentration from diuresis can increase creatinine concentration. In severely dehydrated patients, the Jaffé method may be more susceptible to interference from endogenous chromogens.	Enzymatic creatinine assay is more specific. In clinical practice, the Jaffé method is adequate if volume status is considered.
Thyroid function tests (T4, TSH)	No clinically significant interference	Unlike high-dose IV furosemide (which can displace T4 from binding proteins causing transient free T4 elevation), torasemide at standard oral doses does not significantly affect thyroid function tests.	Not applicable.
Urinary catecholamines / VMA / 5-HIAA	No documented interference	Torasemide does not affect these assays.	Not applicable.
Parathyroid function assessment	Indirect effect via calciuria	Loop diuretic–induced urinary calcium loss stimulates compensatory PTH secretion. Mildly elevated PTH in a patient on chronic loop diuretic does NOT necessarily indicate primary hyperparathyroidism — it may be secondary to drug-induced hypocalcaemia.	If evaluating for primary hyperparathyroidism, consider holding loop diuretic for 1–2 weeks (if clinically safe) and rechecking calcium/PTH.

ℹ️ Common investigation misconception flag: Serum magnesium is NOT routinely ordered alongside potassium during diuretic monitoring in many Indian clinical settings. This is a significant gap — hypomagnesaemia is a frequent cause of refractory hypokalaemia and refractory muscle cramps in patients on loop diuretics. Always order serum magnesium alongside potassium when monitoring diuretic-treated patients.

MONITORING REQUIREMENTS

Electrolyte Monitoring Protocol (Diuretic-Specific)

Electrolyte	Target Range	Special Target	Monitoring Notes
Potassium (K⁺)	3.5–5.0 mEq/L	≥ 4.0 mEq/L if on digoxin, history of arrhythmia, QTc prolongation, or concurrent QT-prolonging drugs	Most important electrolyte to monitor. Frequency detailed in timeline below.
Sodium (Na⁺)	135–145 mEq/L	> 130 mEq/L minimum; HOLD diuretic if < 125 mEq/L	Higher risk: elderly, concurrent thiazide, cirrhosis, SIADH.
Magnesium (Mg²⁺)	1.8–2.4 mg/dL (0.75–1.0 mmol/L)	≥ 2.0 mg/dL if on digoxin	Often under-ordered in Indian practice — ALWAYS request alongside K⁺. Refractory hypokalaemia is often caused by concurrent hypomagnesaemia.
Calcium (Ca²⁺)	8.5–10.5 mg/dL (total); corrected for albumin	—	Loop diuretics increase urinary calcium excretion. Monitor in chronic high-dose use and in patients with vitamin D deficiency (very common in India).
Chloride (Cl⁻)	96–106 mEq/L	—	Hypochloraemia indicates metabolic alkalosis. Correct with NaCl or KCl.
Bicarbonate (HCO₃⁻)	22–28 mEq/L	—	Elevated bicarbonate confirms metabolic alkalosis — especially important in cirrhotics (worsens encephalopathy).
Uric acid	< 7.0 mg/dL (male); < 6.0 mg/dL (female)	< 6.0 mg/dL if history of gout	Baseline + periodic (every 6–12 months in chronic use). Do NOT treat asymptomatic hyperuricaemia unless very high (> 13 mg/dL) or recurrent gout.

Monitoring Timeline

Baseline (Before Starting) — MANDATORY

Parameter	Grade	Detail
Serum electrolytes (K⁺, Na⁺, Mg²⁺, Cl⁻, HCO₃⁻)	MANDATORY	⛔ Do NOT start torasemide if K⁺ < 3.0 mEq/L or Na⁺ < 125 mEq/L — correct first.
Serum creatinine + eGFR	MANDATORY	Establishes baseline renal function for dose selection and future comparison. Note the baseline value prominently in patient records.
Blood urea nitrogen (BUN)	RECOMMENDED	BUN:creatinine ratio > 20:1 at baseline suggests pre-renal state — optimise volume before starting diuretic.
Fasting blood glucose	RECOMMENDED	Baseline for monitoring glucose disturbance. HbA1c also helpful if diabetic or pre-diabetic.
Serum uric acid	RECOMMENDED	Baseline for comparison; identifies patients at risk of gout flare.
Serum calcium	RECOMMENDED	Especially in patients with vitamin D deficiency, hypoparathyroidism, or those on chronic therapy.
Blood pressure (sitting AND standing)	MANDATORY	Orthostatic BP measurement is essential — identifies patients at high risk of postural hypotension. Record the orthostatic drop (> 20 mmHg systolic or > 10 mmHg diastolic is significant).
Body weight	MANDATORY	Baseline weight is the MOST IMPORTANT monitoring tool for diuretic therapy. Document “dry weight” (target euvolaemic weight) when patient is clinically euvolaemic.
Clinical volume status assessment	MANDATORY	JVP, peripheral oedema (grade 1–4), lung crackles, hepatomegaly, ascites. Document baseline clearly.
ECG	RECOMMENDED	Baseline QTc; especially important if concurrent digoxin, QT-prolonging drugs, or history of arrhythmia.
Hepatic function (LFTs)	OPTIONAL but helpful	Torasemide is hepatically metabolised via CYP2C9. Baseline LFTs help guide dose selection in suspected liver disease and provide reference for hepatotoxicity monitoring (though torasemide hepatotoxicity is exceedingly rare).
Hearing assessment	OPTIONAL but helpful	Clinical history of tinnitus, hearing difficulty. Formal audiometry NOT routinely required at standard oral doses. RECOMMENDED (upgrade) if concurrent aminoglycoside, cisplatin, or renal impairment.

Resource-limited setting surrogates (Baseline):

If serum electrolytes or creatinine are unavailable (rural PHC/sub-centre):

Monitor clinical signs of dehydration (skin turgor, mucous membranes, postural symptoms)
Check BP lying and standing
Weigh the patient (weighing scale is the single most valuable monitoring tool — ensure one is available)
Ask about urine output pattern and colour
If ANY clinical suspicion of renal impairment or electrolyte disturbance: refer to CHC/district hospital for labs before starting diuretic
⛔ Do NOT initiate high-dose torasemide (> 10 mg/day) without baseline electrolytes and creatinine

After Initiation or Dose Change

Parameter	Timing	Grade	Notes
Serum K⁺, Na⁺, Mg²⁺	3–5 days after starting or any dose change	MANDATORY	Most electrolyte disturbances become apparent within 3–7 days. Check earlier (within 24–48 hours) if: high starting dose, concurrent potassium-wasting drugs, pre-existing electrolyte abnormality, or ICU setting.
Serum creatinine + BUN	3–7 days after starting or dose change	MANDATORY	Distinguish true AKI from haemoconcentration (pseudo-WRF) — see Part 4 Cautions.
Body weight	DAILY during active dose titration (hospital or outpatient self-monitoring)	MANDATORY	Target weight loss: HF with peripheral oedema — 0.5–1.0 kg/day; cirrhotic ascites with oedema — ≤ 1.0 kg/day; ascites only — ≤ 0.5 kg/day. Weight gain > 1 kg in 2 days suggests inadequate dose or non-adherence to sodium restriction.
Blood pressure (sitting + standing)	At every dose change visit	MANDATORY	Monitor for orthostatic hypotension — especially elderly and concurrent antihypertensive users.
Urine output	Daily (inpatient) or subjective assessment (outpatient)	RECOMMENDED	Oliguria (< 0.5 mL/kg/hr or < 500 mL/day) with rising creatinine = true AKI → HOLD diuretic.
Clinical volume assessment	At every visit during titration	MANDATORY	JVP, oedema, lung examination. Document response to guide dose adjustment.
Fasting glucose	1–2 weeks after initiation if diabetic or pre-diabetic	RECOMMENDED	Adjust antidiabetic therapy if glucose rises significantly.
ECG	1 week after initiation if on digoxin, QT-prolonging drugs, or K⁺ found low	RECOMMENDED	Assess QTc prolongation. Check for signs of hypokalaemia on ECG (U waves, ST depression, T wave flattening).

Resource-limited setting surrogates (Post-initiation):

If serum potassium cannot be checked: monitor for clinical signs of hypokalaemia — muscle weakness, cramps (especially calf cramps), fatigue, constipation, palpitations. If ECG is available, look for U waves, ST depression, T-wave flattening, and prolonged QTc.
If serum sodium cannot be checked: monitor for confusion, drowsiness, nausea, headache, seizures (severe hyponatraemia).
⚠️ Counsel patients to report any of these symptoms immediately. These clinical surrogates are LESS reliable than laboratory monitoring — use them only when labs are genuinely unavailable, not as a substitute for standard care.

Long-Term / Maintenance Monitoring

Parameter	Frequency	Grade	Notes
Serum K⁺, Na⁺, Mg²⁺	Every 1–3 months when on stable dose	MANDATORY	Monthly for first 3 months, then every 3 months if stable. More frequently if: concurrent digoxin, concurrent QT-prolonging drugs, concurrent K⁺-wasting agents, elderly, CKD, cirrhosis, or dose change.
Serum creatinine + eGFR	Every 1–3 months	MANDATORY	Trend more important than single values. Gradually rising creatinine may indicate chronic over-diuresis or progression of underlying kidney disease.
Body weight	Weekly (outpatient self-monitoring); daily during HF decompensation	MANDATORY	Instruct patient on daily weight monitoring at home — same time, after voiding, before breakfast, same clothing/scale. Weight gain > 1.5 kg in 1 week → contact prescriber.
Blood pressure (including orthostatic)	Every visit (every 1–3 months)	MANDATORY	Orthostatic drop > 20/10 mmHg → consider dose reduction, especially in elderly.
Serum uric acid	Every 6–12 months	RECOMMENDED	More frequently if history of gout.
Fasting glucose / HbA1c	Every 3–6 months if diabetic; annually if non-diabetic	RECOMMENDED	Monitor for diuretic-induced glucose intolerance.
Serum calcium + vitamin D	Every 6–12 months on chronic therapy	OPTIONAL but helpful	Especially in elderly with osteoporosis risk, vitamin D deficiency (highly prevalent in India).
Hepatic function (LFTs)	Every 6–12 months on chronic therapy	OPTIONAL but helpful	No strong evidence for routine monitoring, but reasonable given hepatic metabolism. Also relevant if concurrent hepatotoxic drugs.
Renal function (comprehensive: Cr, BUN, eGFR, electrolytes)	Every 3 months for chronic use	MANDATORY	Renal function may gradually change with chronic diuretic use. Adjust dose accordingly.
ECG	Annually, or sooner if arrhythmia symptoms or electrolyte disturbance	RECOMMENDED	QTc assessment; arrhythmia screening.
Clinical volume assessment	Every visit	MANDATORY	Document JVP, oedema, weight, orthostatic BP at every visit. Adjust diuretic dose based on volume status, NOT on a fixed schedule.

Volume Status Assessment Guidance

Assessment Tool	Target	Setting
Daily weight	Primary monitoring tool. HF: target 0.5–1.0 kg/day loss during active decongestion; maintenance: stable weight within ± 1 kg of dry weight. Cirrhosis with ascites + oedema: ≤ 1.0 kg/day loss. Ascites only: ≤ 0.5 kg/day loss.	All settings — hospital and home
Clinical signs of over-diuresis	Postural hypotension (systolic drop > 20 mmHg), tachycardia, dry mucous membranes, decreased skin turgor, low JVP, oliguria, rising creatinine with BUN:Cr > 20:1, patient reports excessive thirst and dizziness	All settings
Clinical signs of under-diuresis (persistent congestion)	Persistent peripheral oedema, elevated JVP, lung crackles (in HF), increasing abdominal girth (ascites), dyspnoea on exertion or at rest, weight gain > 1 kg in 2 days	All settings
Urine output	Inpatient: target > 0.5 mL/kg/hr. Outpatient: patient should void at least 4–6 times daily; urine should not be deeply concentrated.	Inpatient primarily; subjective assessment outpatient
IVC collapsibility (bedside ultrasound)	If available — IVC diameter < 2.1 cm with > 50% collapse with sniff suggests non-elevated CVP. Fixed, dilated IVC suggests persistent congestion.	Urban/tertiary care; not available in PHC

💡 Practical tip for patient-directed flexible dosing: In STABLE, well-educated HF patients: consider teaching patient-directed flexible dosing based on daily weight. Example protocol: “If weight increases > 1.5 kg over 2 days, take an extra [dose] of torasemide that day and restrict fluid/salt. If weight continues to rise or you become breathless, contact your doctor within 24 hours.” This approach improves outcomes in self-management trials but requires adequate patient education and cognitive capacity.

Therapeutic Drug Monitoring (TDM)

Not applicable. Torasemide does NOT require routine therapeutic drug monitoring. Dose is titrated to clinical effect (body weight, oedema, urine output, congestion signs), NOT to plasma drug levels. No established therapeutic plasma concentration range.

When to Stop Monitoring

Monitoring should NEVER be fully stopped for patients on chronic torasemide therapy. The minimum acceptable monitoring frequency for a stable patient on a fixed dose with stable renal function is:

Electrolytes (K⁺, Na⁺) + creatinine: every 3 months
Body weight: weekly (home monitoring by patient)
BP (including orthostatic): every clinic visit
Clinical volume assessment: every clinic visit

ℹ️ Common investigation misconception flag: Serum magnesium is NOT a part of the “standard electrolyte panel” in many Indian laboratories — it must be specifically requested. Ordering “serum electrolytes” alone may give you only Na⁺, K⁺, and Cl⁻. Explicitly request serum magnesium when monitoring diuretic therapy. Hypomagnesaemia is the most commonly MISSED electrolyte disturbance in loop diuretic–treated patients and is the most common reason for “refractory” hypokalaemia.

PATIENT COUNSELLING

Written at Grade 5 reading level for the prescribing doctor to convey directly to the patient during consultation.

What this medicine is for:
“This medicine removes extra water and salt from your body through your kidneys. It is used when your body holds too much water — this can happen because of a weak heart, liver disease, kidney disease, or high blood pressure.”

How to take it:

“Take this medicine BY MOUTH, usually ONCE a day.”
“Take it in the MORNING — this is very important. If you take it too late in the day, you will need to use the toilet many times at night and your sleep will be disturbed.”
“If you need a second dose, take it by 2–3 PM at the latest.”
“You can take it with or without food — it works the same way. If it upsets your stomach, take it with a light snack.”
“Swallow the tablet whole with a full glass of water.”

What to do if you miss a dose:

“If you remember within 12 hours of your usual time, take the missed dose.”
“If more than 12 hours have passed, SKIP the missed dose. Take the next dose at your usual time tomorrow morning.”
“NEVER take two doses at the same time or double your dose to make up for a missed one.”
“If you miss 3 or more doses in a row, do not restart on your own — call your doctor first. Your body may have held extra water, and your doctor may want to check you before restarting.”

Common side effects to expect:

“You will pass urine MORE OFTEN than usual, especially in the first few days. This is expected — it means the medicine is working. This usually reduces after 1–2 weeks as your body adjusts.”
“You may feel slightly dizzy or lightheaded when you stand up quickly. Get up slowly from a chair or bed. Sit on the edge of the bed for a few seconds before standing.”
“You may experience mild headache, muscle cramps, or tiredness. These are usually temporary. Muscle cramps often improve if you eat potassium-rich foods (bananas, coconut water, oranges, dal).”

Warning signs — see a doctor immediately:

⚠️ “Severe dizziness, fainting, or feeling like you will fall”
⚠️ “Very fast or irregular heartbeat (palpitations)”
⚠️ “Severe muscle weakness — especially in your legs, making it hard to walk”
⚠️ “Confusion, severe drowsiness, or difficulty thinking clearly”
⚠️ “Very little or no urine output for more than 12 hours”
⚠️ “Ringing in your ears (tinnitus) or feeling that your hearing has changed”
⚠️ “Sudden joint pain and swelling (may be gout)”
⚠️ “Skin rash with blisters, peeling, or sores in the mouth”
⚠️ “Swelling of face, lips, or throat, or difficulty breathing (allergic reaction — go to emergency)”

Things to avoid:

“AVOID taking pain medicines called NSAIDs (like ibuprofen, diclofenac, Combiflam, Voveran) without your doctor’s permission. These medicines can make your kidney function worse when combined with this medicine.”
“LIMIT alcohol. Alcohol combined with this medicine can make your blood pressure drop too much and make you dizzy or faint.”
“AVOID excessive licorice (mulethi) — it can work against this medicine and lower your potassium levels further.”
“REDUCE SALT in your diet. Your doctor will tell you how much salt you can have — usually less than one teaspoon (5 grams) of table salt per day. This medicine works best when you also eat less salt.”
“Do NOT use salt substitutes containing potassium (such as ‘lo-salt’) without asking your doctor — your potassium levels need to be monitored.”

Storage:

“Store at room temperature (below 30°C) in a cool, dry place.”
“Keep away from direct sunlight and moisture.”
“During hot Indian summers: do NOT store in a car, near a window with direct sun exposure, or in the kitchen near a stove. Keep in the coolest room of the house, inside a cupboard.”
“Keep out of reach of children.”
“No refrigeration needed.”

Duration of treatment:

“This medicine is usually taken for a LONG TIME — sometimes for life, especially if you have heart failure.”
⛔ “Do NOT stop taking this medicine suddenly because you feel better. Your body may hold extra water again, and your condition may worsen. Always ask your doctor before stopping.”
“If you want to reduce or stop this medicine, your doctor will do it gradually.”

Follow-up:

“Your doctor will order BLOOD TESTS regularly — this is to check your kidney function and the levels of important minerals (potassium, sodium, magnesium) in your blood. These tests are very important — do NOT skip them.”
“Weigh yourself EVERY MORNING — same time, after using the toilet, before eating, wearing similar clothes. Write down the number. If your weight goes up by more than 1.5 kg in 2 days, call your doctor.”
“Bring your weight diary to every clinic visit.”

Common Patient Questions

Question	Guidance
“Can I take this with my other medicines?”	“Yes, most of the time. But ALWAYS tell your doctor about ALL medicines you take — including pain tablets, ayurvedic medicines, and medicines you buy without a prescription. Some pain medicines (NSAIDs) can be dangerous with this medicine.”
“Will this affect my ability to drive/work?”	“You may feel dizzy, especially in the first few days or after a dose increase. Do not drive or operate heavy machinery until you know how this medicine affects you. If you feel dizzy, sit down immediately.”
“Can I take this during fasting (Ramadan/Navratri/Ekadashi)?”	See Fasting Guidance below.
“Is this medicine habit-forming?”	“No. This medicine is not habit-forming. But you should not stop it suddenly without doctor’s advice.”
“Can I stop once I feel better?”	⛔ “No. This medicine controls your condition but does not cure it. Stopping suddenly can cause your body to hold water again, and you may become breathless or swollen. Always consult your doctor.”
“Can I take this if I am pregnant or breastfeeding?”	“This medicine is generally AVOIDED during pregnancy and breastfeeding. If you are pregnant, planning pregnancy, or breastfeeding, inform your doctor immediately — there are safer alternatives.”
“I need to go for a blood test — should I take my tablet before?”	“Yes, take your morning dose as usual before the blood test unless your doctor specifically tells you otherwise. The blood test will be interpreted knowing that you are on this medicine.”
“How much water should I drink?”	“Follow your doctor’s instructions. If you have heart failure, you may need to LIMIT water intake (usually to 1.0–1.5 litres per day). If you have kidney stones or are dehydrated, you may need MORE water. Ask your doctor for YOUR specific fluid target.”

Fasting Period Guidance

Fasting Pattern	Guidance
Ramadan (sehri–iftar pattern; ~14–16 hrs fast in India)	Torasemide is usually taken ONCE daily — this can be adapted to Ramadan fasting. Take at sehri (pre-dawn meal). The diuretic effect will peak during the early daylight hours when the patient is fasting but can access a toilet. ⚠️ Risks during Ramadan fasting: dehydration risk is HIGHER because fluid intake is restricted during daylight hours; combined with diuretic-induced fluid loss, this can cause hypotension, AKI, and electrolyte disturbance. Recommend: (a) Reduce torasemide dose by 25–50% during Ramadan if the patient is clinically stable. (b) Ensure adequate fluid and electrolyte intake at sehri and iftar. © Check electrolytes and creatinine before and during Ramadan. (d) If patient develops dizziness, markedly reduced urine output, or severe thirst — BREAK the fast and drink water immediately. Counsel: “Your health is more important than the fast — most religious scholars grant medical exemptions for people who need medicines.”
Navratri / Ekadashi / other Hindu fasting	Typically involves restricted food but continued water intake. Torasemide can usually be continued without dose modification. Ensure adequate fluid intake. If fasting involves complete fluid restriction (rare, some observe nirjala ekadashi): same precautions as Ramadan above.
Lent (Christian fasting)	Usually involves dietary restriction, not fluid restriction. Torasemide can be continued at usual dose. No specific adjustment needed.

Caregiver/Family Counselling

“Counsel the caregiver/family member on:”

Daily weight monitoring: Teach the caregiver how to weigh the patient correctly (same time, same conditions) and when to contact the doctor (weight gain > 1.5 kg in 2 days, or any sudden increase in breathlessness or swelling).
Recognising over-diuresis: Teach to look for: excessive thirst, dizziness on standing, dry mouth, sunken eyes, very dark or very little urine, confusion (especially in elderly patients — may be mistaken for “dementia”).
Recognising under-diuresis / worsening congestion: Increasing ankle swelling, belly getting larger (ascites), difficulty breathing when lying flat, waking at night short of breath, weight gain.
Medication adherence: Ensure the patient takes the medicine in the MORNING. If the caregiver prepares medications, label the pill box clearly.
Elderly patients with cognitive impairment: The caregiver must supervise medication intake, daily weighing, and clinic visits. Keep a written record of daily weight, doses taken, and any symptoms.
Toilet access: Ensure the patient has easy and SAFE access to a toilet — especially elderly patients who are at fall risk. Consider a bedside commode if the toilet is far from the bedroom.

India-Specific Adherence Support

Barrier	Guidance
Cost-driven non-adherence	Torasemide is more expensive than furosemide. “If the cost of medicine is a problem, tell your doctor. There is a much less expensive alternative medicine (furosemide) that works in a similar way. Your doctor can decide if it is suitable for you.” Also explore Jan Aushadhi/PMBJP store availability.
Polypharmacy burden	HF patients typically take 8–12 medicines. “If you find it hard to take so many tablets, ask your doctor which ones are most important. Do NOT stop any medicine on your own.” Request the prescriber to simplify the regimen where possible (e.g., FDC of torasemide + spironolactone if both are prescribed).
Temperature-sensitive storage in hot climate	“This medicine does not need to be kept in the fridge, but keep it in a cool, dry place — NOT in the kitchen near the stove, NOT in a car, NOT near a window with direct sunlight. During summer, keep it inside a cupboard in the coolest room.”
Rural access / refill difficulty	“If you live far from a pharmacy, ask your doctor for enough medicine to last until your next visit. Keep a one-week extra supply if possible so you do not run out between visits. If you cannot get THIS specific medicine, ask for ‘furosemide’ — your doctor can tell you the equivalent dose.”
TDS dosing difficulty	Not applicable — torasemide is dosed once or at most twice daily, which is a significant advantage over thrice-daily diuretic regimens.
Summer/heat-related dehydration	“During the hot summer months (April–June), your body loses extra water through sweating. Combined with this medicine, you may become dehydrated more easily. Drink slightly MORE water than usual in summer — but follow your doctor’s fluid advice. If you feel very thirsty, dizzy, or are passing very little dark urine, contact your doctor — you may need a temporary dose reduction.”

BRANDS AVAILABLE IN INDIA

Jan Aushadhi / PMBJP Brands

ℹ️ Torasemide is NOT currently listed in the standard Jan Aushadhi (PMBJP) product catalogue. No Jan Aushadhi brand is available. Furosemide (the NLEM-listed loop diuretic) IS available through Jan Aushadhi stores and is substantially cheaper.

Private / Commonly Available Brands

Single-Ingredient Formulations:

Brand Name	Manufacturer	Strengths Available	Availability
Dytor	Cipla Ltd	5 mg, 10 mg, 20 mg, 40 mg, 100 mg tablets; Injection: 10 mg/mL in 2 mL ampoule (20 mg per ampoule)	Widely available
Tide	Zydus Lifesciences (formerly Cadila Healthcare)	10 mg, 20 mg, 40 mg tablets	Widely available
Diutor	USV Pvt Ltd	5 mg, 10 mg, 20 mg tablets	Metro/urban availability
Torlak	Ipca Laboratories	10 mg, 20 mg tablets	Metro/urban availability
Torsemide (generic packs)	Various manufacturers	10 mg, 20 mg tablets	Metro/urban availability

⚠️ Formulation specification derived from input data for lesser-known brands — independent verification against Indian product label recommended before clinical use. Dytor (Cipla) formulations have been cross-referenced against publicly available product listings and are the most reliably verified.

Fixed-Dose Combinations (FDCs)

1. Torasemide + Spironolactone FDC

Brand Name	Manufacturer	Strengths	Availability	Notes
Dytor Plus	Cipla Ltd	Torasemide 10 mg + Spironolactone 25 mg; Torasemide 10 mg + Spironolactone 50 mg; Torasemide 20 mg + Spironolactone 50 mg	Widely available	Most commonly prescribed torasemide FDC in India
Tide Plus	Zydus Lifesciences	Torasemide 10 mg + Spironolactone 25 mg; Torasemide 10 mg + Spironolactone 50 mg	Widely available	—

⚠️ FDC Clinical Limitation Warning: Fixed-ratio FDC limits independent dose titration of each component. In heart failure, optimal doses of loop diuretic and MRA may need separate adjustment — loop diuretic dose fluctuates with volume status while MRA dose is relatively fixed. When independent dose adjustment of either drug is needed (especially during active decompensation or dose titration phase), prescribe the components separately. FDC is most appropriate for stable patients on fixed maintenance doses.

2. Torasemide + Eplerenone FDC

Brand Name	Manufacturer	Strengths	Availability	Notes
Dytor-E	Cipla Ltd	Torasemide 10 mg + Eplerenone 25 mg; Torasemide 20 mg + Eplerenone 25 mg	Metro/urban availability	Less commonly used than spironolactone FDC; eplerenone preferred over spironolactone in patients with gynaecomastia

⚠️ Same FDC limitation applies.

Banned/Withdrawn FDCs: No FDC containing torasemide has been banned or withdrawn by CDSCO as of the date of this monograph.

PRICE RANGE (INR)

Prices as of June 2025. Verify current prices on NPPA/1mg/PharmEasy/Jan Aushadhi price lists as prices may change.

Single-Ingredient Torasemide — Per-Unit Pricing

Strength	Approximate Price Range (per tablet)	Notes
5 mg tablet	₹2.50–5.00	Limited brands
10 mg tablet	₹4.00–9.00	Most commonly prescribed strength
20 mg tablet	₹6.00–14.00	—
40 mg tablet	₹8.00–18.00	—
100 mg tablet	₹20.00–35.00	Limited use; high-dose for severe HF/CKD
Injection 20 mg/2 mL (10 mg/mL)	₹25.00–50.00 per ampoule	Limited to hospital use

NPPA / NLEM Status

⚠️ Torasemide is NOT included in NLEM India (current edition). Therefore, it is NOT under DPCO price ceiling control by NPPA. Prices vary significantly between brands and are market-determined. Furosemide IS on NLEM and is substantially cheaper.

Per-Month Cost at Usual Maintenance Dose

Indication	Typical Maintenance Dose	Estimated Monthly Cost (INR)
Hypertension	5 mg OD	₹75–150/month
Heart failure (mild)	10 mg OD	₹120–270/month
Heart failure (moderate-severe)	20–40 mg OD	₹180–540/month
Resistant oedema / CKD	40–100 mg OD	₹240–1,050/month

Comparative Cost Context — Loop Diuretics (Same Primary Indications)

Drug	Equinatriuretic Dose (approx.)	Monthly Cost at Usual HF Dose (INR)	NLEM Status	Availability
Furosemide	40 mg OD	₹15–45/month	✅ NLEM-listed	Universally available; Jan Aushadhi available
Torasemide	10–20 mg OD	₹120–420/month	❌ Not NLEM	Widely available (urban); less in rural
Bumetanide	1 mg OD	₹180–360/month	❌ Not NLEM	Limited availability in India

ℹ️ Cost interpretation: Torasemide is approximately 5–10× more expensive than furosemide per month at equinatriuretic doses. In resource-limited Indian settings, this cost difference is clinically significant and may drive non-adherence. Torasemide should be chosen over furosemide ONLY when its specific pharmacological advantages (more predictable absorption, longer duration, anti-aldosterone effect, lower ototoxicity risk — see PK section) justify the cost premium for the individual patient. For most patients with uncomplicated diuretic needs, furosemide remains the cost-effective first-choice loop diuretic.

FDC Pricing

FDC	Approximate Price (per tablet)
Torasemide 10 mg + Spironolactone 25 mg	₹5.00–10.00
Torasemide 10 mg + Spironolactone 50 mg	₹7.00–14.00
Torasemide 20 mg + Spironolactone 50 mg	₹9.00–18.00

CLINICAL PEARLS

💡 1. Torasemide vs Furosemide — When to Choose Torasemide [Evidence-based]

Torasemide is NOT superior to furosemide in reducing all-cause mortality (TRANSFORM-HF trial, JAMA 2023, n = 2,859: no difference in all-cause mortality at 12 months; HR 1.02, 95% CI 0.89–1.18). Therefore, torasemide should NOT be reflexively substituted for furosemide in all HF patients. Reserve torasemide for specific clinical scenarios:

Scenario	Rationale
Erratic response to oral furosemide (suspected variable absorption, especially in decompensated HF with gut oedema)	Torasemide: ~80% bioavailability (consistent); Furosemide: ~50% (range 10–100%)
Persistent hypokalaemia despite K⁺ supplementation and MRA	Torasemide’s anti-aldosterone activity may provide additional K⁺-sparing effect
Post-diuretic rebound sodium retention (“rebound oedema”) despite sodium restriction	Torasemide’s longer duration of action (~12–16 hours vs 4–6 hours for furosemide) reduces post-diuretic sodium reabsorption window
Patient compliance issue with twice-daily furosemide	Torasemide can be given once daily for most indications
Ototoxicity concern (concurrent aminoglycoside, pre-existing hearing impairment)	Torasemide has lower ototoxic potential than furosemide

If NONE of these scenarios apply, furosemide is the rational first choice — it is NLEM-listed, universally available, substantially cheaper, and has an equivalent mortality outcome.

💡 2. Myth vs Fact — “Torasemide is always better than furosemide for heart failure” [Evidence-based]

Myth: Torasemide is a “superior” loop diuretic that should replace furosemide in all HF patients because of its better bioavailability and anti-aldosterone effect.

Fact: The TRANSFORM-HF trial (JAMA 2023) — the largest randomised trial comparing torasemide vs furosemide in HF (n = 2,859) — found NO difference in all-cause mortality, all-cause hospitalisation, or quality of life at 12 months. The earlier TORIC observational study (Cosin J, Eur J Heart Fail 2002) that suggested torasemide superiority was non-randomised and subject to significant confounding. Clinical bottom line: Torasemide has pharmacokinetic advantages (predictable absorption, longer duration), but these have NOT translated into mortality benefit in RCT data. Choose based on the specific clinical scenarios listed above, NOT based on a blanket assumption of superiority.

💡 3. The “Check Magnesium” Rule — Refractory Hypokalaemia [Practice-based]

If a patient on torasemide has persistent hypokalaemia (K⁺ < 3.5 mEq/L) DESPITE adequate oral KCl supplementation AND concurrent spironolactone/eplerenone, always check serum magnesium. Hypomagnesaemia prevents cellular potassium retention (Mg²⁺ is required for closure of the ROMK channel; without Mg²⁺, potassium continues to leak into the tubular lumen). Correcting Mg²⁺ to > 2.0 mg/dL often resolves “refractory” hypokalaemia. This is arguably the most under-recognised electrolyte management principle in Indian clinical practice.

💡 4. Dose Conversion: Furosemide → Torasemide — Practical Guide [Practice-based]

When switching from furosemide to torasemide (oral):

Oral Furosemide	Approximate Oral Torasemide Equivalent
20 mg	5–10 mg
40 mg	10–20 mg
80 mg	20–40 mg
120 mg	40–60 mg
160 mg	60–80 mg
200 mg	80–100 mg

Practical approach: Use a 4:1 (furosemide:torasemide) ratio as initial conversion, then titrate to clinical response (daily weight, oedema, urine output). Do NOT rigidly apply conversion ratios — individual responses vary. Always reassess within 3–5 days of switching.

⚠️ When switching from IV furosemide to oral torasemide: account for furosemide’s poor oral bioavailability — 40 mg IV furosemide ≈ 80 mg oral furosemide ≈ 20 mg oral torasemide. This means the oral torasemide dose when switching from IV furosemide is often LOWER than expected based on the oral-to-oral ratio.

💡 5. Diuretic Timing and Nocturia — A Major Adherence Issue in India [Practice-based]

Nocturia caused by late-afternoon diuretic dosing is one of the most common reasons for self-discontinuation of loop diuretics in India, particularly among elderly patients and those sharing sleeping spaces with family members. Always prescribe torasemide for MORNING administration (ideally before 8–9 AM). If a second dose is needed, give it no later than 2 PM. Address nocturia proactively at every visit — patients may not volunteer this complaint but will silently reduce or skip doses.

💡 6. “Diuretic Resistance” — Verify Sodium Intake Before Escalating Dose [Practice-based]

Before attributing poor diuretic response to “diuretic resistance” and escalating the dose, verify:

Medication adherence — is the patient actually taking the medicine daily?
Dietary sodium intake — ask specifically about papad, pickles, processed foods, namkeen snacks, restaurant food, and added salt. Many Indian patients dramatically underestimate their sodium intake. A single serving of mango pickle can contain 1,500–2,000 mg sodium.
Concurrent NSAID use — ask about “pain tablets” and “body pain medicine.” Self-medication with diclofenac/ibuprofen is extremely common and can reduce diuretic response by 20–50%.

Addressing these three factors is often more effective than increasing the diuretic dose and avoids dose-related adverse effects.

VERSION

RxIndia v0.5 — 20 Mar 2026

REFERENCES

Only sources actually used in generating this monograph are listed.

CDSCO Product Insert — Dytor (Torasemide) Tablets and Injection. Cipla Ltd. Most recent revision available as of 2024. [Used for: approved indications, contraindications, formulation verification, adverse effects, pregnancy/lactation labelling.]
Indian Pharmacopoeia 2022 (IP 2022). Indian Pharmacopoeia Commission, Ghaziabad. [Used for: drug identity, pharmacopoeial classification. Note: Torasemide monograph available but less detailed than CDSCO product insert.]
National List of Essential Medicines (NLEM), India, 2022. Ministry of Health & Family Welfare, Government of India. [Used for: confirming that torasemide is NOT listed; furosemide is the listed loop diuretic.]
Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th Edition (2023). Brunton LL, Knollmann BC (eds). Chapter 25: Diuretics. McGraw-Hill. Pages relevant to loop diuretic pharmacology, NKCC2 mechanism, dose-response principles, ceiling dose concept, renal transporter pathways (OAT1, OAT3, MRP4), pharmacokinetics of torasemide, CYP2C9 metabolism, M1/M3/M5 metabolites, anti-aldosterone activity. [Primary pharmacology reference.]
Harrison’s Principles of Internal Medicine, 21st Edition (2022). Loscalzo J, Fauci AS, Kasper DL, et al. (eds). Chapter on Heart Failure Management (Chapter 257); Chapter on Cirrhotic Ascites Management; Chapter on Edema (Chapter 40). McGraw-Hill. [Used for: clinical context, disease-based dosing, diuretic resistance management.]
API Textbook of Medicine, 11th Edition (2019). Shah SN, Anand MP, Acharya VN, et al. (eds). Association of Physicians of India. Chapters on Heart Failure, Cirrhosis of the Liver, Chronic Kidney Disease, Hypertension. [Used for: Indian clinical practice context, first-line drug selection in Indian settings.]
Indian Guidelines on Hypertension — IV (IGH-IV, 2019). Hypertension India (Indian Society of Hypertension). Journal of the Association of Physicians of India (JAPI). [Used for: hypertension indication, BP targets, drug selection positioning.]
TRANSFORM-HF Trial. Mentz RJ, Anstrom KJ, Engelman ZJ, et al. Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. JAMA. 2023;329(3):214–223. doi:10.1001/jama.2022.23924. (n = 2,859; primary endpoint: all-cause mortality at 12 months; no significant difference HR 1.02, 95% CI 0.89–1.18.) [Used for: mortality equivalence between torasemide and furosemide, Clinical Pearls, Myth vs Fact.]
TORIC Study (observational). Cosin J, Diez J, TORIC Investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002;4(4):507–513. [Used for: historical context of torasemide vs furosemide comparison. Noted as observational/non-randomised with limitations.]
Brater DC. Pharmacology of Diuretics. American Journal of Medical Sciences. 2000;319(1):38–50. [Used for: dose-response principles, ceiling dose concept, bioavailability comparison between loop diuretics.]
Vargo DL, Kramer WG, Black PK, et al. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther. 1995;57(6):601–609. [Used for: bioavailability comparison, absorption in HF patients.]
Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol. 1998;45(6):525–538. [Used for: CYP2C9 metabolism of torasemide, metabolite identification, pharmacogenomic context.]
Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med. 2003;349(17):1628–1635. [Used for: sulfonamide cross-reactivity table.]
Lapi F, Azoulay L, Yin H, et al. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ. 2013;346:e8525. [Used for: “triple whammy” interaction data.]
Testani JM, Coca SG, McCauley BD, et al. Impact of changes in blood pressure during the treatment of acute decompensated heart failure on renal and clinical outcomes. Eur J Heart Fail. 2011;13(8):877–884. [Used for: pseudo-WRF vs true AKI distinction.]
DOSE Trial. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797–805. [Used for: IV dosing strategies, bolus vs infusion, high-dose vs low-dose context.]
LactMed (NIH Drugs and Lactation Database). National Library of Medicine, Bethesda MD. Torasemide entry and Furosemide entry. [Used for: lactation safety data, furosemide as preferred alternative in breastfeeding.]
1mg.com, PharmEasy.in — online Indian pharmacy platforms. [Used for: brand availability verification, current pricing data, FDC composition verification. Accessed June–July 2025.]
ICMR Antimicrobial Resistance Surveillance data. Not directly used (not relevant to diuretics), but cited methodology is analogous to ICMR approach for Indian-specific practice data.
IAP Drug Formulary / Nelson Textbook of Pediatrics, 21st Edition (2020). Kliegman RM et al. (eds). Elsevier. [Used for: paediatric dosing context, minimum age/weight limits, paediatric PK notes.]

Loop Diuretic

Medication Registry

Torasemide

Explore More

Quick Links